Molecular pharmacology of C3aR modulators by Singh, Ranee
 i 
 
 
 
 
 
 
 
Molecular Pharmacology of C3aR Modulators 
 
MRS RANEE SINGH 
 
D.V.M. (Doctor of Veterinary Medicine) 
M.Sc. (Pharmacology) 
M.Vet.Studies (Laboratory) 
 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2012 
Institute for Molecular Bioscience 
 ii 
ABSTRACT  
 
The complement system plays key roles in both the innate (non-specific) and acquired 
(specific) immune response. Complement activation is a tightly regulated process, which takes 
place in a sequential manner by at least three pathways. All of these pathways generate a small 
anaphylatoxin protein called C3a.  C3a signals immune cells which infiltrate to sites of infection or 
injury and mount inflammatory responses leading to elimination of pathogens or damaged cells and 
induction of adaptive immunity. Genetic deficiency of C3 results in susceptibility to bacterial 
infection. However, in excess C3a can be harmful and catalyses the pathogenesis of many disease 
conditions. To date, there have been no truly selective and potent C3a receptor agonists/antagonists. 
Therefore, the purpose of this thesis was to explore the potential to develop a small molecule C3aR 
agonist/antagonist that can be a useful as a pharmacological probe or biomarker for studying the 
physiological and pharmacological roles of C3a. Chapter 1 briefly describes basic pharmacology 
terminology and reviews current knowledge of GPCRs, GPCR intracellular signalling pathways, 
C3a and C3a-C3aR related intracellular signalling pathways. Understanding the pro-inflammatory 
roles of C3a and its receptor in vitro and in vivo may provide a new therapeutic target for 
autoimmune diseases or inflammatory conditions. Chapter 2 reinvestigated reported C3a receptor 
ligands in a competitive binding assay and a functional assay. Compound affinity was measured by 
competitive binding against [125I]-C3a (80 pM). Compound functional potency (agonist or 
antagonist) was measured by fluorescent detection of intracellular calcium release in differentiated 
U937 cells. Receptor selectivity was measured by receptor desensitization using C3a or C5a, and by 
competitive binding with [125I]-C5a.   C3aR superagonist peptide (WWGKKYRASKLGLAR) and 
newly reported pentapeptides WPLPR (15) and YPLPR (14) (oryzatensin derivatives) were found 
to have no selectivity or agonist potency for C3aR. Four decapeptides (8-11) reported as C5aR 
agonists were shown to be more selective for C3aR than C5aR in a competitive binding assay on 
human isolated monocytes. Structure-activity relationships (SAR) were studied for new 
hexapeptides by calcium release, FWTLAR (20) (EC50 350 nM) and FLTLAR (17) (EC50 320 nM). 
They bound selectively to C3aR (IC50 82 nM, IC50 42 nM respectively) on human PBMCs with no 
binding to C5aR. Selectivity was confirmed by receptor desensitisation experiments. A new C3aR 
peptide antagonist (F1LTChaAR6) was obtained by modifying the leucine at position 4 with the 
bulkier group Cha, showing no agonist activity and binding tightly to C3aR (IC50 238 nM). 
Chapter 3 introduces an oxazole heterocycle into short peptides to restrict conformation freedom in 
an attempt to mimic the C3aR-binding conformation of the C-terminal activating domain of human 
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C3a. This approach produced multiple potent C3aR agonists, including some with equal affinity to 
C3a itself and selectivity for C3aR over C5aR on isolated monocyte derived macrophage cells 
(HMDM). There was a linear correlation between the binding affinity of the compounds and their 
agonist potency. Chapter 4 describes two approaches for obtaining antagonists of C3aR and shows 
some structure-activity relationships. Firstly, a potent new C3aR agonist (56) from Chapter 3 was 
modified by incorporation of a phenyl group at the 5-position of oxazole ring, which improved 
C3aR binding affinity and led to a novel and potent nonpeptidic C3aR antagonist. Secondly, new 
non-peptidic agonists of C3aR were developed from the first reported C3aR antagonist by 
modification of either the linker or hydrophobic region of SB290157 with retention of the terminal 
arginine. Several potent C3aR antagonists were developed from an oxazole-containing compound 
by incorporating a phenyl group at the 5-position of oxazole ring. Two other compounds were 
derived by modifying SB290157 at the linker region through incorporation of a thiazole or oxazole 
ring. Chapter 5 explores the antagonist mechanism of non-peptidic C3aR antagonist, SB290157 
and newly developed antagonist 146, as well as the peptidic antagonist FLTChaAR (25). It reports 
competition with three different classes of C3aR agonists: hC3a, two potent new hexapeptide 
analogues (17 and 20) and two potent new non-peptide agonists (63 and 80). SB290157 and 146 
show competitive and surmountable antagonism against the hexapeptide agonists (17 and 20) and 
non-peptide agonist (63 and 80), supporting binding at the same site(s) on C3aR. Compound 25 
showed insurmountable antagonism of all agonists (hC3a, 17, 20, 63 and 80), suggesting that 25 
binds different sites from these compounds or it may be caused by C3aR internalisation or (pseudo) 
irreversible binding to C3aR. However, 25 is unlikely to be an allosteric antagonist due to 
competition with C3a radioligand in a competitive binding assay. In summary, this study has 
investigated and reported new C3aR agonists and antagonists that can be used to probe influences 
of C3a/C3aR in physiology and pharmacology.  
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1.0 ABSTRACT 
G-protein coupled receptors (GPCRs) or seven-transmembrane receptors are the most 
common class of receptors on cell surfaces, of which more than 800 in the human genome have 
been identified to date. They are also the most common drug targets for the pharmaceutical 
industry. The 7-transmembrane receptor binds to an agonist, which causes the receptor to change 
conformation and this results in intracellular binding to heterotrimeric G proteins and consequently 
signalling by second messenger systems. The GPCR kinases phosphorylate G-protein coupled 
receptor results in increased affinity for arrestins leading to termination of G-protein mediated 
signalling and densensitization of the GPCR to further activation for a period of time. 
The complement system plays an important role in both innate and acquired immunity and 
also acts as a primary mediator of inflammatory processes. Complement consists of over 30 soluble 
plasma proteins that are activated in tightly regulated sequence. One of the major products of this 
activation is the generation of small proteins, C3a and C5a, also known as ‘anaphylatoxins’.  
Anaphylatoxins play major roles in inflammation, priming and amplifying the immune response 
through chemoattraction of immune cells to inflammatory sites and promoting the secretion of 
proinflammatory agents, lysosomal enzymes, and reactive oxygen species (ROS). The biological 
effects of C3a and C5a are mediated through 7-transmembrane G-protein coupled receptor C3aR 
and C5aR respectively on specific target cells resulting in receptor phosphorylation and activation 
of relevant intracellular signal transduction pathways. C3aR are found in myeloid cells such as 
neutrophils, mast cells, eosinophils and basophils, monocytes/macrophages and non-myeloid cells 
for example epithelial cells and endothelial cells. C3a and its receptor have been implicated in 
various pathogeneses of autoimmune diseases and acute inflammatory conditions e.g. asthma, 
sepsis, allergies, lupus erythematosus (SLE), diabetes, psoriasis, arthritis, nephropathy, ischemia-
reperfusion injury and others. The development of C3a potent and selective agonists or antagonists 
has potential for physiological probes or anti-inflammatory drugs.  
This chapter aims to describe the GPCRs and intracellular signalling cascades and 
complement pathways, which are implicated in inflammatory processes. The review focuses on C3a 
and C3aR on the basis of C3a and C3aR structure, the molecular interaction of C3a to its receptor 
and the signalling pathways in biological responses. In addition, the peptide/nonpeptide ligands 
have been developed for C3aR agonist/antagonists. C5a and C5aR are also reviewed in brief.  
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1.1 PHARMACOLOGY TERMINOLOGY 
A Full agonist is a ligand that produces full receptor activation leading to production of the 
system maximal response. Partial agonists produce submaximal receptor activation leading to 
production of submaximal system response. 
Inverse agonists are agonists that can mediate the receptor activity of GPCR systems in two 
different systems. In non-constitutively active system it shows an antagonist effect whereas in 
constitutively activated GPCR systems (in absence of any ligand) it shows the effect of reducing the 
level of constitutive activation (negative efficacy). 
Allosteric agonists (Figure 1.1) function as agonists but activate the receptor through 
interaction at a site distinct from that of the endogenous agonist (common in non-peptide agonists 
for peptide receptor). In contrast, orthosteric agonists bind at the same site as the endogenous 
ligand. 
Allosteric modulator is a ligand that binds to an allosteric site on the GPCR to modulate the 
binding and/or signalling properties of the orthosteric site. 
Allosteric antagonist (inhibitor) is allosteric modulator that reduces orthosteric ligand 
affinity and/or orthosteric agonist efficacy. 
Allosteric enhancer (Potentiator) is allosteric modulators that potentiates orthosteric ligand 
affinitity on the receptor and/or agonists efficacy. 
 
 
Figure 1.1 Diagram of classes of ligands that regulate G-protein-coupled receptors. 
 
An Antagonist is a ligand that does not elicit a biological response itself upon binding to a 
receptor, but blocks or dampens agonist-mediated responses (zero efficacy).  
Reversible competitive antagonism is the most common and most important type, which 
has 2 main characteristics:  
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•In presence of antagonist, the agonist log concentration-effect curve is shifted to the right 
without change in slope or maximum (called surmountable), the extent of the shift being a measure 
of the dose ratio. 
•The dose ratio increases linearly with antagonist concentrations; the slope of this line is a 
measure of the affinity of the antagonist for the receptor. 
 
A non-competitive antagonist mostly involves allosteric antagonism, which can decrease 
the affinity of an agonist for its receptor or prevent conformation changes for receptor activation. A 
dose response curve shows depression of the maximal response. No amount of agonist can 
completely overcome to get the same maximum response.  
Insurmountable antagonist The maximum effect of the agonist is reduced by either 
pretreatment or simultaneous treatment with the antagonist. This can occur in several distinct 
molecular mechanisms such as irreversible competitive antagonism or non-competitive antagonism. 
Schild analysis is the equation derived by Arunlakshana and Schild in 1959 to construct 
linear plots (Figure 1.2) designed to graphically estimate the affinity of competitive antagonists.  
The Schild equation: log (dr-1)= log XB- log KB             
dr = concentration ratio 
KB = equilibrium dissociation constant for the combination of antagonist B with the receptor 
XB= conc. of reversible competitive antagonist B 
 
 
Figure 1.2 Schild Plot. A graph of log (dr-1) against log XB. 
 
Slope > 1 indicates inadequate equilibrium time. 
Slope < 1 indicates removal of agonist by a saturation uptake process or agonist is acting at 
more than one receptor.  
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As stated in the literature by Kenakin (1997), the Kb can be calculated for insurmountable 
antagonists. Kb is calculated from the equation Kb = [B]/Slope-1. By plotting 1/[A] against 1[A’] 
which A is the agonist concentration while A’ is the same concentration of agonist in the presence  
of antagonist. The value of calculated Kb will be more accurate when the maximal response to the 
agonist decreases less than 50% of the maximal response in the presence of antagonist.  
 
1.2 G-PROTEIN COUPLED RECEPTORS 
GPCRs are characterized by seven transmembrane alpha helices joined by intracellular and 
extracellular loop regions (Figure 1.3). GPCRs are membrane receptors that mediate cellular 
response by coupling to intracellular effector systems via G-proteins e.g. muscarinic acetylcholine 
receptor (mAChR), adrenergic receptors and chemokine receptors. The number of GPCRs encoded 
by the human genome has been estimated to be as great as ~800-1000. GPCRs are classified into 
three main families and many subfamilies on the basis of the pharmacological nature of their 
ligands and sequence similarity. 
 
(A).      (B). 
	   
Figure 1.3 (A). Representation of the crystal structure of Bovine Rhodopsin (pdb: 1U19).    
(B). Two-dimensional depiction of Bovine Rhodopsin, which composes of seven-
transmembrane helices TM1 to TM7 connected by three extracellular (EC) and three 
intracellular (IC) loops.   
TM1 TM2 TM3 TM4 TM5 TM6 TM7
N-terminus
C-terminus
EC1 EC2 EC3
IC1 IC2 IC3
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Rhodopsin like–receptor (Class I) is the largest and most diverse of these families that 
consists of rhodopsin, adenosine, melanocortin, neuropeptide, chemokine and others. The secretin- 
like family (Class II) consists of 25 members including the receptors for the GI peptide hormone 
family (eg. secretin, glucagon, vasoactive intestinal peptide) calcitonin and parathyroid hormone. 
The metabotropic glutamate receptor-like family (Class III) is the smallest family and includes the 
GABAB receptor, calcium-sensing receptor and some taste receptors (Table 1.1).   
To date, GPCR-based drugs have become one of the most important in terms of drug 
discovery potential. However, clinically successful GPCR-based drugs have targeted a small 
number of known GPCRs (~30%) especially in the bioamine family, which is a subfamily of Class I 
GPCRs.  The complete human genome sequencing reveals unknown GPCRs. GPCRs with 
unknown endogenous ligand are classified as “orphan”. The identification of new subtypes of 
known GPCRs and orphan receptor has opened opportunity for novel GPCR-based therapeutics and 
has drawn attention from the pharmaceutical industry.  
 
Table 1.1 Family classification of known G-protein-coupled receptors (adapted from 
Chalmers et al., 2002). 	  
Class I (A) 
Rhodopsin-like 
Class II (B) 
Secretin-like 
Class III (C) 
Metabotropic-
glutamate-
receptor-like 
Frizzled/ 
Smoothened 
Amine Acetylcholine Calcitonin Metabotropic 
glutamate 
Frizzled/ 
smoothened 
 α and β 
adrenoceptors 
Corticotropin-
releasing factor 
Extracellular 
calcium-sensing 
 
 Dopamine Gastric inhibitory 
peptide 
Putative 
pheromone 
 
 Histamine Glucagon GABAB  
 Serotonin Growth-hormone-
releasing hormone 
  
 Octopamine Parathyroid hormone   
 Trace amine PACAP   
Peptide Angiotensin Secretin   
 Bombesin Vasoactive intestinal 
polypeptide 
  
 Bradykinin Diuretic hormone   
 C5a 
anaphylatoxin 
Latrophilin   
 FMet-Leu-Phe Brain-specific 
angiogenesis inhibitor 
  
 APJ-like Methuselah-like 
proteins 
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 Interleukin-8    
 CC,CXC,CX3C, 
XC chemokine 
   
 Chemokine-
receptor-like 
   
 Cholecystokinin    
 Endothelin    
 Melanocortin    
 Neuropeptide Y    
 Neurotensin    
 Opioid    
 Somatostatin    
 Tachykinin    
 Vasopressin-like    
 Galanin-like    
 Proteinase-
actvated-like 
   
 Orexin and 
neuropeptide FF 
   
 Urotensin II    
 Adrenomedulin    
 Endothelin-B-
like 
   
 Neuromedin U    
   Hormone protein    
Prosta-
noid 
 Prostaglandin    
  Prostacyclin    
  Thromboxane    
Nucleo-
tide-like 
 Adenosine    
 Purinoceptor type 
U, Y, other 
   
 Cannabinoid    
 Platelet-activating 
factor 
   
 Gonadotropin-
releasing hormone 
   
 Thyrotropin-
releasing hormone 
   
 Melatonin    
 Viral    
 Lysosphingolipid 
and 
lysophosphatidic 
acid 
   
 Leukotriene B4    
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1.2.1 GPCR SIGNALLING 
G-proteins consist of 3 subunits (α, β, γ), which are anchored to the membrane through 
attached lipid residues. Coupling of the alpha-subunit to an agonist-occupied receptor causes the 
bound GDP to exchange with intracellular GTP; the alpha-GTP complex is then dissociated from 
the receptor and from the βγ complex, and interacts with a target protein; for example it may be an 
enzyme such as adenylate cyclases, and phospholipases or ion channels. The regulation of these 
second messengers modulates the level of intracellular mediators for example cAMP, intracellular 
Ca2+, phosphoinositide and DAG, which in turn activate or inhibit effectors (PKA, PKC and PI-
3K), which lead to a biological response. The βγ complex may also activate a target protein (target 
2). The GTPase activity of the α-subunit is increased when the target protein is bound, leading to 
hydrolysis of the bound GTP to GDP, whereupon the α subunit recombines with βγ (Figure 1.4). 
1. Resting State
! "#
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target 
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2. Agonist binds to receptor
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target 
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Figure 1.4 The function of G-protein. G-protein consists of three subunits: α, β, γ that are 
anchored to the membrane. Binding of agonist to receptor causes the exchange of bound GDP for 
GTP the complex then dissociates from the receptor and from the βγ complex and interacts with a 
target protein (target 1) such as adenylate cyclase. The βγ complex also activates a target protein 
(target 2) for example GPCR kinase or mitogen-activated protein kinase. The activation is 
terminated by increasing of GTPase activity of α-subunit when it is bound to the target protein, 
which leads to hydrolysis from GTP to GDP. The α-subunit then recombines with βγ. (adapted from 
Rang et al., 2007).  
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A feedback mechanism occurs after the activation of the receptor by agonist that helps to 
decrease responsiveness and prevent the overstimulation of the receptor. There are three families of 
regulatory molecules that control the process of desensitization: second messenger-dependent 
protein kinases, GPCR kinases (GRKs) and arrestins (Ferguson et al., 1996; Lefkowitz, 1993; 
Zhang et al., 1997a). Desensitization is started by phosphorylation of activated G-protein coupled 
receptors by GRKs and/or second messenger-dependent protein kinases, which promotes the 
translocation of the cytosolic adaptor arrestin proteins to the membrane. Arrestin proteins then bind 
to the receptor and promote internalisation.  GPCRs can be divided into two classes (A or B) 
according to their affinity for the β-arrestin. Class A receptors bind to β–arrestin 2 with higher 
affinity than β–arrestin 1 while Class B receptors bind to both with the same affinity. Class A 
receptors dissociate from β–arrestin soon after internalization. Class B receptors remain associated 
with β–arrestin throughout receptor internalization. Class A receptors can return to the cell surface 
rapidly, in approximately 30 mins. In contrast, class B receptors remain associated with β–arrestin 
and the endosome for around 1 hour after activation (Oakley et al., 2001; Oakley et al., 2000). 
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Figure 1.5 GPCR complex with potential activators and diverse biological functions  
(Figure adapted from Marinissen et al., 2001).  
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1.2.2 CLASSIFICATION OF G-PROTEINS AND INTRACELLULAR 
PATHWAYS 
G-protein-mediated signal transduction results in many different biological functions in the 
human body. There are numerous subtypes of G-proteins, which are commonly classified by their 
alpha subunits. This subunit is divided into 4 families (Gαs, Gαi/Gαo, Gαq/Gα11, Gα12/Gα13)(Figure 
1.5 and Table 1.2). Unlike alpha-subunits (16 subunits) there is only a small range of β and γ- 
subunits: five β-subunits and twelve γ-subunits. 
  (1) Gαs couple to amine receptors for catecholamines, histamine and serotonin as well as 
many other receptors and stimulates adenylyl cyclase, causing increased cAMP formation (Table 
1.2).  
(2) Gαi is the first subtype in the Gi family, which is designated with the “i” letter due to its 
ability to inhibit adenylyl cyclase, which decreases cAMP formation. Gαi is associated with opioid 
and cannabinoid receptor amongst others. It is blocked by pertussis toxin, which prevents 
dissociation of αβγ.  Gαo has limited effects from the alpha subunit, it effects mainly from the βγ 
subunit. Like Gαi its effects are blocked by pertussis toxin, which occurs mainly in the nervous 
system. 
(3) Gαq is associated with amine, peptide and prostanoid receptors. It activates 
phospholipase C, increasing production of the second messengers inositol (1,4,5) triphosphate (IP3) 
and diacylglycerol (DAG). 
(4) Gα12/Gα13 is activated by certain GPCRs. The activation occurs by the exchange of GDP 
for GTP, which facilitates the activation of Rho-GDP. Rho is activated and in turn activates Rho 
kinase. Rho kinase can phosphorylate a variety of substrate proteins and can control a range of 
cellular functions such as smooth muscle cell contraction, proliferation, angiogenesis and synaptic 
remodelling. 
Gβγ subunit of G-protein coupled receptor associates with similar target protein for Gα 
subunits. It activates potassium channels, inhibits voltage-gated calcium channels, activates GPCR 
kinase, and activates mitogen-activated protein kinase cascades. Many Gβγ isoforms have been 
identified but specific functions are not yet known. 
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Table 1.2 Classification of Gα subunits and their effectors  	  
 
Family 
 
Subtype 
 
Effector 
Gα Gαs ↑ Adenylyl cyclase 
 Gαolf ↑ Adenylyl cyclase 
Gi Gαi1 ↓ Adenylyl cyclase 
 Gαi2  Rap 1 GAP 
 Gαo ↑ GTPase of tubulin, ↑c-Src 
 Gαz ↓Ca2+, ↑K+ channels 
 Gαt ↑ cGMP-PDE 
 Gαg  unknown 
Gq Gαq ↑ PLCβ 
 Gα11 ↑ GRK 1-3 
  ↑ Bruton’s tyrosine kinase (Gαq) 
  ↑ p63-RhoGEF 
  ↑ K+ channels 
G12 Gα12 ↑ Na+/H+ exchaner 
  ↑ PLD 
 Gα13 ↑ p115RhoGEF 
  ↑ iNOS 
  ↑ PLCe 
  ↑ E-cadherin 
 
PDE, phosphodiesterase E; iNos, inducible nitric oxide synthase, PLD, phospholipase D;  
GEF, guanine nucleotide-exchange factor. 
(Table adapted from Cabrera-Vera et al., 2003) 
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Figure 1.6 Signal transduction in G-protein-coupled receptors. The type 2 beta-adrenergic 
receptor regulated diverse signaling pathways. (Figure adapted from Rosenbaum et al., 2009). 	  
Targets for G-proteins (Figure 1.6) 
• Adenylyl cyclase/cAMP: adenylyl cyclase catalyses formation of the intracellular 
messenger cAMP. cAMP activates various protein kinases that control cell function 
in many different ways by causing phosphorylation of various enzymes, carriers and 
other proteins. 
• Phospholipase C/ inositol triphosphate (IP3)/diacylglycerol (DAG): Catalyses the 
formation of second intracellular messengers, IP3 and DAG, from membrane 
phospholipid. IP3 acts to increase free cytosolic Ca2+ by releasing Ca2+ from 
intracellular compartments. Increased free Ca2+ initiates many events, including 
contraction, secretion, enzyme activation and membrane hyperpolarization.  DAG 
activates protein kinase C, which controls many cellular functions by 
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phosphorylating a variety of proteins. Receptor-linked G-protein also regulates 
Phospholipase A2 (formation of arachidonic acid, eicosanoids). 
• Ion channels (e.g. potassium and calcium channels) thus affecting membrane 
excitability and transmitter release etc. 
 
1.3 COMPLEMENT AND INFLAMMATION  
Inflammation is a local protective event. It causes a complex series of events including dilation 
of arteries, capillaries and venules, increased vascular permeability, increased blood flow and 
exudation of fluids and plasma proteins. These processes occur rapidly and are followed by 
adhesion of leukocytes to the vascular endothelium with subsequent influx of cells into the 
surrounding tissue. Complement is involved in inflammatory response. The direct effects of certain 
complement activation products, anaphylatoxins, can also stimulate the synthesis and/or secretion 
of many other inflammatory mediators. 
In 1920, the first four complement components were described (C1, C2, C3 and C4) and later 
in 1958 five more components had been identified. The letter C has been used to designate 
complement components along with number corresponding to the sequence in which the protein 
components are discovered, although, this number did not represent their activation sequence. The 
sequence of activation starts from C1 to C9 except for C4, which activated after C1 and before C2. 
C1 is composed of three subcomponents designated C1q, C1r and C1s. The cleavages of 
complement components resulting in fragments are designated by the name of the original 
component (e.g. C3) followed by a lowercase letter such as C3a and C3b. Inactive fragments have 
the lowercase letter “i” before the abbreviation such as iC3b. 
 
1.4 COMPLEMENT CASCADE 
The complement system is a key component of the immune defence against infectious 
organisms (bacteria, viruses, parasites) or tissue damage caused by chemicals, physical damage, 
radiation or neoplasia. The complement network is composed of over 30 soluble plasma proteins 
and receptors that play key roles in both innate (non-specific) and acquired (specific) immune 
responses (Sunyer et al., 2005). Activation of complement enables the host to distinguish between 
self and non-self, tagging the latter with complement proteins that facilitates lysis of bacteria and 
damaged cells as well as their elimination from the host. Complement activation is tightly regulated 
process in which it is activated in a sequential or cascade reaction. Complement activation is the 
result of the assemblage of individual components each of which activates the next component.  
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The cascade is completed when all nine in sequence of complement component (C1, C4, C2, 
C3 to C9) are activated.  There are three distinct pathways called the classical pathway, the 
mannose-binding lectin pathway and the alternative pathways, which activate complement cascade 
as illustrated in Figure 1.7.  
The classical pathway is activated by antigens that bind to the antibodies (or antibody-
dependent) IgM and certain IgG3 and IgG1 antibody isotypes which are the most efficient 
activators, resulting in rearrangment of Fc-conformation which increases affinity of the Fc domains 
of antibody for C1q - the first component of complement (Lachmann et al., 1984). The classical 
pathway has 3 phases: (1) the initiation phase (involving C1, C4 and C2) (2) the amplification 
phase (involves C3) and (3) the membrane attack phase (involves components C5b, C6, C7, C8 
and C9). Once C1q is activated by binding to a specific antigen, the C1 binding sites are exposed to 
the Fc region of antibodies. C1 is a Ca2+-dependent complex of three polypeptides: (1) C1q, a 
protein with six immunoglobulin binding sites linked by collagen-like fibrils, which in turn 
activates through rearrangement the structure of (2) C1r and then (3) C1s, a serine protease that 
goes on to cleave C4 and then C2. C4 is cleaved by C1s into fragments C4a (anaphylatoxin) and 
C4b. In the presence of Mg2+ ions, the bound C4b interacts with the C-terminal C2a which renders 
C2 susceptible to cleavage by C1s. C2 is cleaved by C1s into two fragments C2b (small) and C2a 
(large). C2b diffuses while C2a remains bound to C4b. Joining of C4b and C2a and attachment to 
antigen-antibody complex leads eventually to the formation of C4b2a (or C3 convertase) that 
cleaves the component C3 into C3a and C3b. Some of the C3b is deposited on the membrane of the 
target cell (or called opsonises), where it acts as a site for the attachment of phagocytic cells and 
acts as an opsonin. 
In contrast, activation of the Mannose-binding lectin pathway is initiated independently of 
immunoglobulins, by mannose-binding lectin-associated serine proteases (MASP). The activation 
of serine protease MASP-1 and MASP-2 (structurally and functionally similar to C1r and C1s, 
respectively) are triggered by the binding of mannose-binding lectin (MBL; structurally similar to 
C1q) to mannose-containing carbohydrate moieties (sugar structures such as mannose, fructose, 
glucose and N-acetyl-glucosamine) on the microbial, or viral cell surfaces but not in mammalian 
molecules. The complex of MBL and MASP-1 and MASP-2 then cleaves and activates C4 and C2 
in a similar way to the classical pathway (Monk et al., 2007; Yang, 2006). The lectin pathway is 
sometimes included as part of the classical pathway because it produces the same C3 convertase 
(C4b2a) following C3 being cleaved into C3a and C3b and then the C3b binding to the C3 
convertase to form C5 convertase.  
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Figure 1.7 Complement activation pathways (Figure adapted from Sarma et al., 2011). 
 
The alternative pathway is a more direct pathway that is activated in the absence of 
antibodies. The alternative pathway is initiated by many microbial cell wall components, such as 
zymosan (fungi), LPS (endotoxin) and teichoic acid, as well as other foreign surfaces and also 
protein A, C-reactive protein, cobra venom factor, polysaccharides and damaged tissue (Ganter et 
al., 2007; Gasque, 2004). The biological relevance of the alternate pathway is its ability to provide 
an amplification loop for the classical pathway. The mechanism of initiation of the pathway is not 
clearly understood, however it is thought to involve continuous low-rate hydrolysis (“tick-over”) of  
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a thioester bond within the complement protein C3 to produce a molecule, C3(H2O) which has 
structure and function that resembles C3b but is unstable unless it binds to the microbial cell 
membrane surface. In healthy cells, there are various control mechanisms that prevent the 
continuous activation of C3 and undesirable effects from complement activation.  In the presence of 
factor B, D and properdin, C3(H2O) is converted to C3bBbP, which is the C3 convertase of the 
alternative pathway (Yang, 2006). Factor B is structurally and functionally similar to C2. Factor D 
cleaves factor B into two fragments, Ba and Bb. The biological role of Ba is unknown. Bb binds to 
C3b, which become susceptible to Factor D. Factor D acts similarly to C1s (serine protease). It has 
no activity on Factor B until the binding of Factor B to C3b, which forms the C3 convertase of the 
alternative pathway. Properdin is a gamma-globulin consisting of identical subunits which are held 
together by a covalent bond. There are two forms of properdin, native and activated, which differ 
from each other only by a small conformational change. The native properdin acts indirect by 
slowing the dissociation of Bb from C3b, which stabilizes C3bBb complex extending the half-life 
10-fold (Ehrnthaller et al., 2011). The activated form of properdin binds to C3b (in the absence of 
Factor B) and promotes the assembly of C3bBb. 
 After C3 is cleaved by C3 convertase, C3b binds to C3 convertase (either C4b2a3b or 
C(3b)nBbP) forming C5 convertase which cleaves C5 into C5a and C5b. C5b binds to C6, C7 and 
C8 and multiple C9s to form the membrane attack complex (MAC), C5b678(9)n, which perforates 
membranes of micro-organisms by generating a cylindrical structure. The membrane pores lead to 
osmotic imbalance resulting in the lysis of the target cell and subsequent elimination from the body. 
This tagging (opsonisation) by C3b and synthesis of convertases directly on foreign antigen 
surfaces enables the host to eliminate pathogens and damaged cells without creating too many 
potent pro-inflammatory complement proteins that might otherwise damage the host.  
The cleavage of C3 by C3 convertase or C5 by C5 convertase occurs at a site close to the N-
termini of their α-chains (Figure 1.8) (Frank, 1997; Hugli, 1986; Muller-Eberhard, 1988; Volanakis 
et al., 1998) and leads to the generation of large fragments, C3b or C5b along with small activation 
fragments, C3a and C5a which are potent anaphylatoxins (Figure 1.7 and 1.8). These 
anaphylatoxins have the ability to trigger degranulation of mast cells, basophils and neutrophils, and 
therefore release vasoactive substances such as histamine, prostaglandins, kinins and serotonin. 
Also, they are potent chemotactic agents in the recruitment of immune cells to the sites of infection 
or damage. While C5a is the more potent mediator of leukocyte degranulation or phagocyte 
chemotaxis and many other functions, C3a is present at an approximately 20-fold higher 
concentration in plasma than C5a (Chenoweth et al., 1979; Ember et al., 1997; Gerard et al., 1994).  
Recently, there were reports that the complement acts not only in the “inflammation processes” but 
is also involved with the coagulation cascade (Amara et al., 2008; Laudes et al., 2002; Markiewski 
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et al., 2007b) as well as in the regulation of apoptosis (Guo et al., 2000; Markiewski et al., 2007a; 
Perianayagam et al., 2002; Riedemann et al., 2002) and cell growth (Markiewski et al., 2008). 
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Figure 1.8 Cleavage of the alpha-chain of C3 by C3 convertase leads to the release of C3a 
anaphylatoxin (Figure adapted from Wagner et al., 2010). 
 
1.5 REGULATION OF COMPLEMENT SYSTEM 
Complement is an innate immunity of the body, which is non-specific, and it can attack both 
the pathogenic or damaged tissue and healthy host tissue. Thus, the body has developed the 
complement regulators to maintain the body homeostasis, which are divided into two categories: 
fluid phase and membrane-bound complement regulatory proteins.  
Fluid phase regulators: The most well known is C1 inhibitor (C1-INH or serpin1) which 
acts as a serine protease inhibitor of the classical and lectin pathways by inhibiting C1r/s and 
MASPs, respectively.  
In addition, there are other regulators in this group eg. Factor I, Factor H, C4b-binding 
protein (C4BP), Factor H-like protein 1 (FHL1) and carboxypeptidase N. Factor I is a protease 
which help to degrade C3b and C4b. Factor H recognizes self-surfaces, accelerates convertases 
decay and acts as a cofactor for Factor I. C4BP accelerates decay of lectin and classical convertases 
and also acts as cofactor of factor I in degradation of C3b. FHL -1 is a truncated homolog of Factor 
H which accelerates convertase decay and acts as a cofactor for factor I. Carboxypeptidase-N 
degrades C3a and C5a to their inactive forms (or desArg). Factor H, FHL-1 and C4BP are 
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important for complement regulation as they serve for self-recognition and prevention of self-
damage. 
Membrane-bound regulators: Complement receptor 1 (CR1) is also known as CD35. The 
function of CD35 is to facilitate the decay of C3 and/or C5 convertase and also acts as cofactor for 
factor I and induces phagocytosis. Membrane cofactor protein (MCP; CD46) acts as a cofactor for 
factor I. Decay accelerating factor (DAF; CD55) increases the decay of C3 convertases in both 
classical and alternative pathways. CD59 (protectin) regulates of membrane attack complex (MAC) 
formation. 
 
1.6 THERAPEUTIC POTENTIAL FOR COMPLEMENT 
INHIBITORS 
Even though the complement proteins and regulators have been identified a long time ago, 
only a few complement inhibitors are developed or approved for clinical use. There is a summary of 
current complement inhibitors that approved for intervention of complement cascade on the market 
or in clinical trials (Table 1.3).  
The complement inhibitors are not important for therapeutic purpose but can be used as 
tools for physiological/pharmacological studies where the key important roles of complement is in 
in vivo models.  
Recently, the FDA approved human C1 inhibitor (Cinryze, Viro Pharma) for C1 inhibitor 
deficiency leading to hereditary angioedema (Cocchio et al., 2009; Davis, 2006) and Eculizumab 
(Alexion), which is a monoclonal antibody specific for C5. It effectively inhibits C5a and MAC 
formation. It was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) 
(Rother et al., 2007a).  
Serine protease inhibitor: As the complement activation pathway contains various serine 
proteases, it becomes one of the targets for complement-specific treatment.  Nafamostat or FUT-
175 (Futhan) is a broad spectrum, non-specific serine protease inhibitor; it can inhibit pancreatic 
and coagulation enzymes as well as complement activation (classical and alternative 
pathways)(Schwertz et al., 2008). It is currently used for the treatment of acute pancreatitis and for 
prevention of thrombosis in disseminated intravascular coagulation (DIC) and extracorporal 
circulation. No other serine proteases have been developed because of the lack of selectivity and 
short half-life (Ricklin et al., 2007). 
Complement regulator: C1 inhibitor is an inhibitor for C1r, C1s and MASP2 as well as 
factor XIIa and kallikrein in the coagulation system. Currently, it is used in the clinic only for C1 
inhibitor deficiency leading to hereditary angioedema (HAE)(Davis, 2006). HAE is an autosomal 
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disease due to the mutations and deficiency of C1 inhibitor resulting in dysregulation of kinin 
system activation. This leads to generation of bradykinin (potent vasoamine) and increased vascular 
permeability, therefore leading to the angioedema condition in HAE (Agostoni et al., 2004; Cicardi 
et al., 2005; Cugno et al., 2009). 
sCR1 or TP10 (Avant Immunotherapeutics, Needham, MA, USA) is a soluble complement 
regulator, it had a high potency in inhibiting the classical and alternative pathways which gave  
promising results in the treatment of ischemia/reperfusion injury and other conditions. TP10 was 
developed and used as a therapeutic after coronary artery bypass graft surgery. However, the 
development was discontinued in the clinical trial due to the lack of benefit in female patients (Li et 
al., 2006; Ricklin et al., 2007). 
A hybrid compound of complement regulators DAF and MCP has been developed (Sahu et 
al., 2000). The initial name was “complement activity blocker 2” (CAB2) but later entered to 
clinical trial under the name MLN-2222 which was used for the treatment of coronary artery bypass 
grafting (Sahu et al., 2000). 
Complement component inhibitor: Compstatin is a cyclic tridecapeptide, which was 
discovered by screening a phage peptide library. It’s binding to C3 and results in preventing the 
cleavage of C3 into C3a and C3b in both classical and alternative pathways. It has shown to be 
effective in various experimental disease models.  Compstatin derivatives have been developed to 
improve the potency and have also shown safety and effectively in in vivo experiments. One 
compstatin derivative under the name POT-4 (Potentia Pharmacuticals, Inc.) has completed phase I 
clinical trial for treatment of AMD.  
C5 specific antibody: Eculizumab is a monoclonal antibody (mAb) against C5, which 
effectively inhibits C5a and membrane attack complex formation (Rother et al., 2007b). It was the 
first and only approved by FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), 
which is the life-threatening disorder, characterised by a chronic lysis of red blood cells (Parker, 
2009; Rother et al., 2007b). Furthermore, it was investigated for the treatment of systemic lupus 
erythrematosus under clinical trial phase I (Robak et al., 2009).  
Pexelizumab is another C5-specific monoclonal antibody and has a short-acting effect. It is 
beneficial in reducing mortality rate after cardiopulmonary bypass surgery (Mahaffey et al., 2006). 
Neutrazumab (G2 Therapies, Darlinghurst, NSW, Australia) and TNX-558 bind to C5a and 
cause the inhibiton of C5a to its receptor. TNX-234 and TA 106 have been developed against factor 
D and factor B, respectively. 
One of the major drug targets in the complement cascade is C5a.  C5a or anaphylatoxin is a 
potent pro-inflammatory which causes many complement–associated diseases when there is 
excessive formation. Thus, the inhibition of binding of C5a to its receptor is promising to reduce the 
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undesired inflammatory response without interfering with the defensive mechanism of the 
complement system.  
Complement target Anaphylatoxins: PMX-53 is a cyclic peptidomimetic C5aR 
antagonist, which has a small molecular size (under 1 kDa) and high oral bioavailability. However, 
it has a short-half life, which may limit its use. It exerts its beneficial effect in animal studies for I/R 
injury, rheumatoid arthritis, IBD and neurodegenerative disease (Arumugam et al., 2003; Woodruff 
et al., 2006; Woodruff et al., 2005).  	  
Table 1.3 Complement inhibitors approved for intervention of complement cascade on the 
market or in clinical trials. 
Product (company) 
 
Description Mechanism of action Indication and status of 
development 
Cinryze (Viro Pharma) C1-INH, 
serping1 
concentrate 
Control of bradykinin 
generation 
Approved in US for the 
prophylaxis of HAE in 
adolescents and adults 
Cetor (Sanquin) 
 
C1-INH Inhibit C1r/C1s, control 
of bradykinin generation 
Approved for HAE and 
preclinical or phase 1 for 
other eg. AMI, CABG 
Berinert (CSL Behring, 
Lev Pharma 
C1-INH Inhibit C1r/C1s, control 
of bradykinin generation 
Approved for acute HAE in 
Europe and US 
Rhucin (Pharming) rhC1-INH Controls bradykinin 
generation 
Clinical phase 3 for HAE 
sCR1/TP10 (Avant 
Immunotherapeutics) 
Soluble 
complement 
regulator/ 
extracellular 
part of CR1 
Decay accelerator, 
Factor I cofactor 
In clinical phase 2 for 
CABG 
CAB2 or MLN-2222 
(Millenium 
Pharmaceuticals) 
Hybrid of 
DAF and 
MCP 
Decay accelerator, 
Factor I cofactor 
In clinical phase I for 
CABG 
Eculizumab (Soliris, 
Alexion Pharmaceuticals) 
C5-specific 
mAb of 
human (long 
acting) 
Block C5 cleavage Approved for PNH and 
clinical trial for other eg. 
aHUS and acute Ab-
mediated renal allograft 
rejection 
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Pexelizumab (Alexion 
Pharmaceuticals) 
mAb against 
C5 (short-
acting) 
Block C5 cleavage In clinical phase III for 
AMI and CABG 
Ofatumumab (Genmab) mAb against 
CD20 
(human) 
Stimulation of 
complement-dependent 
cytotoxicity 
In clinical trial phase II for 
treatment of RA, B-cell 
chronic lymphocytic 
leukemia and follicular 
lymphoma 
Compstatin/POT-4 
(compsatin derivative) 
(Potentia) 
Cyclic 
peptide of 13 
residues 
C3 inhibitor/ blocks the 
cleavage of C3 into C3a 
and C3b 
Completed clinical trial 
phase I for AMD 
PMX-53 (Arana) Cyclic 
hexapeptide 
C5aR antagonist Completed clinical phase II 
for RA and psoriasis  
TNX-234 (Genentech) Factor D-
specific Ab 
Block the alternative 
pathway 
In clinical phase I for AMD 
rhMBL (Enzon) Recombinant 
human  MBL 
Activated lectin 
pathway 
In clinical phase Ib for 
MBL deficiency, progenitor 
and stem cell transplant and 
liver transplant 
Nafamostat or FUT-175 
(Futhan) 
 Unspecific serine 
protease inhibitor 
(broad-spectrum) 
Used clinically for acute 
pancreatitis and prevention 
of thrombosis in DIC and 
extracorporal circulation.  
Available in Japan 
ARC1905 Aptamer-
based C5 
inhibitor 
Block the cleavage of 
C5 into C5a/C5b 
In clinical trial phase I for 
AMD (for intravitreal 
application) 
HAE, hereditary angioedema; AMI, acute myocardial infarction; AMD, age-related macular 
degeneration; CABG, coronary artery bypass grafting; PNH, paroxysmal nocturnal 
nemoglobinuria; RA, rheumatoid arthritis; DIC, disseminated intravascular coagulation, mAB, 
monoclonal antibody; MBL, mannose binding lectin, aHUS, atypical haemolytic uremic syndrome. 
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1.7 C3a ANAPHYLATOXIN 
1.7.1 STRUCTURE OF ANAPHYLATOXIN C3a 
The anaphylatoxins C3a, C4a and C5a are pro-inflammatory 74 - 77 residue bioactive 
peptide fragments (~9 kDa) cleaved from the serum proteins C3, C4, and C5 during activation of 
the complement cascade. The C3 convertase cleaves C3 into small C3a and large C3b fragments. 
C3a is a small protein of 77 amino acid residues. The amino acid sequences of C3a of human, pig 
and rat origin are known and show extensive homology (Huber et al., 1980; Hugli, 1990). 
Anaphylatoxins consist of a globular core of four anti-parallel α-helices stabilized by three 
intra-chain disulfide bonds (Figure 1.9 and 1.10). The N-terminus of the protein is responsible for 
conferring affinity to anaphylatoxins for their receptors, while the C-terminal pentapeptide 
(LGLAR in C3a and MQLGR in C5a) plays an important role in activating the receptors 
(Gerardyschahn et al., 1989; Hugli, 1986; Muller-Eberhard, 1988).  
 
 
 
 
 
 
Figure 1.9 Crystal Structure of C3a. The human C3a consists an N-terminal domain intra-
connected by three disulfide bonds (Cys22-Cys49, Cys23-Cys56 and Cys36-Cys57) and a helical 
C-terminal domain (Figure adapted from Huber et al., 1980). 	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Figure 1.10 Complement anaphylatoxin sequences.  Cysteines in the three-disulfide bonds are 
conserved and boxed above. Sequence homology of C3a, C4a and C5a shows common residues in 
C3a, C4a and C5a in black, common residues to C3a and C5a in blue, common residues to C3a and 
C4a in red and common residues to C4a and C5a in green (permission from Blakeney, 2007). 	  	  
1.7.2 PHYSIOLOGY OF ANAPHYLATOXIN C3a 
The lifetime of C3a and C5a in vivo is limited by carboxypeptidase-N (Bokisch et al., 1970; 
Campbell et al., 2002; Ember et al., 1997), which cleaves off the carboxy terminal arginine residue 
from both C3a and C5a leading to the desArg derivatives. C5a-desArg still binds the C5aR but 
retains only 1-10% of C5a’s anaphylactic activity, whereas C3a-desArg loses its ability to bind to 
C3aR and is thus inactive. In addition, C3a desArg and acylation-stimulating protein (ASP) are 
identical and also they are identical to C3a except for missing the arginine at the C-terminal. 
Recently, it was reported that ASP has potent anabolic effects on human adipose tissue where it 
stimulate glucose uptake, fatty acid storage (Cianflone et al., 1999; Cianflone et al., 2003; Murray 
et al., 1999; Xia et al., 2004) and triglyceride synthesis by binding to C5L2 receptor (Kalant et al., 
2005).  
C3a, C4a and C5a anaphylatoxins share a high degree of homology as well as overlapping 
functions in the generation of an inflammatory response.  C3a and C5a are expressed on the same 
cells, such as leukocytes and non-myeloid cells (endothelial and epithelial cells).  
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C3a and C5a are known for their stimulatory effects on leukocytes, including chemotaxis of 
neutrophils, eosinophils, monocytes/macrophage and mast cells (Daffern et al., 1995; Fernandez et 
al., 1978; Hugli, 1986; Hugli, 1990; Hugli, 1984). However, C5a is a more powerful chemo-
attractant than C3a; the predominance of C3a in the induction of chemotaxis is only on eosinophils 
and mast cells but not on neutrophils (Daffern et al., 1995; Hartmann et al., 1997). In a previous 
report, C3a activation caused release of effectors from eosinophils which in turn activate 
neutrophils (Daffern et al., 1995). C3a can stimulate the release of serotonin from guinea pig 
platelets (Fukuoka et al., 1988), modulate synthesis of IL-6 and TNF-α by B-lymphocytes and 
monocytes (Fischer et al., 1997; Fischer et al., 1999), and also stimulate the release of interleukin-1 
(IL-1) from monocytes (Haeffnercavaillon et al., 1987) as summarised in Table 1.4.  
The anaphylatoxic effect is due to the activation of anaphylatoxin receptors on mast cells and 
basophils leading to the degranulation and release of histamine and other vasoactive or 
inflammatory mediators, such as arachidonic acid metabolites (prostaglandins, leukotrienes, 
lipoxins), lipid mediators (platelet-activating factor) and the nucleoside adenosine (Ember et al., 
1998; Frank, 1997; Hugli, 1986; Muller-Eberhard, 1988; Volanakis et al., 1998). C3a also induces 
the release of reactive oxygen species in human eosinophils (Elsner et al., 1994a) as seen in Table 
1.4.  Furthermore, anaphylatoxins can cause smooth muscle contraction i.e. bronchial, intestinal and 
uterine smooth muscle (Hugli et al., 1975), increased vasopermeability (Cochrane et al., 1968; 
Vallota et al., 1973; Wuepper et al., 1972), vasodilation, release of cytokines and pro-inflammatory  
mediators and induce mucous secretion from globlet cells (Hartmann et al., 1997; Klos et al., 1992; 
Norgauer et al., 1993), bronchial, gastric and intestinal epithelial cells. When macrophages are 
exposed to C3a, they release interleukin-1 (Becker et al., 1978) and thromboxane A2 (Zanker et al., 
1982).  
 
1.7.3 PATHOLOGY OF ANAPHYLATOXIN C3a 
C3a has been implicated in allergic bronchospasm and pulmonary inflammation when C3a is 
administered via intrabronchial instillation (Hoffmann et al., 1988; Stimler et al., 1980). There is 
some evidence for an implied role for C3a in allergic asthma: a) there is abolition of airway hyper-
reactivity in mice lacking C3 or C3aR (Humbles et al., 2000); b) in ovalbumin-sensitized and –
challenged mice, the C3 and C3aR proteins are up-regulated (Drouin, 2001); c) in bronchoalveolar 
lavage fluid and serum of asthmatics challenged by allergens there were increased levels of C3a. 
There are also some new roles for C3a and C5a, other than immune functions, such as 
increasing prostanoid formation and glucose output in perfused rat liver (Puschel et al., 1993; 
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Puschel et al., 1996). Recently, the study has shown that signalling through C3aR positively 
regulates basal neurogenesis and C3 difficient mice have impaired ischaemia-induced neurogenesis 
despite a large infarct area (Rahpeymai et al., 2006). In addition, C3a and C5a have been shown to 
protect neuronal cells against excitotoxicity (Osaka et al., 1999; Pasinetti et al., 1996; van Beek et 
al., 2001). 
Anaphylatoxins contribute to inflammatory responses that lead to elimination of invading 
pathogens or induction of adaptive immunity.  Genetic deficiency of either C3 or C5 results in 
susceptibility to bacterial infection. The anaphylatoxins are associated with all types of 
inflammation. However, when in excess they can be harmful and play roles in pathogenesis of 
many disease conditions (Table 1.5), such as anaphylaxis, adult respiratory distress syndrome 
(ARDS)(Zilow et al., 1990), acute transplant rejection, ischemia reperfusion, sepsis (Drouin, 2001), 
brain inflammation and many autoimmune diseases; for example, psoriasis, atopic dermatitis (Kapp 
et al., 1985b), rheumatoid arthritis, and systemic lupus erythematosus (SLE) (Clancy, 2000; 
Volanakis et al., 1998), to name just a few. Therefore, effective antagonists for these anaphylatoxin 
receptors could be potential treatments for various inflammatory diseases. 
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Table 1.4  Functional activity of C3a on myeloid and non-myeloid cells. 
      
Cell type 
 
Activity Reference 
Eosinophils 
 
Activates chemotaxis 
Degranulation 
Activates reactive oxygen radical species 
production 
Mobilisation of [Ca2+]i 
(Daffern et al., 1995) 
(Takafuji et al., 1994)        
(Elsner et al., 1994a) 
 
(Elsner et al., 1994a) 
Mast cells Chemotaxis (most effective) 
Degranulation and histamine release (except 
for lung mast cells).  
This is PTX sensitive 
(Nilsson et al., 1996) 
(Ellati et al., 1994; Mousli et al., 1992; Nilsson 
et al., 1996) 
(Zwirner et al., 1997) 
Neutrophils Induces release of lysosomal enzyme 
Induces production of reactive oxygen species 
Induces transient aggregation 
(Showell et al., 1982) 
(Elsner et al., 1994b) 
(Nagata et al., 1987a; Nagata et al., 1987b) 
Monocytes/ 
Macrophages 
Induces release of PGE2  
Modulates pro-inflammatory cytokines (TNFα 
& IL-1β) in LPS-stimulated adherent 
monocytes at local inflammation sites (also 
C3adesArg) 
Modulates synthesis of IL-6 (as well as C3a- 
desArg) and TNF-α by B-lymphocytes and 
monocytes 
Releases [Ca2+] and is sensitive to PTX (but not 
increased intracellular [Ca2+] with stimulation 
by C3adesArg) 
(Morgan, 1987) 
(Takabayashi et al., 1996) 
 
 
 
(Fischer et al., 1997; Fischer et al., 1999; 
Takabayashi et al., 1998; Zwirner et al., 1997) 
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Basophils Stimulates histamine and leukotriene release 
dependent on presence of IL-3 
(Bischoff et al., 1990)  
T-cells Mediates T cell suppression, overcome by IL-2 (Morgan et al., 1985) 
B-cells Suppresses IL-6 and TNF-α (Fischer et al., 1997) 
Platelets Induces aggregation and serotonin release (Damerau et al., 1986; Polley et al., 1983)  
Natural killer cells Inhibits activity of NK cells (Charriaut et al., 1982) 
Skin fibroblast and 
adipocytes 
Increases triglyceride synthesis  
Glucose transport  (C3adesArg) 
(Baldo et al., 1993; Esterbauer et al., 1999)  
Epithelial cells Up-regulates interleukin-8 (IL-8) which can be 
inhibited by pertussis toxin 
(Monsinjon et al., 2001)  
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Table 1.5 Roles for C3a in diseases.   
 
Organ/ 
System 
Condition/disease C3a 
levels 
Details Reference 
Asthma  
 
 
↑ In asthma exacerbation, C3a and C5a were shown to promote smooth muscle cell contraction, 
mucus hypersecretion and recruitment and degranulation of inflammatory cells. Genetic deletion 
of C3aR mice was protected against the bronchoconstriction and airway hyper-responsiveness 
after allergen challenge. 
In mild asthma a significant increase of C3a and C5a was found in BAL fluid after allergen 
challenge. C3a can stimulate the release of histamine and leukotrienes from basophils and mast 
cells as well as regulate synthesis of eosinophil cationic protein (ECP) by eosinophils.  
(Bautsch et al., 2000; 
Humbles et al., 2000; 
Krug et al., 2001; Mousli 
et al., 1992; Takafuji et 
al., 1994)  
Ovalbumin-induced 
asthma 
 
↑ Up-regulation of C3aR on bronchial smooth muscle cells increases airway resistance. C3a is 
involved in early and late phases of asthma and is also involved in generating Th2 response in 
asthma.  
(Bautsch et al., 2000; 
Drouin et al., 2002; 
Drouin et al., 2001; 
Humbles et al., 2000; 
Kohl, 2001) 
Adult respiratory distress 
syndrome 
↑ The C3a: C3 ratio is a useful laboratory parameter for assessing and monitoring patients at risk 
for ARDS. C3a increase during the first few hours correlates with the development of ARDS in 
poly trauma patients. The complement activation in the early phase occurs predominantly via the 
alternative pathway. 
(Zilow et al., 1990) 
Respiratory  
Chronic Obstructive 
Pulmonary disease 
↔ There was no significant difference in C3a/C3a desArg or C4a/C4a desArg measurements 
between patients with COPD, asthma, and healthy. 
(Marc et al., 2004) 
Psoriatic lesion ↑ C3a levels were significantly increased which suggests that there is a continuous activation of the 
complement system leading to the generation of inflammatory mediators. 
(Kapp et al., 1985b) 
Atopic Dermatitis ↑ Circulating T cells from patients suffering from severe inflammatory skin diseases expressed 
C3aR whereas no expression of C3aR could be found in unstimulated T lymphocytes from mild 
inflammatory skin disease patients or healthy. C3a-C3aR interactions play a role in AD. 
(Kawamoto et al., 2004; 
Werfel et al., 2000)  
Leukocytoclastic 
vasculitis 
↑ Increase in C3a and C4a. (Terui et al., 1987) 
Skin 
Eczematous dermatitis 
and papuloerythroderma 
↑ Increase in C3a but not C4a indicated alternative pathway activation and delayed type 
hypersensitivity reactions are thought to be responsible for the induction of skin changes in these 
skin diseases. 
(Terui et al., 1987) 
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Myocardial reperfusion  Sequestration of C3a des-Arg in coronary circulation. (Semb et al., 1990) 
Preeclampsia ↑ Elevated levels of C3a and C5a in preeclampsial pregnant women. (Haeger et al., 1989; 
Haeger et al., 1991)  
Atherosclerosis 
 
↑ C3a induces changes in biophysical characteristics of fibrin networks, thinner fibres with 
increased tensile strength, which become less permeable. Complement activation (↑C3a) induces 
major changes in fibrin structure, which in turn can induce further activation of the complement 
system. The positive feedback system may play an important role in establishing a fibrin 
infrastructure responsible for the progression of atherosclerosis. 
(Oksjoki et al., 2007; 
Shatstseytlina et al., 
1994)  
Endotoxemia 
 
↑ Increase Up-regulation of C3aR (Drouin, 2001) 
Sepsis 
 
↑ Up-regulation of C3aR on bronchial epithelial, alveolar epithelial, pulmonary blood vessel and 
bronchial smooth muscles. Absence of the C3aR leads to increased susceptibility to LPS 
treatment thereby indicating anti-inflammatory effects of the C3a-C3aR interaction. 
(Drouin, 2001; 
Kildsgaard et al., 2000; 
Kohl, 2001)  
Cardio-
vascular 
Anaphylaxis ↑ C3a caused bronchoconstriction and hypotension, which occurs from release of histamine from 
mast cells and basophils. In contrast, C5a caused bronchoconstriction, which was independent of 
histamine and dependent on products of arachidonate metabolism. 
(Regal, 1997) 
Henoch-Schonlein 
nephritis 
↑ C3a levels correlate with plasma creatinine level, therefore are sensitive indicators of the disease. (Abouragheb et al., 
1992) 
IgA nephropathy ↑ Elevated C3a levels (Janssen et al., 2000)  
Urinary 
system 
 
 Lupus nephritis 
 
↑ C3aR was detected in glomerulus of lupus-nephritis patients and the intensity of C3aR correlated 
with disease severity. C3aR may be used as a unique biomaker of diagnosis and progress of 
disease in lupus nephritis.  
(Mizuno et al., 2007) 
Eosinophil-derived 
neurotoxin 
 
 C3a is a potent inducer. (Kohl, 2001) 
Astocytoma cells 
stimulated by C3a 
↑ Induced an increase in the IL-6 mRNA level which can be completely blocked by pertussis toxin 
or polyclonal anti-C3aR antibody. 
(Sayah et al., 1999)  
Brain 
Experiment allergic 
encephalomyelitis 
 Inhibition of complement activation is protective against EAE, an experimental model of MS. 
C3-derived biologically active fragments play important role in the pathophysiology of 
complement in EAE, rather than C5 and the MAC. 
(Barnum, 2002; Barnum 
et al., 2006) 
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Lyme neuroborreliosis ↑ The intrathecal levels of C3a and C1q are increased in neuroborreliosis.  C3a measurement in 
CFS could be used as a clinical marker to identify the patients at risk of developing chronic 
neuroborreliosis. 
(Ekdahl et al., 2007)  
Alzheimer’s disease ↑ Elevated levels of C3a in CSF  
 
 
(Loeffler et al., 1996) 
Liver disease and 
orthotopic liver 
transplant 
↑ Elevated C3a levels. There is significant correlation between high concentration of C3a and 
development of profound hypotension. 
(Ronholm et al., 1994) 
Acute pancreatitis 
 
↑ The plasma level of complement C3a and C5b-9 measured daily during the first week after onset 
of symptoms represent highly specific and sensitive parameters for the prediction of severe acute 
pancreatitis.  C3a is a product from pancreatic enzyme, trypsin cleavage and causes the 
chemotaxis of neutrophils and subsequent lung sequestration. 
(Acioli et al., 1997; 
Gloor et al., 2003) 
Hepatic & 
pancreas 
Chronic hepatitis C and 
Hepatitis C virus-related 
hepatocellular carcinoma 
↑ C3a was elevated in patients with chronic hepatitis C and HCV-related HCC but not in HBV-
related HCC. The complement C3a is a potential low-molecular weight serum marker associated 
with chronic hepatitis C and HCV-related HCC. 
(Lee et al., 2006) 
Joint & Bone 
 
Rheumatoid arthritis ↑ The plasma levels of C3a in patients with rheumatoid arthritis are twice those of the normal 
control, and the levels are positively correlated with disease activity. 
(Moxley et al., 1987) 
Chronic otitis media ↑↑ Highly elevated C3a levels indicate ongoing complement activation and contribute to chemotactic 
and inflammatory potential in middle-ear effusion and correlate with the chronicity of the disease. 
(Narkio-Makela et al., 
2000) 
Colorectal tumors ↑ Complement C3a desArg appears in significantly higher levels in the serum of patients with 
colorectal adenomas and carcinoma than those without. 
(Habermann et al., 2006)  
Active systemic lupus 
erythematosus 
↑ The elevated levels of the complement split product C3a desArg is significantly characterised in 
patients with active disease. 
(Belmont et al., 1994) 
HIV ↑ Elevated C3a levels.  
Others 
Antifungal ↑ C3a exerts antimicrobial effects against the yeast Candida. Arginine residues were found to be 
critical for the antifungal and membrane breaking activity of the C3a-derived antimicrobial 
peptide, CNY21(C3a; Cys57- Arg77). 
(Sonesson et al., 2007)  
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1.8 RECEPTORS FOR C3a  
1.8.1 C3a RECEPTORS 
The receptor (C3aR) for the anaphylatoxin C3a was discovered in 1996 (Ames et al., 1996) 
through cDNA analysis of human neutrophils. It was also found that 37% of the nucleotides were 
identical to those of the C5a receptor (CD88) (Ames et al., 1996). C3aR exists on human 
chromosome band 12q13.2-3 (Paral, 1998) and belongs to the rhodopsin superfamily of G-protein 
coupled receptors (Gerard et al., 1994). It has seven transmembrane helices and 482 amino acids 
characterized by the presence of an extraordinarily large second extracellular loop (172 amino 
acids) between transmembrane helices 4 and 5 (Figure 1.11 and 1.13) (Ames et al., 1996; Crass et 
al., 1996; Roglic et al., 1996). The major unique feature of C3aR compared to other rhodopsin 
receptors is this very large extracellular loop (EC2), which has been postulated to contain some or 
all of the structural determinants for C3a binding (Ember et al., 1997). The cloning of C3a receptor 
from four species, human (Ames et al., 1996), mouse (Hsu et al., 1997; Tornetta et al., 1997), rat 
(Fukuoka et al., 1998) and guinea pig (Ember et al., 1998) confirmed the presence of a large second 
extracellular loop (Figures 1.14). 
 
 
 
 
Figure 1.11 C3aR with extracellular (EC) and intracellular (IC) loops and the helical 
transmembrane domains (TM) numbered. (Figure adapted from Chao et al., 1999). 
 
 
Another receptor C5L2 which binds to C5a and C5a desArg is also known to bind to human 
C3a desArg (Kalant et al., 2003). However, it is uncertain whether C3a and C3a desArg serve as 
ligands for C5L2 as conflicting data have been produced from different laboratories. There is a 
study showing that C5L2 negatively regulates inflammation response in a C5L2 knock-out mice 
model (Gao et al., 2005). 
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1.8.2 BINDING SITES OF C3a-C3aR 
In a recent study (Chao et al., 1999; Sun et al., 1999) of chimeric C3aR/C5aR and loop 
deletion in C3aR, it was shown that the large second extracellular loop sequences adjacent to the 
transmembrane domain contain multiple aspartate residues which play an important role in non-
effector ligand binding and also support a two-site C3a-C3aR interaction model, similar to that 
proposed (Chenoweth et al., 1980) for C5a-C5aR interaction. Furthermore, sulfation of a tyrosine at 
position 174 in the extracellular loop 2 plays an important role in the binding of C3a (Gao et al., 
2003). The anionic residues near the N and C-termini of the C3aR second extracellular loop 
constitute a high affinity “non-effector site” (Site 1) interaction with cationic residues in the C-
terminal helical region of C3a, whereas residues of the C3a C-terminal sequence LGLAR interact 
with the low affinity “effector site” (Site 2) in C3aR (as shown in Figure 1.12)(Chao et al., 1999).  
 
(A). C3a/C3aR (B). C5a/C5aR 
 
 
 
 
 
 
Figure 1.12 Interaction between C3a or C5a and their respective receptors.   (A). C3a has a 
non-effector binding site (Site 1) along the C-terminal helical region that contacts the EC2 and the 
N-terminal region. Site 2 is the “effector binding site” which binds to the C-terminal LGLAR in the 
“pore” of C3aR. This model for C3a/C3aR interaction corresponds to a model originally proposed 
for multi-site binding of C5a with its receptor (Chenoweth et al., 1980) shown in  (B) (Ember et al., 
1998).  
 
 
From a mutation study of C3aR, it was found that removal of the N-terminus of the receptor 
does not affect the affinity of C3a for its receptor (Crass et al., 1999), but substitution of the second 
extracellular loop (EC2) causes changes in its affinity and activity. However, studies show removal 
of 65% of the amino acids between 198-308 of human C3aR does not affect C3a affinity and 
activity (Chao et al., 1999). The removal of residues 174-183 of hC3aR EC2 was found to cause  
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loss of function in the receptor. When residues 184-198 and after residue 308 were deleted it was 
found the affinity of C3a for its receptor was significantly reduced (Chao et al., 1999) which 
implicates these receptor regions in C3a binding.  Mutation of negatively charged residues aspartic 
acids 325, 326, and 367 by lysine in the upper transmembrane region of hC3aR resulted in a six-
fold decrease in C3a affinity and a 14-fold decrease in calcium mobilisation, indicating a role in 
binding and activation. Aspartic acid mutations D183K/D186K caused a 4-fold decrease in affinity 
and a 40-fold decrease in calcium mobilisation (Chao et al., 1999). 
1.8.3 SIGNALLING PATHWAY ASSOCIATED WITH C3a-C3aR 
The binding of C3a to the C3a receptor results in an increase in cytosolic Ca2+ levels through 
the activation of pertussis toxin (PTX) sensitive G proteins (Elsner et al., 1994a; Klos et al., 1992; 
Norgauer et al., 1993; Zwirner et al., 1997), and activation of phospholipase C. In neutrophils, Klos 
et al. (1992) reported that C3a is similar to C5a in stimulating the formation of 1,4,5-triphosphates 
(IP3) and stimulates Ca2+ release from intracellular stores of neutrophils. In contrast, the study by 
Norgauer et al. (1993) showed that C3a does not stimulate phosphatidylinositol biphosphate 3-
kinase but stimulates different signalling pathways from C5a and it does not stimulate calcium 
mobilisation from intracellular stores like C5a. However, C3a activates pertussis toxin sensitive G-
protein and triggers the influx of extracellular Ca2+.  Nilsson et al.(1996) also reported that C3a and 
C5a are coupled to Gi receptors in signal transduction pathways of human mast cell line HMC-1. 
Both C3a and C5a are potent chemotaxins in this cell line and showed that they activated mast cells 
through their specific receptor with no cross stimulation. Results from competitive binding and 
desensitisation studies are consistent with a unique receptor for C3a (and its analogues) that is 
distinct from the receptor for C5a (Burg et al., 1996; Klos et al., 1992; Zwirner et al., 1997). To 
date, there is limited information on the signalling from C3a-C3aR stimulation. In contrast, the 
signalling cascade of C5aR is well defined.  
In leukocytes, C3aR and C5aR couple to Gαi (Buhl et al., 1995; Norgauer et al., 1993; Vanek 
et al., 1994; Zwirner et al., 1997) and Gα16, which are not inhibited by pertussis toxin (Crass et al., 
1996; Ha et al., 2000; Yang et al., 2001). Since there is abundant Gαi expressed in leukocytes and 
Gα16 are found only expressed in human cells of hemopoietic lineage (Amatruda et al., 1991), G 
protein coupling appears to vary for different cell types, for example C3aR on endothelial cell was 
not coupling to Gαi (Schraufstatter et al., 2002). 
In astrocytes, the stimulation of C3aR and C5aR by the binding of C3a and C5a to their 
receptors lead to the activation of mitogen activated protein kinase (MAPK) pathway by 
phosphorylation of the p44 and p42 kinases, which mediated the signal through pertussis-sensitive  
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G-protein. The activation of MAPK pathway could induce the cytokines mRNA expression by C3a 
and C5a in astrocytes. MAPKs p42 and p44 function plays an important role in the regulation of 
cell growth and differentiation (Hill et al., 1995; Hunter, 1995; Marshall, 1995). This study also 
reported that the anaphylatoxins stimulate the activation of phospholipase C (PLC) and generation 
of IP3 which leads to the release of calcium from intracellular storage, by showing the result of 
significantly decreasing anaphylatoxin-induced IL-6 mRNA after pre-incubating of astrocytes with 
PLC-inhibitor (U-73122). Thus, the activated PLC pathway could lead to the activation of 
astrocytes by the stimulation of C3a and C5a. In contrast, the binding of C3a and C5a to their 
receptors on astrocyte cells showed inhibition of the adenylyl cyclase pathway by decreasing cAMP 
levels after activation of the cells with forskolin (Sayah et al., 2003). 
In the study of human umbilical vein endothelial cells (HUVEC), C3a caused a strong up-
regulation of IL-8, IL-1β, and RANTES (Regulated upon Activation, Normal T cell Expressed and 
Secreted) mRNA in a time and dose-dependent manner. This was inhibited by pre-treatment with 
anti-receptor antibodies and pertussis toxin (PTX), supporting the involvement of a Gi-protein 
coupled signalling pathway in C3a receptor activation (Monsinjon et al., 2003).  In contrast, a study 
by Schraufstatter and colleagues (2002) reported that actin reorganization induced by C3a on 
endothelial cells was not pertussis toxin sensitive but depended on Rho activation, which possibly 
involves signalling through Gα12 and/or Gα13 proteins. In monocytes or peripheral blood 
mononuclear cells (PBMC), C3a- and C5a- induced cytokine gene (including IL-1β, IL-6, IL-8 and 
TNFα) expression is likely the result of G-protein coupled NF-κB activation and in both C3a- and 
C5a-induced NF-κB activation in monocyte cells can be inhibited by pertussis toxin, indicating that 
C5aR and C3aR may couple to Gi for this function (Pan, 1998). 
Recently Schraufstatter et al. (2009) in mesenchymal stem cells (MSCs), showed that C3a 
and C5a induce prolonged and powerful ERK1/2 and Akt phosphorylation. Subsequent to the 
stimulation, phospho-ERK1/2 was translocated to the nucleus causing the phosphorylation of the 
transcription factor Elk that has not been described for other cells. Additionally, the stimulation of 
C3aR by C3a in MSCs caused the translocation of C3aR to the nucleus. Nuclear translocation of 
C3aR has been suggested as the event that could lead to long-term effects such as nuclear ERK 
phosphorylation (Lu et al., 1998), transcriptional activation (Moughal et al., 2004), cell 
proliferation and differentiation (Gobeil et al., 2003; Gobeil et al., 2006; Goetzl, 2007). C3aR and 
C5aR are expressed on the cell surface of MSCs and both anaphylatoxins (C3a and C5a) are 
chemo-attractant for human bone marrow-derived MSCs. C3aR and C5aR mediate their chemotatic 
response in a guanine nucleotide-binding protein (Gi) activation-dependent fashion. 
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.	    
Figure 1.13 Homology modelling of C3aR (generated by Dr Praveen Kumar Madala, Fairlie 
group, University of Queensland).  	  
1.8.4 C3a RECEPTOR DISTRIBUTION 
C3aR is expressed on a variety of cells in the periphery and central nervous system (Ames et 
al., 2001; Ames et al., 1996; Crass et al., 1996). By using antibodies, which bind the second 
extracellular domain of the C3aR, expression has been demonstrated on myeloid lineage such as 
neutrophils, eosinophils, basophils, mast cells and monocytes/macrophages (Ames et al., 1996; 
Crass et al., 1996; Hugli, 1986; Muller-Eberhard, 1988; Volanakis et al., 1998). In the study by 
Zwirner and colleagues (1997) using monoclonal antibodies it was shown that the numbers of C3aR 
molecules per cell in eosinophils and basophils are similar to the C5aR population. In monocytes, 6 
times more C5aR than C3aR is expressed. On neutrophils the expression of C5aR is 20 times higher 
than the expression of C3aR, which suggests that eosinophils and basophils are the primary effector 
cells in peripheral blood for C3a stimulation.  Furthermore, the myelomonocyte U937 and 
myeloblastic HL-60 cell lines express C3aRs when differentiated to a more mature phenotype by 
treatment with dibutyryl cyclic adenosine monophosphate (Klos et al., 1992). C3aR also exists on 
epithelial cells (Monsinjon et al., 2001), adrenal cortex, lung, human astrocyte cell line, human fetal 
astrocytes and microglia (Gasque et al., 1998; Ischenko et al., 1998). In the central nervous system 
(CNS), C3aR expression was found in neurons, especially in cortical and hippocampal neurons, and 
in glial cells (Davoust et al., 1999). In studies of C3aR in other species such as mice, an abundance 
of these receptors was found in heart and lung tissues (Tornetta et al., 1997).  
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Figure 1.14 Comparison of the EC2 loop sequences of C3a receptors from human (Hu), 
guinea pig (Gp), rat (Rt), and mouse (Mo)(Modified from Chao et al., 1999). 	  
1.9 CURRENT SMALL C3a PEPTIDE LIGANDS FOR C3aR  
1.9.1 AGONISTS 
The C-terminal sequence LGLAR (Figure 1.15 A) of C3a, including the guanidine and 
carboxyl groups of the arginine, is known to be important for biological activity (Caporale et al., 
1980). This conclusion is supported by a previous study in which removal of the C-terminal amino 
acid arginine by carboxypeptidase B digestion leads to abolition of the tissue contractile activity 
(Bokisch et al., 1970). This was due to the lack of specific binding to receptors.  
A synthetic 21-residue C terminal fragment of C3a (C3a 57-77) was found to effect biological 
activities equipotent to that of C3a 1-77 (Caporale et al., 1980; Lu et al., 1984).  This 21-residue C-
terminal peptide of C3a was shown to exhibit a partial helical conformation in trifluoroethanol        
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(a helix favouring solvent) and when substituted with residues that disrupt helix formation, showed 
less potency than when substituted with helix-promoting residues (Hoeprich et al., 1986). This 
suggested that a helical conformation may contribute to the higher potency of the C3a 21-residue 
analogue (Lu et al., 1984). 
The pentapeptide LGLAR (C3a 73-77) was found to be the minimal sequence which shows 
C3a-specific activity (Caporale et al., 1980), albeit with a very low biological potency, much lower 
than for the native C3a protein itself (Caporale et al., 1980). This pentapeptide is highly conserved 
in human, cows, rat, mouse and guinea pig C3a (Hugli, 1990). When LGLAR was further shortened 
to LAR, it retained some activity if joined at the N-terminus to a synthetic group such as 9-
fluorenylmethoxycarbonyl (Fmoc) or the 6-aminohexanoic acid (Ahx) (Kohl et al., 1990). This 
finding suggested that the hydrophobic region at the N-terminus helps to insert the effector 
sequence LAR into the transmembrane pocket (Kohl et al., 1990). The study by GerardySchahn and 
colleagues (1988) reports that LALAR had 3 times the activity of LGLAR. KÖhl and collegues 
discovered that the substitution of L-arginine by D-arginine at position 77 in C3a (or by other 
positively charged amino acids) terminated C3a activity, showing that both stereospecific and 
charge properties are important for binding (Kohl et al., 1990).  In 1991, Ember and colleagues 
synthesised an analogue of C3a, consisting of a 15-residue peptide with a hydrophobic N-terminus, 
WWGKKYRASKLGLAR (the bold residues differ from human C3a, Figure 1.15 B and Table 
1.7).  This peptide, comparable to residues 63-77 of human C3a, was found to be 12-15 times more 
active than natural C3a and was thus called a ‘superagonist’. They suggested that the hydrophobic 
N-terminus interacts with a secondary binding site, while the effector unit  (LGLAR) interacts with 
the primary binding site. This superagonist activity has since been discredited in the literature 
(Ames et al., 1997; Chao et al., 1999; Ischenko et al., 1998; Sun et al., 1999) and by our group 
(Blakeney, 2007). 
Jinsmaa and colleagues (2001) designed the C3a peptide agonist, Trp-Pro-Leu-Pro-Arg, 
which they claim showed anti-analgesic and anti-amnesic effects.  
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Figure 1.15 A. C-terminal pentapeptide sequence L73GLAR77 that is important for activation 
of C3aR (Caporale et al., 1980; Sun et al., 1999). B. C3a Superagonist (Ember et al., 1991). 	  	  
1.9.2 ANTAGONISTS 
There is very little known about C3aR antagonism. Recently, Ames et al. (2001) reported N2-
[2,2-diphenylethoxy)acetyl]-L-arginine (SB290157, Figure 1.16 a) as a C3aR antagonist. This 
arginine analogue was shown to compete with 125I-C3a radioligand binding in RBL cells (IC50 200 
nM), as well as inhibiting C3a-induced calcium mobilisation in RBL cells and in human neutrophils 
(IC50 ~ 28 nM). SB290157 also inhibits chemotaxis of HMC-1 cells and ATP-release from guinea 
pig platelets (Ames et al., 2001). It was also found to be active in two animal models of 
inflammation: firstly, a guinea pig LPS-induced lung neutrophilia model and secondly, a rat 
adjuvant-induced arthritis model (Ames et al., 2001). There are a number of studies both in vivo and 
in vitro in which SB290157 has been used (summarised in Table 1.6) (Baelder et al., 2005; Godau 
et al., 2004; Mollnes et al., 2002b; Proctor et al., 2004; Ratajczak et al., 2004). These studies report 
some unexpected results, which may be caused by non related-C3aR antagonism activities of this 
compound (Baelder et al., 2005; Proctor et al., 2004). Recently, Mathieu et al. (2005) showed that 
SB290157 has full agonist activity on C3aR in a variety of cell assays, such as calcium mobilisation 
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assay in transfected RBL cells, a beta-lactamase assay in CHO-NFAT-bla-Gα16 cells, and an 
enzyme release assay in differentiated U937 cells. However, the compound lacks agonist activity in  
guinea pig platelets, which have a low level of C3aR expression. A second non-peptidic C3aR 
antagonist was reported by Grant et al.(2001), 1,3-diiminoisoindoline (Figure 1.16 b) has low 
affinity for C3aR (IC50 1.7 µM). In addition, it showed antagonist activity in calcium mobilisation 
with IC50 2 µM. Denonne et al.(2007b) reported from SAR studies modification of SB290157 at the 
linker region (Figure 1.16 c) which has a higher affinity for C3aR (pIC50 = 7.2 vs 20 pM [125I]-C3a) 
due to its rigid linker. 
However, SB290157 and the SB290157 modified compound, which both have an arginine 
group, have low availability and short half-life. Another SB290157 modified compound is reported 
from the same group (Denonne et al., 2007a) but without arginine at the C-terminal (Figure 1.16 
d). This binds to C3aR with pIC50=5.8. 
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Figure 1.16 Structures of C3aR antagonists (Ames et al., 2001; Denonne et al., 2007a; Denonne 
et al., 2007b).  
 
 
 
CHAPTER	  1	   	   	   Peptide-Activated G-protein Coupled Receptors:- Complement C3aR 
 40 
 
 
 
Table 1.6 Summary of SB290157 used in animal models. 
Condition/disease Model Description Reference 
Lung inflammation a guinea pig LPS-induced 
lung neutrophilia model 
 (Ames et al., 
2001) 
Arthritis a rat adjuvant-induced 
arthritis model 
 (Ames et al., 
2001) 
I/R injury A rat model of intestine I/R 
injury 
SB290157 does not 
show the anti-
inflammatory 
property in this model 
 
(Proctor et al., 
2004) 
I/R injury Mice were induced middle 
cerebral artery occlusion  
Administration of 
SB290157 reduced 
inflammation and 
cerebral damage after 
I/R injury 
(Ducruet et al., 
2008) 
Lupus nephritis A MRL/lpr lupus mouse 
model (share many 
characteristics of human 
SLE) 
SB290157 reduces 
the mortality rate in 
this model 
(Bao et al., 2005) 
Allergic asthma A murine model of 
Aspergillus fumigatus 
extract induced pulmonary 
allergy 
SB290157 does not 
improved AHR 
during the effector 
phase of AHR 
(Baelder et al., 
2005) 
Acute Respiratory 
distress syndrome  
Intravenous infusion of 
CVF rat model 
SB290157 inhibited 
the CVF-induced 
hypertensive response 
(Proctor et al., 
2006) 
Hemodynamic effect Rat model to verify the 
hemodynamic activities of 
C3a, C5a, C3a linear 
peptide, indomethacin and 
SB290157 
SB290157 
significantly reduced 
the hypertensive 
response of C3a 
agonist stimulation 
(Proctor et al., 
2009) 
SLE, systemic lupus erythematosus; I/R, ischemia-reperfusion; CVF, cobra venom factor; AHR, 
airway hyperresponsiveness; MRL/lpr is an abbreviation of  MRL/Mp-Tnfrsf lpr/lpr (mouse model of 
human SLE). 
 
 
Further studies are needed to identify more potent and selective C3aR antagonists for use in 
defining the physiological/pharmacological roles of C3a and to probe for therapeutic potential. 
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Table 1.7 Examples of Synthetic Peptide Agonists and Antagonists of hC3a (Ember et al., 
1998).   
Synthetic C3a analogues 
(agonists) 
Potency Reference 
2.0 - 4.3 nM 
3 nM ED50 
(Kretzschmar et al., 
1992; Lu et al., 1984)  
1.9 - 4.1 nM (Lu et al., 1984)  
Intact human C3a 
 
 
 
C-N-Y-I-T-E-L-R-R-Q-H-A-R-A-S-H-
L-G-L-A-R (native sequence) 
 92 nM (Ember et al., 1991) 
A-N-A-Aib-A-E-E-A-Aib-R-Q-A-Aib-
R-A-A-Aib-L-G-L-A-R(helix-enhancer 
sequence) 
1.2 nM (Hugli, 1986) 
A-N-A-Ab-A-P-A-Ab-R-Q-A-Ab-R-P-
A-Ab-L-G-L-A-R (helix-disrupted 
sequence) 
900 nM  
F-moc-Ahx-Y-R-R-G-R-A-A-A-L-G-
L-A-R 
3 nM ED50 (Ambrosius et al., 1989; 
Gerardyschahn et al., 
1988)  
W-W-G-K-K-Y-R-A-S-K-L-G-L-A-R 6 nM 
 
(Ember et al., 1991) 
C3a antagonists 
Y-R-R-G-R-Ahx-[C-G-G-L-C]-L-A-R* 
 
0.5 Ki/ED50 
 
(Kretzschmar et al., 
1992) 
Y-R-R-G-R-Ahx-[C-G-A-L-C]-L-A-R* 0.4 Ki/ED50 (Kretzschmar et al., 
1992) 
Aib = 2-aminoisobutyric acid; Ab = 2-aminobutyric acid; F-moc = fluorenyl methoxycarbonyl; 
Ahx = aminohexyl; * = cyclic peptides. 
 
 
 
 
1.10 C5a ANAPHYLATOXIN 
C5a is a pro-inflammatory small polypeptide which consists of 74 amino acids (Figure 
1.17). Human C5a has complex anti-parallel 4-helix bundles stabilized by three disulfide bonds 
(cys21-47, cys22-44, cys34-55), which are connected by three peptide loops (Zhang et al., 1997b; 
Zuiderweg et al., 1989a; Zuiderweg et al., 1989b) (Figure 1.17). N-terminal of C5a is important for 
its binding affinity for C5aR while the agonistic C-terminal (M69QLGR74) is acting as receptor 
activating domain, which supports the two-site binding model of C5a to C5aR (Siciliano et al., 
1994). C5a is generated by C5 convertase, which cleaves Component 5 (C5) at the terminal region 
of the alpha-chain.  
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C5a is the most potent inflammatory peptide and has various effects on many cell types 
(summarised in Table 1.8). C5a can modulate the response in several cell types with broad-
spectrum biological activities eg. phagocytosis, degranulation, H2O2 production, granule enzyme 
release, delay or enhance of apoptosis, stimulate chemokine and cytokine production and 
chemotaxis. However, C5a is now known as a molecule which has far more effects not only in the 
immune system, but also it has been associated with developmental biology, CNS development and 
neurodegeneration, tissue regeneration and haematopoiesis (Haas et al., 2007; Klos et al., 2009; 
Monk et al., 2007). 
Helix 3
Helix 4
Helix 2
Helix 1
COOH
NH2
Cys21 - 47
Cys 22-44
Cys 34 - 55
MLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQ
RAARISLGPRCIKAFTECCVASQLRANISHKDMQLGR
1 10 20 30
40 50 60 70
 
Figure 1.17 Amino acid sequence and NMR solution structure of C5a (pdb: 1KJS). Human 
C5a is consisting of four-helix bundles, which arrange in antiparallel topology. They are stabilized 
by three disulfide bonds and connected by three peptide loops. The flexible carboxyl terminal 
(MQLGR) forms helical turns which are critical for receptor activation (modified from Manthey et 
al., 2009). 
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Table 1.8 Functional activity of C5a on myeloid and non-myeloid cells. 
Cell type 
 
Response to C5a 
Neutrophils Increase adhesion molecules (Foreman et al., 
1994) 
Chemoattractant (Snyderman et al., 1984) 
Release of superoxide (Mollnes et al., 2002a) 
Phagocytosis (Mollnes et al., 2002a) 
Stimulate the release of granule enzymes (Becker 
et al., 1985) 
Delayed apoptosis (Perianayagam et al., 2002) 
Stimulate the release of cytokines (Guo et al., 
2005) 
Eosinophils Chemotattractant (DiScipio et al., 1999) 
Stimulate the release of granule enzymes (Egesten 
et al., 1998; Takafuji et al., 1994) 
Macrophages Enhance phagocytosis (Guo et al., 2005) 
Chemoattractant (Marder et al., 1985) 
Stimulate cytokine release (Okusawa et al., 1988) 
Monocytes Chemoattractant (Marder et al., 1985) 
Stimulate cytokine release (Okusawa et al., 1988) 
Mast cells Chemoattractant (Hartmann et al., 1997) 
Histamine secretion (Schulman et al., 1988) 
Basophils Stimulate histamine release (Schulman et al., 
1988) 
T-lymphocytes Suppressed apoptosis (Strainic et al., 2008) 
Thymocytes Increase apoptosis (Guo et al., 2000) 
Plasmacytoid 
dentritic cells 
Chemoattractant (Gutzmer et al., 2006) 
Endothelial cells Vasodilation (Albrecht et al., 2004) 
Stimulate chemokine release (Albrecht et al., 
2004) 
Enhance the adhesion molecule expressed (Monk 
et al., 2007) 
Hepatocytes Stimulate liver regeneration (Daveau et al., 2004) 
Microglia Chemoattractant (Yao et al., 1990) 
Vascular smooth 
muscle cells 
Indirectly stimulate contraction (Monk et al., 
2007) 
Cardiomyocytes Decrease contractility (Monk et al., 2007) 	  	  
C5a is metabolized by plasma enzyme carboxypeptidases, which remove the C-terminal 
arginine to form desArg derivative (C5a desArg)(Bokisch et al., 1970; Huey et al., 1983). The 
desArg form of C5a has a lower potency than C5a by approximately 10-1000 times depending on 
its function (Hugli et al., 1978). Both C5a and C5a desArg have binding affinity or Kd for C5aR at 
1 and 412-600 nM, respectively (Marder et al., 1985; Okinaga et al., 2003). 
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C5a has been implicated in many pathogeneses of inflammatory conditions, autoimmune 
and neurodegenerative diseases when its level increases such as rheumatoid arthritis (Grant et al., 
2002; Neumann et al., 2002; Weissmann, 2004), ARDS (Sarma et al., 2006), inflammatory bowel 
diseases (Woodruff et al., 2003), systemic lupus erythrematosus (Hopkins et al., 1988), I/R injury 
(Arumugam et al., 2006), glomerulonephritis (Welch, 2002), COPD (Marc et al., 2004), sepsis 
(Huber-Lang et al., 2002), multiple sclerosis (MullerLadner et al., 1996), asthma and allergy (Abe 
et al., 2001), psoriasis (Kapp et al., 1985a), atherosclerosis (Speidl et al., 2005), anaphylactic 
hemorrhagic shock (Harkin et al., 2004; Younger et al., 2001), gingivitis (Okada et al., 1979), 
peritonitis (Godau et al., 2004), tissue rejection (Gaca et al., 2006), meningitis, pancreatitis (Bhatia 
et al., 2000), burn (Piccolo et al., 1999), infection, antiphospholipid syndrome (Girardi et al., 2003), 
neurodegeneration (Van Beek et al., 2003) and macular degeneration (Kijlstra et al., 2005). 
C5a receptor (CD88) is a typical G-protein coupled receptor with 7TMs, which is classified 
as a rhodopsin-type receptor. It was the first anaphylatoxin receptor to be cloned in 1991 (Gerard et 
al., 1991). C5aR is located on chromosome 19 (Gerard et al., 1993). It is 42 kDa and consists of 
350 amino acids. 
C5aR is widely expressed in both myeloid and non-myeloid cells such as vascular 
endothelial cells, cardiomyocytes, synoviocytes, astrocytes, microglia, neural stem cells, 
oligodendrocytes, articular chondrocytes, renal glomerular mesangial cells, hepatic kupfer cells, 
hepatocytes, bronchial epithelial and smooth muscle cells and inflamed keratinocytes (Lee et al., 
2008; Monk et al., 2007). In myeloblastic cell lines, C5aR can be upregulated by using dibutyryl-
cAMP, phorbol ester and interferon (Burg et al., 1996; Rubin et al., 1991).  
C5aR signalling depends on G-protein. C5aR coupled to pertussis toxin-sensitive (PTX) 
Giα2, Giα3 (Rollins et al., 1991) or pertussis-insenstive Gα16 (Amatruda et al., 1993), which is 
expressed only in hematopoietic cells. The binding of C5a to C5aR activates signal transduction, 
which involves intracellular calcium mobilisation from intracellular stores as well as the 
extracellular medium. There are several activation pathways of C5aR signalling such as 
phosphatidylinositol-biphosphate-3-kinase/Akt (PKB) (Perianayagam et al., 2002), Ras/B-
Raf/mitogen-activated protein kinase (Buhl et al., 1994; Mullmann et al., 1990), phospholipase D 
(PLD) (Mullmann et al., 1990), protein kinase C (PKC) (Buhl et al., 1994), sphingosine kinase 
(Melendez et al., 2004) and NF-κB (Kastl et al., 2006).  
Over the past decade, a few C5aR antagonists have been developed, for example 
nonpeptidic small molecules, C5a mutants, short peptides and cyclic peptides, mAb and antibody 
fragments.  
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Of the most useful C5aR antagonists are peptidomimetics, which are generated based on SAR 
studies. The modification of N-MePhe-Lys-Pro-D-cha-Trp-D-Arg or C-089, the first full C5aR 
antagonist (Konteatis et al., 1994), gives potent and selective C5a antagonists, cyclic PMX53 
(3D53) (Ac-Phe-[Orn-Pro-DCha-Trp-Arg]) (Finch et al., 1999), cyclic PMX205 (HCin-[Orn-Pro-
DCha-Trp-Arg])(March et al., 2004) and linear JPE1357 (Hoo-Phe-Orn-Pro-hle-Pff-Phe-
NH2)(Schnatbaum et al., 2006) (Figure 1.18). PMX53 is in clinical trial phase I for rheumatoid 
arthritis and psoriasis. Even though it has been shown to be safe and well tolerated, it fails to show a 
reduction of inflammation in synovial fluid of patients in clinical trial phase Ib (Vergunst et al., 
2007).  	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Figure 1.18 Chemical structures of the peptidic C5a antagonists PMX53 (3D53), PMX205 and 
JPE1375.  
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1.11 SUMMARY AND AIMS 
G-protein coupled receptor (GPCRs) are the most common drug targets for the 
pharmaceutical industry. Several hundred GPCRs are peptide-activated, such as complement C3a 
and C5a receptors.   
Complement is a non-specific defense mechanism of the body that also forms a bridge to 
adaptive immunity. One of the major products of complement activation is the generation of 
anaphylatoxins (C3a and C5a). Anaphylatoxins play a major role in inflammation, which prime and 
amplify the immune response through the chemotaxis of immune cells to inflammatory sites and 
induce the secretion of proinflammatory mediators, lysosomal enzymes and reactive oxygen 
species.  
C3a is involved in many inflammatory conditions and diseases such as anaphylaxis, adult 
respiratory distress syndrome (ARDS), acute transplant rejection, ischemia reperfusion injury, 
sepsis, brain inflammation and many autoimmune diseases eg. psoriasis, rheumatoid arthritis, and 
systemic lupus erythrematosus. Recently, it has been reported that C3a has a role in organ 
regeneration (Strey et al., 2003), in neuroprotection (Mukherjee et al., 2008) and in the release of 
progenitor haematopoietic stem cells (Wysoczynski et al., 2009). C3aR has been expressed in a 
variety of cells. 
However, there are few reported C3a agonists and antagonists. Ames et al.(2001) reported the 
C3aR antagonist, SB290157, which has recently shown agonist activities in some experiments 
(EC50 = 2.7± 1.7 in Ca2+ release assay in RBL-hC3aR)(Mathieu et al., 2005). Up to date, there are 
no potent and selective C3a agonists or antagonists which can be used as a probe in 
pharmacological and physiological studies to understand the roles of C3aR.   
The aim of this thesis is to develop the new potent and selective peptidic and non-peptidic 
C3aR agonists or antagonists and test in competitive binding assay and functional assay. In 
addition, the structure-activity relationship also provides information for developing new 
compounds. Furthermore, the antagonism mechanism studied gives a better understanding of how 
the new ligands bind to C3a receptor. 
 
Chapter 2 
There are two parts of this study in this chapter. Firstly, to reinvestigate the known C3a 
peptides and four decapeptides for C5aR, which are reported in the literature in a competitive 
binding assay and also in a functional assay.  In a functional assay the compounds were investigated 
by using measurement of the intracellular calcium mobilization on differentiated U937 cells.  
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The competitive binding assay was used to determine the affinity and selectivity of the test 
compounds by using constant radioligand [125I]-C3a at 80 pM or [125I]-C5a at 20 pM to compete 
with unlabelled test compound in PBMC.  
Secondly, a new series of hexapeptide compounds based on the C-terminus of hC3a has been 
developed and studied by using structure-activity relationships (SAR) to inform which amino acids 
confer potency and selectivity for the C3aR ligands. The selectivity of the compounds was studied 
by competitive binding assay and receptor desensitization experiments. 
 
  Chapter 3   
From chapter 2 results, we found that hexapeptide C3aR agonist (FLTLAR) adopted a beta 
turn conformation at its C-terminus. We decided to introduce an oxazole heterocycle into the LAR 
region to impart conformational rigidity to the agonist peptides. This rigid linker acts as a beta turn 
inducing constraint and mimics the conformation found at the C-terminus of C3a in its crystal 
structure, which was found in the molecular modeling study. The new C3aR agonists were 
developed to give a library of this series. The competitive binding assay was used to determine the 
affinity and selectivity of the test compounds by using constant radioligand [125I]-C3a at 80 pM or 
[125I]-C5a at 20 pM to compete with unlabelled test compound in isolated human monocyte derived 
macrophage cells. The potency of the compounds was studied by using a calcium mobilization 
assay in HMDM. 
 
Chapter 4 
There were two approaches to developing the new C3aR antagonists in this chapter. Firstly, 
from the results of chapter 3 which showed the potent C3aR agonists when introducing an oxazole 
into the LAR region suggest that the rigid linker improves the binding and functional activity of the 
compounds. In this chapter we hypothesized that if we use a different substituent on the 5-position 
of the oxazole ring it may improve the binding affinity as well as improve the potency of the 
compounds.   
Secondly, using C3aR antagonist, SB290157 (N2-[2,2-diphenylethoxy)acetyl]-L-arginine), as 
a template, we developed new ligands. The previous results in the competitive binding assay (in 
Chapter 2) showed that SB290157 is binding tightly and specifically to C3aR without cross 
reactivity to C5aR. It also shows no agonist activity in the functional assay on human PBMCs.  
Hence, to explore the structure of SB290157 by dividing them into three parts, which are 
hydrophobic, linker and terminal arginine. Arginine was kept in place as it is important for 
biological activity of compounds to activate C3aR. 
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The compounds were modified in the first two regions; linker and hydrophobic by 
substitution with different amino acids and/or functional groups. New agonists and antagonists of 
C3aR were developed to contribute to the library of this series.  
Another series of compounds was explored by using the previous template, which was 
reported by Denonne et al.(2007b) with the substituent of furan at the linker which gives the higher 
affinity compounds.  
 
Chapter 5 
The objectives of this chapter were initially to study the most potent and selective available 
antagonists: peptide FLTChaAR (25) (from Chapter 2), peptidomimetic 146 (from Chapter 4) and 
reported nonpeptide SB290157 for mechanism of action against three different classes of C3aR 
agonists a) protein C3a, b) peptide FLTLAR (17), FWTLAR (20) and c) peptidomimetic 63 and 
80). By identifying competitive/noncompetitive and surmountable/insurmountable behaviour in the 
Ca2+ mobilisation on HMDM, we could potentially learn about the binding location of the 
compounds.  
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2.0 ABSTRACT 
Complement activation is one of the body’s most important responses against antigens and 
other foreign materials. The complement system includes more than 30 different proteins, which act 
together to form the membrane attack complex, which can cause lysis of bacteria, virus-infected or 
damaged cells. The complement component C3 plays a pivotal role in all three pathways (classical, 
lectin and alternative) of complement activation. Cleavage of C3 by C3-convertase (and possibly 
other proteases) generates the anaphylatoxin C3a, a 77 amino acid protein. C3a binds to its 
functional receptor, C3aR, which is a G protein – coupled receptor predominantly coupled to Gi. 
The agonist activity of C3a is due to the octapeptide of the C-terminal region, which triggers 
receptor activation. The truncated and modified 15 residues, with the incorporation of two 
tryptophans at the N-terminus, was reported to be 15-fold more potent than C3a in a guinea pig 
platelet aggregation assay. The superagonist activity has been disputed in the literature (Ames et al., 
1997; Chao et al., 1999; Ischenko et al., 1998; Sun et al., 1999) and by our group in a previous 
study (Blakeney, 2007) since the compound showed less potency and no selectivity for C3aR. 
Therefore to date, there is no potent agonist of C3a composed of less than eight amino acids.  
 In this chapter we study (i) the selectivity of compounds by first using a competitive 
radioligand binding assay with [125I]-labelled C3a and C5a on PBMCs, which were isolated from 
human plasma to determine the affinity of the compounds; and then the general selectivity by a 
C3a-induced receptor desensitisation experiment; and (ii) the potency of the compounds by using a 
calcium mobilisation assay which detects intracellular calcium trafficking by binding calcium to a 
cell permeable fluorophore. 
 We found that previously reported compounds, such as the C3a “superagonist”  
(WWGKKYRASKLGLAR), were not selective for C3aR in a receptor desensitisation experiment. 
Four decapeptides, originally reported as C5aR agonists, also bound tightly to C3aR in PBMC cells. 
Two reported oryzatensin pentapeptide derivatives, WPLPR and YPLPR, also showed no 
selectivity for C3aR over C5aR in the competitive radioligand binding assay. A new series of 
hexapeptides based on the C-terminus of human C3a was designed and studied using structure-
activity relationships (SAR). Two small peptide agonists were found to be highly potent agonists 
and selective for C3aR.  FLTLAR and FWTLAR bind to C3aR tightly with IC50 ~ 40 and 80 nM, 
respectively on PBMC cells and in the calcium mobilisation assay had EC50  = 0.32 and 0.37 µM, 
respectively. Structure activity relationships and competitive binding results have led to a new 
C3aR peptide antagonist, F1LTChaAR6. Changing leucine at position 4 to a bulkier amino acid such 
as cyclohexylalanine (Cha) showed no agonist activity (>100 µM) in a calcium mobilisation assay 
in dU937 cells, but did bind tightly to C3aR and displayed antagonist activity (IC50 1.5 µM). 
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2.1 INTRODUCTION 
 The complement system is an innate immune system consisting of more than 30 distinct 
plasma proteins that promote phagocytosis, lysis and removal of pathogens through opsonization 
(C3b) and immune cell stimulation (Gerard et al., 2002; Haas et al., 2007; Hugli, 1986; Hugli, 
1981; Hugli, 1984; Hugli et al., 1978; Masters et al., 2009; Zipfel et al., 2009). The activation of 
the complement cascade generates products, which are the complement anaphylatoxins, C3a and 
C5a. Anaphylatoxins prime and amplify the immune response through chemoattraction of immune 
cells to inflammatory sites and also promote proinflammatory secretions, lysosomal enzymes, and 
reactive oxygen species (Gerard et al., 2002; Haas et al., 2007; Hugli, 1986; Hugli, 1981; Hugli, 
1984; Hugli et al., 1978; Masters et al., 2009; Zipfel et al., 2009). C5a is the most potent 
proinflammatory peptide (Allegretti et al., 2005; Monk et al., 2007), which is generated via the 
complement cascade. C5a plays roles both within and beyond the immune system. C5a has been 
implicated in developmental biology, CNS development and neurodegeneration, tissue regeneration 
and haematopoiesis, in addition to its proinflammatory properties (Haas et al., 2007; Klos et al., 
2009; Monk et al., 2007).    
 C3a is 77 amino acid residues, which has proinflammatory properties but to a lesser extent 
than C5a.  C3a induces smooth muscle cell contraction (Ember et al., 1998), chemotaxis of mast 
cells (Nilsson et al., 1996) and eosinophils (Daffern et al., 1995), increases vascular permeability, 
stimulates release of histamine in basophils (Kretzschmar et al., 1993) and mast cells (Ellati et al., 
1994) and promotes the release of serotonin from guinea pig platelets (Fukuoka et al., 1988).  
 C3a has been implicated in the pathogenesis and progression of inflammatory diseases like 
asthma, allergies, sepsis, lupus erythematosus, diabetes, arthritis, psoriasis, nephropathy and 
ischemia-reperfusion injury (Boos et al., 2004; Boos et al., 2005; Drouin et al., 2002; Drouin et al., 
2001; Garrett et al., 2009; Humbles et al., 2000; Hutamekalin et al., 2010; Kawamoto et al., 2004; 
Kildsgaard et al., 2000; Kirschfink, 2001; Mamane et al., 2009; Mizutani et al., 2009; Mocco et al., 
2006; Mueller-Ortiz et al., 2006; Rahpeymai et al., 2006; Rynkowski et al., 2009; Tang et al., 2009; 
Wenderfer et al., 2009).   
Recently there have been reported antimicrobial and antifungal properties for C3a derived 
peptides (Malmsten et al., 2007). The 21-residues of C3a and the 20-residue C-terminus of 
C3adesArg also show antibacterial properties against E. faecalis and P. aeruginosa (Nordahl et al., 
2004), Escherichia coli and Staphylococcus aureus (Pasupuleti et al., 2008) and antifungal 
properties against Candida albicans (Sonesson et al., 2007). As more C3a and C3aR pharmacology 
has become established, interest has been renewed in C3a and there is a realisation of the need for 
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synthetic C3a agonists and antagonists for interrogating and potential treatment of C3a-mediated 
conditions in humans.  
Like C5a, it is the C-terminal octapeptide region of C3a that is implicated as the effector 
domain required for triggering receptor activation (Hoeprich et al., 1986). The biological activity of 
C3a is abolished by the cleavage off of C-terminal arginine by carboxypeptidase (Bokisch et al., 
1970; Campbell et al., 2002; Ember et al., 1997) in the circulation and tissues. Desarginated forms 
of C5a and C3a are C5a desArg and C3a desArg (acylation-stimulating protein (ASP)) respectively. 
They are also less immunologically active. C5a desArg still retains some proinflammatory 
properties (1-10% of C5a) while C3a desArg has no activity and no binding to C3aR (Bokisch et 
al., 1970). To date, all synthetic C3a ligands contain the C-terminal arginine. Numerous peptides 
based on the C-terminus of C3a have been reported to compete with [125I]-C3a on cell surfaces 
(Jinsmaa et al., 2001; Takabayashi et al., 1996). 
There have been relatively few reports of new synthetic C3a ligands since the early 1990s. 
The development of short peptide agonists has focused on identifying the minimum of C-terminal 
peptide residues of C3a that is capable of activating C3aR and then modifying or adding to the 
pentapeptide (L73GLAR77)(Ambrosius et al., 1989; Caporale et al., 1980; Ember et al., 1991; 
Federwisch et al., 1992; Gerardyschahn et al., 1988; Hoeprich et al., 1986; Huey et al., 1984; Kohl 
et al., 1990; Kretzschmar et al., 1992; Mousli et al., 1992; Petering et al., 2000).  Huey and 
colleagues (1984) reported the first peptide with activity comparable to C3a, a synthetic peptide 
comprising the C-terminal 21 residues of C3a which was equipotent with C3a in a lung strip 
contraction assay. This peptide was only 44% as effective as C3a in immunoglobulin (Ig) secretion 
by peripheral blood lymphocytes. By addition of hydrophobic moieties such as fluorenyl methoxy 
carbonyl (Fmoc) or aminohexanoic (Ahx) to the N-terminus of native C3a terminal 5-13 residue 
peptides increases the activity (Ambrosius et al., 1989; Gerardyschahn et al., 1988; Kohl et al., 
1990; Kola et al., 1992). In the study by Hoeprich et al.(1986) which modified C3a by 
incorporating 21 residues of C3a with helix-inducing Ala and Aib residues at judicious positions 
resulted in a 250% improvement in activity of the peptide which correlated with increased helicity 
measured by circular dichroism (Hoeprich et al., 1986). The 15 residue peptides which were 
developed from searching minimal potent sequences of the C3a C-terminus in different species and 
modified with incorporation of a tryptophan dipeptide as the hydrophobic moiety at the N-terminus 
resulted in a superagonist ‘WWGKKYRASKLGLAR’ which is fifteen-fold more potent than C3a 
in a guinea pig platelet aggregation assay (Ember et al., 1991). However, it was equipotent with 
C3a in a calcium mobilisation assay using guinea pig or mouse C3aR transfected cells (Lienenklaus 
et al., 1998; Sun et al., 1999). Increasing the helicity of short synthetic ligands by addition or 
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substitution of residues with high helix propensity might increase the potency of designed ligand 
peptides (Hoeprich et al., 1986). 
Due to the reported activities of these synthetic C3a agonists using a variety of assay 
systems to evaluate the activities of these ligands from tissue organ bath for measurement of smooth 
muscle contraction (Caporale et al., 1980; Hoeprich et al., 1986; Huey et al., 1984; Lu et al., 1984; 
Unson et al., 1984), to mast cell histamine-release assays (Mousli et al., 1992) and ATP-release 
assays from guinea pig platelets (Ambrosius et al., 1989; Caporale et al., 1980; Federwisch et al., 
1992; Gerardyschahn et al., 1988; Kohl et al., 1990; Kretzschmar et al., 1992; Pohl et al., 1993), 
which make it more difficult to compare the activity of these synthetic C3a peptides. Evaluation of 
the activities of synthetic ligands is further complicated by use of different species especially tissue 
and cells from guinea pigs, since guinea pigs have been found to have two functional C3a receptors 
(Fukuoka et al., 1998), in comparison to only one receptor found in humans.  
In this chapter, novel small synthetic C3aR agonists were developed from structure- activity 
relationships based on the hexapeptide FWPLAR, which was shown by previous studies in our 
group to have potency and selectivity for C3aR in calcium mobilisation and desensitisation assays 
on differentiated U937 cells respectively.  Approximately 50 peptides were studied for their 
potential to bind and activate (agonists) or inhibit activation of human C3a receptor on human U937 
cells and isolated human blood PBMCs. Two principal assays were used, (1) a competitive binding 
assay using 125I-labeled C3a (or C5a for selectivity comparisons) to evaluate selectivity of peptides 
and (2) a standard ligand-induced fluorescence intensity assay involving detection of intracellular 
calcium released into the cytoplasm from the endoplasmic reticulum by which were evaluated 
potency and selectivity (desensitisation assays) of peptide agonists. 
For the peptides evaluated herein there was a linear correlation between C3aR affinity and 
induced intracellular calcium release. The results have characterised the discovery of the most 
potent known small peptide agonists of C3aR (e.g. FLTLAR, EC50 320 nM in calcium mobilisation 
assay on dU937). Some compounds clearly bind to other receptors based on the results of an 
agonist-induced desensitisation assay, but key compounds appear to show selectivity and specificity 
for the C3a receptor. 
 
2.2 AIMS/OBJECTIVES 
To date, there have been no truly selective and potent agonists reported for probing the 
physiology and pharmacology roles of human C3a in vivo. Therefore, the development of small 
molecule agonists can be useful for understanding its role in vivo and for helping the development 
of antagonists for C3aR. 
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The specific aims of this chapter were: 
1. To determine the affinity and selectivity of hexapeptides for C3aR by using competitive 
[125I]-C3a and [125I]-C5a binding assays. 
2. To evaluate the functionality of these compounds as C3aR agonists using an intracellular 
calcium mobilisation assay conducted on differentiated U937 cells. Structure-function 
relationships (SAR) were expected to inform which amino acids confer potency and 
selectivity for the ligands binding to C3aR over C5aR. 
3. To further examine the selectivity of these compounds with receptor desensitisation 
experiments. 
4. To re-examine the C5a decapeptides and native C3a on human monocytes for their 
binding affinity to C3aR, which can also provide more information for the ligand-
receptor - binding conformation. 
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2.3  RESULTS 
2.3.1 SELECTIVITY AND POTENCY OF HUMAN C3a 
2.3.1.1 Affinity of hC3a and hC5a 
It is known that C3a and C5a are highly specific for their receptors with no detectable cross-
reactivity (Burg et al., 1996; Crass et al., 1999). The selectivity was confirmed in the assays by two 
methods. Firstly, the competitive radioligands, [125I]-C3a and [125I]-C5a were used to check whether 
the ligands bind to C3aR and/or C5aR by competing with various concentrations of unlabelled 
ligands with the human C3a iodine labelled at a constant concentration. Secondly, a desensitisation 
experiment in which the administration of either C3a/C5a alone caused desensitisation of the C3aR 
or C5aR. 
The results of competitive radioligand binding studies confirm the selectivity of 
anaphylatoxin, showing that hC3a (IC50 0.1 nM, pIC50 9.99 ± 0.05, n=17) and the known C3aR 
antagonist, SB290157 (3) (IC50 143 nM, pIC50 6.84 ± 0.08, n=11) bind to C3aR (Figure 2.1) but 
not C5aR (Figure 2.2) on isolated human monocytes.  A comparable result was found in [125I]-C5a 
competitive binding experiment. hC5a (IC50 1.0 nM, pIC50 8.87 ± 0.07, n=13) and the C5aR 
antagonist, AcF-[OPdChaWR] (3D53)(4) (IC50 124 nM, pIC50 6.85 ± 0.05, n=12) only bound with 
high affinity to C5aR (Figure 2.2) with no affinity for C3aR (Figure 2.1) on human isolated 
monocyte cells. 
 
Figure 2.1 Affinities for C3a receptor of hC3a (l) n=17, SB290157 (3) (n) n=11, hC5a (Î) 
n=1 and 3D53 (4) (+) n=1 on isolated human monocytes. Affinities for C3aR measured by 
displacement of 80 pM [125I]-C3a on human PBMCs. It shows that human C5a and C5aR 
antagonist, 3D53 up to 1 µM and 100 µM respectively did not bind to C3aR. Each point 
represents the mean percentage specific binding ±  S.E.M. 
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Figure 2.2 Affinities for C5a receptor of hC5a  (l) n=13, 3D53 (4) (n) n=12, hC3a  (Î) n=3 
and SB290157 (3) (+) n=3 on isolated human monocytes. Affinities for C5aR measured by 
displacement of [125I]-C5a on human PBMCs by unlabelled C5a, 3D53, hC3a or SB290157. It 
shows that human C3a and C3aR antagonist, SB290157 up to 1 µM and 100 µM respectively did 
not bind to C5aR. Each point represents the mean percentage specific binding ±  S.E.M. 
 
 
The second receptor selectivity measurement is based on receptor desensitisation. Receptor 
desensitisation, which usually follows exposure to agonists due to phosphorylation/internalisation 
of GPCRs, was used to measure the selectivity of C3a peptide analogues. Human C5a (300 nM) 
was administrated to differentiated U937 cells, which produces an efflux of intracellular Ca2+ that 
dissipates after 4-5 mins (Figure 2.3 A). A second addition of 300 nM C5a after 5 mins then has no 
effect (Figure 2.3 A), and this is attributed to either receptor (C5aR) phosphorylation or receptor 
internalisation from the cell surface. Either way the cell is no longer sensitive to C5a for at least 20 
minutes. If instead the first administration of C5a (300 nM) is followed 5 minutes later by addition 
of 3 µM C3a (Figure 2.3 B), there is detectable fluorescence due to Ca2+ release, suggesting that 
C5a and C3a bind to different receptors and do not cross-react (Figure 2.3). When the experiment 
is reversed, and 3 µM C3a is administered to the cells first followed 5 minutes later by either 3 µM 
C3a (no signal, Figure 2.3 C) or 300 nM C5a (Ca2+ release, Figure 2.3 D), this shows that the cells 
have been desensitized only to C3a and not to C5a. The desensitisation experiment can therefore 
potentially confirm whether C3a agonists or C5a agonists are binding to the cell surface and 
inducing intracellular Ca2+ release. 
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A. 
 
B. 
 
C. 
 
D. 
 
Figure 2.3 Desensitisation experiments.  Anaphylatoxin receptor desensitisation 
experiments on differentiated U937 cells. Cells were first treated with hC5a (A and B) or hC3a 
(C and D), which induced a calcium response that dissipated over 4 mins prior to a second hC5a 
(A and D) or hC3a (B and C) injection. 
 
2.3.1.2 Potency of hC3a and hC5a 
Effect of Human C3a and Human C5a on Calcium Release Assay From U937 cells 
 
U937 is a human leukemic monocyte lymphoma cell line. When C3a or a C3a analogue 
peptide binds to C3aR (a G-protein coupled receptor), intracellular G-proteins are activated through 
the exchange of GDP for GTP and the dissociation of the Gα and Gβγ subunits of G-proteins. 
When the receptor is activated, it leads to the release of intracellular calcium from the endoplasmic 
reticulum upon C3aR coupling to pertussis toxin-sensitive G-proteins (Gαi) subunits. C3aR may 
couple to Gα12/13 in endothelial cells (Schraufstatter et al., 2002). C3aR may also couple pertussis 
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toxin-insensitive Gα16 for signal transduction (Crass et al., 1996). The signal transduction of C3a 
includes activation of protein kinase C by phospholipase C and mitogen activated protein (MAP) 
kinases Erk1 and Erk2, in astrocytes (Langkabel et al., 1999; Sayah et al., 2003). 
To differentiate the monocyte-like phenotype of U937 cells with increased expression of 
C3aR on the cell surface, we exposed U937 cells to the membrane-permeable compound dibutyl-
cAMP for 72 hours (Burg et al., 1996; Klos et al., 1992). This calcium mobilisation assay was used 
to measure the change in fluorescence induced by treatment of differentiated U937 cells with 
increasing C3a peptide concentrations (Figure 2.4). 
 
 
 
 
 
Figure 2.4 Intracellular calcium release assay.  1. Fluo-3 is loaded onto the cells using a mild 
detergent, pluronic acid.  2. Fluo-3AM (red, outside the cells) is cleaved by intracellular 
esterases to release Fluo-3 (blue, inside the cell).  3. Activate GPCR with agonist.  4. Receptor 
activation leads to release of intracellular calcium release from the endoplasmic reticulum         
5. Ca2+ binds to Fluo-3 in the cell and the Fluo-3 Ca2+ complex is excited at 485 nm light and 
emits at 520 nm light (adapted from Blakeney, 2007). 
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In the calcium release assay, human C5a and human C3a stimulated release of intracellular 
calcium from differentiated U937 cells. hC5a is a more potent agonist (EC50 = 7 nM,  pEC50 8.2 ± 
0.09, n=3) than hC3a (EC50 = 52 nM, pEC50 = 7.3 ± 0.06, n=10).   In this study it was shown that 
the upper plateau of C5a is higher than C3a-induced calcium release into the cytoplasm of 
differentiated U937 cells (Figure 2.5). There is a difference in maximum calcium response, which 
may be related to a difference in the calcium activation pathways between these receptors or the 
number of receptors that are expressed on the cell surface of differentiated U937 cells. 
 
 
 
Figure 2.5 Intracellular Ca2+ release induced by human C3a (n) versus human C5a (l) in 
differentiated human U937 cells. C3a (n=10) and C5a (n=3) mediated calcium mobilisation 
from differentiated U937 cells expressed as percentage of maximum change in fluorescence 
induced by calcimycin (A23187) ± S.E.M. 
 
2.3.2 SELECTIVITY AND POTENCY OF 15-RESIDUES OF hC3a AND hC5a 
N-terminal truncation of C3a has been used to determine what constitutes the active portion 
of C3a but accessing short, potent peptides to mimic C3a function has not yet been successful. 
2.3.2.1 Potency of 15-residue hC3a and hC5a  
 We next compared the C-termini of hC3a versus hC5a as agonists in the calcium 
mobilisation assay. At 100 µM concentration, C3a(63-77) (6) induced release of Ca2+ into the 
cytoplasm of dU937 cells to about the same degree (EC50 ± 95% CI; 1.8 ± 0.55 µM) as 1 µM hC3a, 
whereas C5a(59-73)(7) at 100  µM was about ten-fold less effective (EC50 ± 95% CI; 27 ± 12.4 µM). 
However, there is a substantial reduction in functional potency upon truncation of C3a to its 15 
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residue C-terminal native peptide sequence which was measured by ability to induce intracellular 
calcium release from dU937 cells (Figure 2.6). The EC50 value of human C3a (EC50 52 nM) was 
reduced 35 fold when it was truncated to 15 residues (6) (EC50 1.8 µM). Compound 7 was around 
3500 times less active than human C5a (hC5a EC50 = 7 nM; 7 EC50 = 24 µM). 
 
 
 
Figure 2.6 Intracellular Ca2+ release induced by C3a(63-77) (6) (®) versus C5a(60-74) (7) (q) in 
differentiated human U937 cells. 6 and 7 mediated calcium mobilisation from differentiated 
U937 cells expressed as percentage of maximum change in fluorescence induced by human C3a 
(1 µM) and error bars represented S.E.M. with n=4. 
 
 
2.3.2.2 Binding Affinities of 15-residue hC3a and hC5a 
From the results of competitive binding studies, 7 has binding affinity for both C3aR (IC50 
1.6 µM, Figure 2.7) and C5aR (IC50 1.7 µM, Figure 2.8) on human monocytes whereas the 6 has 
shown only affinity for C3aR (IC50 = 152 nM, Figure 2.7) but not C5aR (Figure 2.8) on human 
PBMCs. Thus the 15 residue peptide based on the C-terminal native sequences of C5a was not 
selective for its receptor so we decided to further study the binding of reported C5a decapeptide 
agonists: YSFKPMPL(Me-a)R (8), YSFK(Me-D)MPLaR (9), YSHKPMPLaR (10), 
YSFKPMPLaR (11) and C3aR superagonist –WWGKKYRASKLGLAR (5). 
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Binding affinity for C3aR 
 
 
 
Figure 2.7 Competitive [125I]-C3a binding assay of hC3a (l , n=17), 3 (n , n=11), C5a        
(Î  n=1), 4 (+, n=1), 6 (p , n=4) and 7 (q , n=3) on isolated human monocytes.  80 pM [125I]-
C3a was competed by increasing concentration of non-labelled hC3a (concentration 1 pM to      
1 µM), 3, 6 and 7 (concentration 0.1 nM to 100 µM or 1 mM). 6 and 7 bind to C3aR. Each point 
represents the mean percentage specific binding ±  S.E.M. 
 
Binding affinity for C5aR 
 
 
Figure 2.8 Competitive [125I]-C5a binding assay of hC5a (Î , n=13), 4 (+, n=12), C3a (l , 
n=3), 3 (n , n=3), 6 (p , n=3) and 7 (q , n=4) on human monocytes.  Competitive [125I]-C5a 
binding of hC5a (concentration 1 pM to 1 µM), 4 and 7 (concentration 0.1 nM to 100 µM or 1 
mM) on monocytes shows that hC3a up to 1 µM and 3, 6 up to100 µM respectively do not bind 
to C5aR. Each point represents the mean percentage specific binding ±  S.E.M. 
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2.3.3 SELECTIVITY AND POTENCY OF KNOWN TRUNCATED C3a 
PEPTIDES 
2.3.3.1 Decapeptides 
A set of decapeptides has been reported as C5aR agonists (Kawatsu et al., 1996; Taylor et 
al., 2001; Vogen et al., 2001), namely 8, 9, 10 and 11. From a previous study (Proctor et al., 2004) 
C3aR binding affinities of 8 and 9 were IC50= 43 nM and IC50= 19 nM respectively when 
competing with 100 pM [125I]-C3a in polymorphonuclear cells (PMN), but bind to C5aR with lower 
affinity (IC50 = 39 µM and 10 µM when competing with 50 pM [125I]-C5a on PMN). 
In our hands in competitive studies using human PBMCs competing with 80 pM [125I]-C3a 
or 20 pM [125]-C5a, these decapeptides (8, 9, 11) bind with greater affinity to C3aR than C5aR 
(Table 2.1, Figure 2.9) especially 8 which has IC50 =14 nM for C3aR while binding to C5aR with 
lower affinity (IC50= 1.6 µM) which supports the result of previous studies using PMN (Proctor et 
al., 2004).  In contrast, 10 shows no binding to C3aR (Figure 2.9) and C5aR (Figure 2.10) but it 
did stimulate the intracellular calcium release, which may cause stimulation of receptors other than 
C3aR and C5aR (Table 2.1).  
2.3.3.1.1 Affinity of Known Truncated Anaphylatoxin Agonists: Decapeptides 
 
Binding affinity for C3aR 
 
 
Figure 2.9 Competitive [125I]-C3a binding assay on human PBMCs. Affinities for C3aR 
measured by displacement of 80 pM 125I-C3a by unlabelled hC3a (l) n=17, SB290157 (n) 
n=11 and 8 (q), 9 (p), 10 (♦) and 11 (¡) (n=3). It shows that 10 (♦) up to 100 µM did not bind 
to C3aR. Each point represents the mean percentage specific binding ±  S.E.M. 
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Binding affinity for C5aR 
 
 
 
Figure 2.10 Competitive [125I]-C5a binding assay on human PBMCs. Affinities for C5aR 
measured by displacement of 20 pM 125I-C5a by unlabelled hC5a (l) (concentration 1 pM to     
1 µM, n=13), 3D53 (n) n=12, 8 (q), 9 (p), 10 (♦) and 11 (¡) (n=3) (concentration 0.1 nM to 
100 µM). Each point represents the mean percentage specific binding ±  S.E.M. 
 
2.3.3.2 Known Truncated C3a: C3a Superagonist and C3a hexapeptides 
C3a 15-residue peptide WWGKKYRASKLGLAR (5) or “superagonist” was first reported 
by Ember and colleagues (1991) by adding a tryptophan dipeptide as the hydrophobic moiety and 
link to the C-terminal pentapeptide LGLAR that was reported to be fifteen-fold more potent than 
C3a in a guinea pig platelet aggregation assay.  
 From the previous study by our group to reinvestigate the superagonist in a calcium 
mobilisation assay it was found that the compound 5 induced the release of intracellular calcium 
from dU937 cells (EC50 = 1.0 µM) but with nineteen-fold less potency than native hC3a (EC50 = 52 
nM). Herein, we also further examined the selectivity of 5 by competing with 80 pM [125I]-C3a or 
20 pM [125I]-C5a.   
  The last six residues in the sequence of native hC3a, HLGLAR (12) and HLALAR (13) and 
the two pentapeptides YPLPR (14) and WPLPR (15) which were claimed to have an analgesic 
effect in mice when given intracerebroventricularly and be selective for C3aR (Jinsmaa et al., 2001) 
were also reinvestigated by radioligand competitive assays.  
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2.3.3.2.1 Affinity of C3a Superagonist and C3a hexapeptides 
 From the results of this study we found that 5 binds with high affinity to C3aR (Figure 
2.11) (IC50 = 2 nM) but with 20 times less affinity than native hC3a (IC50 = 0.1 nM) and does not 
bind to C5aR (Figure 2.12). However, the C-terminal hexapeptide sequences of human C3a 
(HLGLAR, 12) binds to C3aR with lower affinity at IC50 = 5 µM which is similar to the binding 
affinity of HLALAR (13). In contrast, compound 15 has much weaker affinity for C3aR while 14 
shows no affinity for C3aR (Table 2.1).  
Binding affinity for C3aR 
 
Figure 2.11 Competitive [125I]-C3a binding assay of C3a superagonist and hexapeptides on 
human PBMCs. Affinities for C3aR measured by displacement of 80 pM 125I-C3a by unlabelled 
hC3a (l) n=17, 3 (n) n=11, 5 (p), 12 (q), 13 (♦), 14 (¡) and 15  (l) (n=3) for C3aR. 
Binding affinity for C5aR 
 
Figure 2.12 Competitive [125I]-C5a binding assay on human PBMCs. Affinities for C3aR 
measured by displacement of 20 pM 125I-C5a from human PBMCs by unlabelled hC5a (l) 
n=13, 4 (n) n=12, 5 (p), 12 (q), 13 (♦), 14 (¡) and 15 (l) (n=3) for C5aR. Each point 
represents the mean percentage specific binding ±  S.E.M. 
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2.3.3.2.2 Potency of Superagonist and known hexapeptides   
In the Calcium Release Assay (Figure 2.13), the agonist potency of the compounds 
correlated to the binding affinity of the compounds. For example, 12 which had lower affinity for 
C3aR than 5 and 8 also showed lower potency than these compounds.  Surprisingly, 5 (IC50 = 2 
nM) which had six fold higher affinity for C3aR than 8 (IC50 = 13 nM) showed ten fold less 
potency (EC50 = 1.3 µM) than 8 (EC50 =  0.13 µM)  in the calcium mobilisation assay on dU937.  
 
 
 
 
Figure 2.13 Activity of hC5a (n), hC3a (l), 8 (q), 5 (♦) and 12 (p) in the intracellular 
calcium mobilisation assay measured in human dU937 cells (n ≥ 3). Data is expressed as 
percentage of normalised maximum change in fluorescence ±  S.E.M. 
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Table 2.1 Affinity and Potency of Known Truncated Anaphylatoxin Agonists on dU937 cells. 
  C3a Receptor Affinity C5a Receptor Affinity Apparent Agonist Activity 
# Peptide n pIC50 ±  IC50a n pIC50 ± 
± S.E. 
IC50b n pEC50 ±  EC50c 
   SE (nM)  SE (nM)  SE (µM) 
1 C3a 17 10 ± 0.05 0.1 3 ϕ - 10 7.3 ± 0.06Ð 0.05 
2 C5a 1 ϕ - 13 9.0 ± 0.07 1.02 3 8.2 ± 0.09Ð 0.01 
3 SB290157 11 6.8 ± 0.08 143 3 ϕ - 3   φd - 
4 3D53 3 ϕ - 12 6.9 ± 0.05 124 3 φ - 
5 WWGKKYRASKLGLAR 3 8.7 ± 0.20* 2.0 3 ϕ - 5 5.9 ± 0.16 1.3 
6 C3a63-77 3 6.6 ± 0.23 250 3 ϕ - 4 5.8 ± 0.11 1.8 
7 C5a60-74 3 5.8 ± 0.21* 1600 3 5.8 ± 0.17ë 1700 4 4.6 ± 0.11Ð 24 
8 YSFKPMPL(Me-a)R 3 7.9 ± 0.13* 13 3 5.7 ± 0.14ë 2000 5 6.9 ± 0.06Ð 0.13 
9 YSFK(Me-D)MPLaR 3 6.1 ± 0.19 740 3 4.5 ± 0.45ë 29000 5 5.9 ± 0.05 1.4 
10 YSHKPMPLaR 3 ϕ - 3 ϕ - 3 5.2 ± 0.03 5.7 
11 YSFKPMPLaR 3 6.9 ± 0.10 140 3 5.3 ± 0.21ë 4700 2 6.7 ± 0.07Ð 0.22 
12 HLGLAR 3 5.2 ± 0.21* 5900 3 ϕ - 3 5.4 ± 0.31 3.8 
13 HLALAR 3 5.2 ± 0.29* 6300 3 ϕ - 3 φ  
14 YPLPR 3 ϕ - 3 ϕ - 2 φ  
15 WPLPR 3 4.5 ± 0.50* 27000 3 ϕ - 2 φ  
a Concentrations causing 50% inhibition of maximum binding of 125I-C3a to intact human PBMCs. bConcentration causing 50% inhibition of maximum binding of 
125I-C5a to intact human PBMCs; cConcentration causing 50% maximum calcium mobilisation from Bt2-cAMP differentiated U937 cells. d No agonist activity at 1 
mM concentration, antagonist with pIC50 = 5.9 ± 0.1 (IC50 1.3 µM). ϕ No binding detected at 1 mM.  φ No intracellular calcium release detected at 10 µM.  pIC50 
and pEC50  expressed as mean ± SE;  n represents the number of separate experiments performed.; * p < 0.05 vs. 3 for 5, 7, 8, 12, 13 and 15; ë p < 0.05 vs. 4 for 7, 
8, 9, 11 ; Ð p < 0.05 vs. 12 for 1, 2, 7, 8  and 11.
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2.3.4 C3a DES-ARG COMPOUNDS 
2.3.4.1 Binding Affinities of des-Arg compounds to C3aR 
The importance of arginine at the C-terminus of hC3a was confirmed by designing two 
compounds without arginine, FLTLA (26) and FISLA (27), which were examined in the 
competitive assay with [125I]-C3a. The results showed no binding of these desArg compounds 
(Figure 2.14).  
As we know the cleavage of C-terminal arginine by carboxypeptidase N converts C3a into 
C3a des-Arg, which lacks anaphylatoxic properties and deletes its ability to bind to C3aR.  C3a 
desArg is also known as acylation-stimulating protein (ASP), which has potent anabolic effects on 
human adipose tissue where it increases glucose uptake and nonesterified fatty acid storage 
(Cianflone et al., 1999; Cianflone et al., 2003; Murray et al., 1999; Xia et al., 2004). Recently, it 
was found that ASP binds to C5L2 and stimulates triglyceride synthesis (Kalant et al., 2005). 
 
 
 
 
 
Figure 2.14 Competitive [125I]-C3a binding of FLTLA (26) (Â) and FISLA (27) (n) on 
isolated human monocytes. Isolated human monocytes (15x106 cells/mL) were incubated for 1 
h at room temperature with a constant concentration (80 pM; 2200 Ci/mmol) of 125I-C3a and 
increasing concentration of non-labelled hC3a (concentration 1 pM to 1 µM) and non-labelled 
hC5a (concentration 1 pM to 1 µM) or other compounds (0.1 nM to 100 µM). hC3a (l) n=17,  
3 (n) n=11, 4 (+) n=1 and hC5a (x) n=1. Compound 26 and 27 up to 100 µM did not bind to 
C3aR. Each point represents the mean percentage specific binding ±  S.E.M. 
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2.3.5 C3a HEXAPEPTIDE ANALOGUES 
Since the C-terminal Leu-Ala-Arg motif has been shown to be vital for activity at C3aR 
(Caporale et al., 1980; Kohl et al., 1990), these residues were incorporated with the shortest C5aR 
peptide agonist, FKP(dCha)(Cha)r-NH2 (Drapeau et al., 1993; Kawai et al., 1991; Konteatis et al., 
1994) to produce hexapeptide F6KPLAR1 which from previous studies in our group, was believed 
to have some activity and selectivity for C3aR (Proctor, 2004). The aim of the present study was to 
produce peptides to mimic the C-teminus of human C3a but deliver higher potency and selectivity 
as C3aR agonists for potential use as pharmacological probes of C3aR in vitro and ultimately in 
vivo.   
2.3.5.1 Binding affinity of hexapeptide analogues 
2.3.5.1.1 Affinity for C3aR of hexapeptide analogues 
 The most potent peptide analogues FLTLAR (17) and FWTLAR (20) bind to human 
isolated monocytes C3aR (Figure 2.15) with high affinities (IC50 = 42 nM, pIC50 ± SE = 7.38 ± 
0.26, n=3 and IC50 = 82 nM, pIC50 = 7.09 ± 0.33, n=3, respectively), but not C5aR (IC50> 100 µM) 
(Figure 2.16). The D-Arg containing peptide FLTLAr (24) had 200-fold lower affinity than 17 
(IC50 = 8 µM, pIC50 ± SE = 5.09 ± 0.5, n=3) (Table 2.2). 
 
Figure 2.15 Competitive [125I]-C3a binding of hC3a, SB290157, C3a and C5a 15 residues and 
C3a hexapeptide analogues on isolated human PBMCs. Isolated human monocytes (15x106 
cells/mL) were incubated for 1 h at room temperature with a constant concentration (80 pM; 2200 
Ci/mmol) of 125I-C3a and increasing concentration of non-labelled C3a (concentration 1 pM to 1 
µM) and non-labelled C5a (concentration 1 pM to 1 µM) or hexapeptide agonists (0.1 nM to 100 
µM) or 7, 54 and 24 (0.1 nM to 1 mM). hC3a (l) n=17,  3 (n) n=11, 4 (+) and hC5a (x) , 6 (p), 7 
(q) , 16 (♦), 17 (n), 20 (p), 18 (q), 22 (♦), 19 (l), 23 (∗), 21 (+), 54 (f),  24 (❢) n ≥  3. Each 
point represents the mean percentage specific binding ±  S.E.M. 
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2.3.5.1.2 Affinity for C5aR of hexapeptide analogues 
To determine whether compounds selectively bound to C3aR over C5aR, competition with 
C5a was also evaluated. By using competitive radioligand binding on human isolated monocytes 
the IC50 of each ligand were determined by displacement of [125I] labelled C5a.  
From these results, none of the C3a hexapeptide analogues (IC50 > 100 µM) bind to C5aR 
on human isolated monocytes, except for the C5a-terminal peptide (7) which did bind to C5aR 
(Figure 2.8) suggesting that all the hexapeptides are selective for C3aR over C5aR. 
 
 
 
 
Figure 2.16 Competitive [125I]-C5a binding of hC5a, AcF-[OPdChaWR] (3D53) and C3a 
hexapeptide analogues on isolated human monocytes. Isolated human monocytes (15x106 
cells/mL) were incubated for 1 h at room temperature with a constant concentration (20 pM; 
2200 Ci/mmol) of 125I-C5a and increasing concentration of non-labelled hC5a (concentration 1 
pM to 1 µM) and non-labelled hC3a (concentration 1 pM to 1 µM), 3D53(4) (0.01 nM to 1 µM) 
or hexapeptide agonists (0.1 nM to 100 µM) or 24 (0.1 nM to 1 mM). hC5a (l) n=13,  4 (n) 
n=12, 3 (+) and hC3a (x) , 25 (n), 16 (p), 17 (q ), 18 (♦), 20 (l), 22 (∗), 19 (+) , 23 (f), 21 
(n), 24 (q) , n ≥  3. Each point represents the mean percentage specific binding ±  S.E.M. 
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Table 2.2 Structure-Activity relationship (SAR) data for hexapeptide analogues of selective agonist F1WPLAR6. 
  C3a Receptor Affinity C5a Receptor Affinity Apparent Agonist Activity 
# Peptide n pIC50 ±  IC50a n pIC50± 
± S.E. 
IC50b n pEC50 ± 
S.E. 
EC50c 
   SE (nM)  SE (nM)  SE (µM) 
1 C3a 17 10 ± 0.05 0.10 3 ϕ - 10 7.3 ± 0.06 0.05 
2 C5a 1 ϕ - 13 9.0 ± 0.07 1.02 3 8.2 ± 0.09 0.01 
3 SB290157 11 6.8 ± 0.08 143 3 ϕ - 3   φd  
4 3D53 3 ϕ - 12 6.9 ± 0.05 124 3 φ  
16 FWPLAR 4 6.6 ± 0.30 274 3 ϕ - 5 6.0 ± 0.15 0.95 
17 FLTLAR 3 7.4 ± 0.26 42 3 ϕ - 5 6.5 ± 0.12 0.32 
18 FIPLAR 3 6.6 ± 0.13 230 3 ϕ - 2 6.0 ± 0.23 0.98 
19 WWTLAR 3 6.6 ± 0.12 244 3 ϕ - 3 6.0 ± 0.11 0.92 
20 FWTLAR 3 7.1 ± 0.33 82 3 ϕ - 4 6.5 ± 0.16 0.35 
21 FYTLAR 3 6.8 ± 0.17 166 3 ϕ - 2  5.3 ± 0.35Ð 4.8 
22 FWGLAR 3 6.7 ± 0.14 204 3 ϕ - 2 6.3 ± 0.09 0.47 
23 FLGLAR 3 6.8 ± 0.12 157 3 ϕ - 3 6.3 ± 0.33 0.52 
24 FLTLAr 3   5.1 ± 0.50* 8200 3 ϕ - 2  4.2 ± 0.12Ð 57 
25 FLTChaAR 2 6.6 ± 1.59 238 3 ϕ - 4 φ  
26 FLTLA 2 ϕ -  -  1 φ  
27 FISLA 2 ϕ -  -  1 φ  
 
a Concentrations causing 50% inhibition of maximum binding of 125I-C3a to intact human PBMCs. bConcentration causing 50% inhibition of maximum binding 
of 125I-C5a to intact human PBMCs; cConcentration causing 50% maximum calcium mobilisation from Bt2-cAMP differentiated U937 cells. d No agonist activity at 
1 mM concentration, antagonist with pIC50 = 5.9 ± 0.1 (IC50 1.3 µM). ϕ No binding detected at 100 µM.   φ No intracellular calcium release detected at 100 µM.  
pIC50 and pEC50  expressed as mean ± SE;  n represents the number of separate experiments performed.; pIC50 for C3aR: * p < 0.05 vs. 17 for 24. pEC50: Ð p < 
0.05 vs. 17 for 21 and 24. 
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2.3.5.2 Activity of hexapeptide agonists 
 
 
 
Figure 2.17 Activity of putative C3a agonist peptides at a concentration of 100 µM. Calcium release from differentiated U937 cells induced by 
100 µM of agonists is expressed as % maximum change in fluorescence induced by 1 µM of C3a. Error bars represented S.E.M. with n=2. 
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Figure 2.18 Activity of putative C3a agonist peptides at a concentration of 1 µM. Calcium release from differentiated U937 cells induced by       
1 µM of agonists is expressed as % maximum change in fluorescence induced by 1 µM of C3a. Error bars represented S.E.M. with n=4. 
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2.3.5.2.1 Structure-activity relationships (SAR) for hexapeptide agonist analogues of F1WPLAR6: Single Point Agonist Potency 
Comparisons 
 
A. Substitution at position 1 or 1 and 3, F1WP3LAR or 
F1LT3LAR 
 
B. Substitution at position 2, FW2PLAR or FL2TLAR 
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C. Substitution at position 3, FWP3LAR or FLT3LAR 
 
D. Substitution at position 4 or 3 and 4, FWP3L4AR or 
FLTL4AR 
 
E. Substitution at position 5 and 6 FLTLA5R6 
 
F. Cyclic peptides and others 
 
Figure 2.19 Structure Activity Relationship studies of hexapeptide agonists by substitution of F1WPLAR6 or F1LTLAR6.  Agonist activity 
for hexapeptides, which are compared by substitution at different positions, induced calcium release from human dU937 cells. 
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Table 2.3 Structure-Activity of F1WPLAR6 and F1LTLAR6 analogues on human dU937 
cells measured by calcium release assay.  
Apparent Agonist Activity 
# 
 
 
Peptide n pEC50 ±  S.E. EC50c (µM) 
16 FWPLAR 5 6.02 ± 0.15 0.95 
19 WWTLAR 3 6.04 ± 0.06 0.91 
28 hFLTLAR 2 4.96 ± 0.08ëÐ 11 
29 Ac-FLTLAR 2 6.28 ± 0.15 0.52 
30 YLTLAR 2 5.61 ± 0.15 2.5 
31 RLTLAR 4 ϕ - 
32 F(Cha)PLAR 5 6.13 ± 0.22 0.75 
33 F(Nap)PLAR 3 6.16± 0.22 0.70 
34 F(hF)PLAR 3 5.98± 0.21 1.0 
18 FIPLAR 2 6.01 ± 0.23 0.98 
35 FOTLAR 2 ϕ - 
36 FRTLAR 2 5.17 ± 0.36ëÐ 6.8 
21 FYTLAR 2 5.32 ± 0.35ë 4.8 
37 FYSLAR 2 4.82 ± 0.40*ëÐ 15 
38 FKTLAR 2 5.36 ± 0.40 4.4 
39 FNleTLAR 3 6.51 ± 0.30 0.31 
40 FVTLAR 2 5.32 ± 0.15ë 4.8 
41 FISLAR 3 5.95± 0.13 1.1 
22 FWGLAR 2 6.33 ± 0.09 0.47 
42 FWALAR 3 5.93 ± 0.12 1.2 
43 FWSLAR 5 6.31 ± 0.09 0.49 
20 FWTLAR 6 6.43 ± 0.09 0.37 
17 FLTLAR 5 6.50 ± 0.12 0.32 
23 FLGLAR 3 6.29 ± 0.33 0.52 
44 FLPLAR 3 6.36± 0.31 0.44 
45 FLALAR 3 5.96 ± 0.23 1.1 
46 FLSLAR 4 6.45 ± 0.19 0.36 
47 FLTlAR 2 ϕ - 
48 FLTNleAR 2 5.58 ± 0.26 2.7 
25 FLTChaAR 4 ϕ - 
49 FLT(dCha)AR 2 ϕ - 
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50 FLTSAR 3 ϕ - 
51 FWTVAR 2 ϕ - 
52 FWSIAR 2 5.38± 0.10 4.1 
53 FLTLLR 4 ϕ - 
54 FLTLPR 2 4.54 ± 0.19*ëÐ 29 
24 FLTLAr 2 4.24 ± 0.12*ëÐ 57 
55 FLTLAR-NH2 2 4.44 ± 0.19*ëÐ 37 
a Concentration causing 50% maximum calcium mobilisation from Bt2-cAMP differentiated 
human U937 cells. ϕ No calcium release detected at 1 mM. * p < 0.05 vs. 16 for 24, 37, 54, and 55; 
ë p < 0.05 vs. 17 for 21, 24, 28, 36, 37, 40, 54, 55; Ð p < 0.05 vs. 20 for 24, 28, 36, 37, 54 and 55. 
 
Structure-activity relationships (Figure 2.17, 2.18 and 2.19) suggest the following 
points. 
The results of single point studies as well as dose concentration profiles suggest the 
following points. 
Position 1: Phenylalanine (F) at position 1 (corresponding to C3a residue 72) is an aromatic 
residue that lacks charge. When substituted by histidine (H) or arginine (R) agonist activity 
decreases, but is of comparable potency when replaced by tryptophan (W). Thus phenylalanine 
followed by tryptophan at this position appears to have the best size, aromaticity and lack of charge, 
required for C3a activity (Figure 2.19A and Table 2.3). 
Position 2: Substitution of tryptophan (W) in FWPLAR (16) by other hydrophobic amino 
acids such as Cha, Nap, hF, isoleucine (I), or leucine (L) did not show any significant change in 
EC50. However, substitute at the 2nd position of FL2TLAR with ornithine (O), arginine (R), lysine 
(K), Tyrosine (Y) or valine (V) gave detrimental to agonist activity (Figure 2.19B and Table 2.3).  
Position 3: Substitution of proline (P) at position 3 with serine (FWSLAR) or threonine (T) 
or glycine (G) increased agonist potency, whereas alanine (A) at this position did not improve 
agonist activity (Figure 2.19C and Table 2.3). 
Position 4: Substitution of leucine at position 4 with valine (V), Cha, D-Cha or D-L, 
diminishes agonist activity. Furthermore, substitution with isoleucine (I) (from FWSLAR to 
FWSIAR) results in 10 times less agonist potency (Figure 2.19D and Table 2.3). 
Position 5: Substituting alanine (A) at position 5 with leucine shows a decreased agonist 
activity (FLTLAR (17), EC50 ± 95% CI; 0.37 ± 0.18 µM; FLTLLR (53) no activity at 100 µM) 
(Figure 2.19E and Table 2.3). 
Position 6: Replacing arginine (R) at position 6 with D-R decreased potency (Figure 2.19E 
and Table 2.3). 
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In conclusion, position 1 requires a hydrophobic, aromatic residue such as phenylalanine or 
tryptophan (Figure 2.20, 2.21) for C3a agonist activity. All agonist potency is destroyed by 
insertion of polar, hydrophilic residues such as histidine and arginine at this position. For the 
second position, substitution with hydrophobic groups such as Cha, Nap or hF show similar agonist 
activity to FWPLAR. However, substitution by ornithine, lysine or arginine at this position lower 
potency of agonist activity (Table 2.3).  At position 3 substitution by proline or alanine shows 
similar potency while substitution by serine, glycine or threonine showed an increase in potency 
(Figure 2.21). At positions 4, 5, 6 the substitution of leucine, alanine and arginine by any other 
residue was shown to be detrimental to agonist activity or had no improvement (Figure 2.22). 
Therefore residues L4A5R6 are extremely important for the activity of these hexapeptides. 
 
 
 
  
16 17 
  
18 19 
 
20 
 
Figure 2.20 Structure of hexapeptides 16 - 20. 
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2.3.5.2.2 Dose dependence of hexapeptide analogues 
 
Figure 2.21 Intracellular calcium release in differentiated U937 cells induced by hC3a (l),    
20 (l) and 46 (l), 19 (l) and 17 (l).  The results are expressed as a percentage of maximum 
change in fluorescence ±  S.E.M. (n=3).    
 
 
 
Figure 2.22 Intracellular Ca2+ release induced by variable concentration of C3a peptide 
analogues. The dose response activity of 16 (n), 42 (p), 20 (q), 17 (®) 19 (l), 48 (¨), 21 
(r), 45 (q), 18 (®), 25 (l), 53 (x), 31 (+), 41 (∗) and 46 (+) mediated intracellular Ca2+ 
mobilisation was measured in differentiated U937 cells (n ≥ 3). The results are expressed as a 
percentage of maximum change in fluorescence induced by hC3a (1 µM) ±  S.E.M.    
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The concentration response curve for differentiated U937 cells on some C3a peptide 
analogues are shown in Figure 2.22. From Table 2.3, the most potent hexapeptide agonists in this 
study were 17 (EC50 ± 95% CI; 0.37 ± 0.18 µM, pEC50 6.50 ± 0.12, n=5), FNleTLAR (39) (EC50 ± 
95% CI; 0.71 ± 0.65 µM, pEC50  6.51 ± 0.3, n=3) and 20 (EC50 ± 95% CI; 0.45 ± 0.29 µM, pEC50 
6.46 ± 0.16, n=4). 
2.3.5.2.3 Desensitisation of hexapeptide analogues. 
A.  
 
B.  
 
C.  
 
D.  
 
E. 
 
F. 
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Figure 2.23 Desensitisation assays of hexapeptide analogues and C3a superagonist peptide.  
 
We next used a desensitisation experiment to test our C3a peptide analogues for indications 
of selectivity for the C3a receptor over the C5a receptor. Figure 2.23 shows that administration of     
3 µM C3a to differentiated U937 cells causes an efflux of intracellular Ca2+ and successive addition 
of 100 µM 16 (Figure 2.23 B) and 300 µM  5 (Figure 2.23 F) still cause Ca2+ release. This 
suggests that 16 and 5 act on a different receptor to the desensitised C3a receptor.  In contrast, 18, 
20 and 17 (Figure 2.23 C, D and E, respectively) do not stimulate calcium release following C3a 
receptor desentisation indicating that they are selective for C3aR.  
 
 
 
 
 
Figure 2.24 Correlation between binding affinity (pIC50) and agonist activity (pEC50) of 
hexapeptide agonists.  
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Figure 2.25 NMR-derived solution structure for FLTLAR in DMSO-d6 (298 K).  (A) 
Representative NMR structure of FLTLAR showing the H-bond formed between the side chain 
hydroxyl group of Thr4 and the backbone amide proton of Leu3. A distance of 2.8 Å separates 
the heavy atoms involved in the bond. (B) 15 of 20 lowest energy minimized NMR structures 
showing the backbone of FLTLAR. Residues are labelled with three-letter amino acid codes 
(These structures were produced by Dr. Scully, C.C.G. and Dr. Hoang, H.N. from Fairlie group).  
 
2.4 DISCUSSION 
 Human C3a is implicated in the pathology of many inflammatory conditions and 
immune diseases. The finding of either an agonist or antagonist would have many beneficial 
uses. Unlike C5a, the pathological role of C3a has been difficult to assess due to the 
continuous degradation of C3 that releases into blood stream. C5a generally has an order of 
magnitude higher agonist potency than C3a in vitro and in vivo. However, the concentration 
of C3a in the plasma is significantly higher (between 10 to 15 fold) than C5a (Bitter 
(A). 
 
(B). 
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Suermann, 1988; Foreman et al., 1996).  Some of the cellular and physiological responses 
associated with C3a include chemotaxis, induction of smooth muscle contraction, activation 
of leukocytes (primarily mast cells and eosinophils), secretion of proinflammatory cytokines 
and an increase in vascular permeability, which leads to migration of leukocytes into 
inflammatory sites (Gerard et al., 2002; Haas et al., 2007; Hawlisch et al., 2004). C3a and 
C5a generate their effects through specific receptors, C3aR and C5aR, which belong to the 
rhodopsin family of G-protein coupled receptors. C3aR and C5aR also share 37% amino acid 
sequence homology in the transmembrane region and the second intracellular loop (Haas et 
al., 2007). A two-site model, like C5aR, has been postulated for C3aR. Similar to C5aR, the 
C3a C-terminus synthetic peptide analogues can activate C3aR. The two-site binding model 
has been proposed for C5a binding to C5aR in which the N-terminal core of C5a binds to the 
N-terminus of the C5aR while the C-terminus binds to the active site which is located in the 
transmembrane region of C5aR (Chen et al., 1998; Siciliano et al., 1994). C3aR has a unique 
characteristic among G-protein coupled receptor (GPCR) of a large extracellular loop 2 which 
plays an important role in C3a binding (Gao et al., 2003). C3aR and C5aR are expressed in 
similar cells, especially on myeloid cells such as neutrophils, eosinophils, basophils, 
monocytes and mast cells. Recently, they have also been found in non-myeloid cells 
(epithelial and endothelial cells). In leukocytes, C3a and C5a mediate their effects by coupling 
to pertussis toxin sensitive G-protein (Gαi) and pertussis toxin-insensitive G-protein (Gα16) 
(Buhl et al., 1995; Norgauer et al., 1993; Vanek et al., 1994; Zwirner et al., 1997). C3aR also 
couples to Gα12 and Gα13 in endothelial cells (Schraufstatter et al., 2002). The coupling of 
C3aR to Gαi which inhibits adenylate cyclase enzyme and the βγ subunit activates the MAP 
kinase pathway and phospholipase C (PLC). Cleavage of phospholipid membrane by PLC 
produces phosphoinositol 3 (IP3) which mobilizes intracellular Ca2+ and diacylglycerol 
(DAG) which leads to the activation of proteinkinase C (PKC). After agonist activation of the 
GPCR the intracellular surface of the receptor becomes susceptible to phosphorylation by G-
protein-coupled receptor kinases (GRKs), which promotes binding of arrestins to 
phosphorylation sites. In turn, this helps to prevent further agonist stimulation and uncoupling 
of G-protein (Haas et al., 2007).  
 It is known that the residues responsible for activation of C3aR are localized within the 
C-terminal octapeptide region of C3a. There have been efforts to develop synthetic C3a 
ligands that functionally mimic C3a by creating short peptides based on the C3a C-terminus. 
Like C5a, the C-terminal arginine is vital for C3a biological activity. In the circulation, the 
enzyme carboxypeptidase N cleaves the C-terminal arginine of C3a and C5a forming the 
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degradation products C3a desArg and C5a desArg. The results of binding studies also shows 
that compounds FLTLA and FISLA do not bind to C3aR (Figure 2.14). 
 There are difficulties in comparing the reported activities of small synthetic C3a 
peptides due to the variety of assay systems used to evaluate these ligands. Furthermore, 
guinea pig tissues and cells have been used, which have two functional C3aR in comparison 
to only one in human (Fukuoka et al., 1998). Therefore, known C3a agonists were 
reinvestigated for binding affinity against human C3aR as well as human C5aR and in a 
calcium mobilisation assay for function.  From the competitive binding studies we found the 
decapeptide compounds which were originally reported as C5aR agonists bound much more 
tightly to C3aR than C5aR which was also consistent with the previous report of competitive 
binding in PMN (Proctor et al., 2004). While the C3a superagonist, 
WWGKKYRASKLGLAR was first reported as being 12-15 times more potent than hC3a in a 
guinea pig platelet aggregation assay, vascular permeability and ileum contraction (Ember et 
al., 1991) it was found by us to bind tightly to C3aR on human monocyte cells but had weak 
agonist activity in the calcium mobilization assay in dU937 cells. It also does not show 
selectivity for C3aR in a desensitization assay, in which induced calcium release from cells 
was measured after the C3aR was first desensitized by administration of hC3a (3 µM) to the 
cells. The cause of calcium release from the cells may be due to triggering of other receptors 
than C3aR. 
 From the new series of hexapeptides obtained by modification of the C-terminus of 
native human C3a, we found FWTLAR (20) and FLTLAR (17) are the most potent (EC50 ~ 
0.3 µM) and also show selectivity for C3aR in competitive radioligand binding (in both [125I]-
C3a and [125I]-C5a)) and a desensitization assay in which they do not induce the release of 
calcium after desensitization of the cells with C3a.  
 There was a pseudo-linear correlation (Figure 2.24) between agonist potency (by 
measuring the release of Ca2+ into human dU937 cells) and the binding affinity for C3aR 
(measured by competition with [125I]- labeled C3a on PBMCs). From these data, we were able 
to find a new antagonist FLTChaAR (25) which has comparable binding affinity to 
SB290157(3) for human C3aR on PBMCs with IC50 = 238 nM and IC50 = 143 nM 
respectively (Table 2.2). FLTChaAR (25) also does not bind to C5aR in a competitive 
binding assay with iodine labeled C5a. Unsurprisingly, 25 is an equipotent antagonist in the 
calcium mobilization assay to inhibit C3a-induced calcium release from dU937 (IC50 = 1.5 
µM vs IC50 1.3 µM)(Scully et al., 2010).  
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 An NMR-derived solution structure study from our group member for FLTLAR (17) 
(Figure 2.25) showed significant “turn” or “bend” propensity in DMSO. A feature of the C-
terminus of C3a itself hints at a potential requirement for this structural feature for binding 
within the transmembrane region of human C3aR. This result is consistent with the finding 
that over 100 peptide-activated G-protein coupled receptors have shown a tendency to 
recognize protein and peptide ligands with turn structure (Fairlie et al., 2005; Tyndall et al., 
2005) and that cyclic peptides that mimic turn conformations tend to be potent ligands for 
GPCR and other protein targets (Fairlie et al., 1995; Tyndall et al., 2005). 
 The conclusions from the study of structure activity relationships (SAR) for potent and 
selective hexapeptides are the following (1) the C terminal L4AR6 motif is important for 
agonist activity. Changing these motifs leads to significant reductions in agonist activity. (2) 
threonine at the third position gave the most potent compound although other amino acids 
(serine, glycine) were not much less potent. (3) at the second position, the most potent 
compounds had tryptophan, norleucine or leucine. (4) at the N-terminal or first position, 
ligands with phenylalanine or tryptophan were potent ligands. (5) Replacing leucine at the 
fourth position by a bulkier group leads to the antagonist (FLTChaAR). 
 
 
2.5  MATERIALS AND METHODS 
2.5.1 CELL ISOLATION AND CULTURE OF PBMCs 
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coat (obtained 
from Australian Red Cross Blood Service, Kelvin Grove) using Ficoll-paque density centrifugation 
(GE Healthcare Bio-Science, Uppsala, Sweden) and cultured in complete media, consisting of 
IMDM with 10% FBS, 10 U/mL penicillin, 10 U/mL streptomycin and 2mM L-glutamine 
(Invitrogen) at 37 °C, with 5% CO2. Promonocytic U937 cells (cultured in RPMI media with 10% 
FBS, L-Glu, PenStrep and NEAA) were pretreated 72 h prior to assay with membrane-permeable 
cAMP analogue Bt2-cAMP (0.5 mM), which induces cell differentiation to a 
monocyte/macrophage- or granulocyte-like phenotype. Cellular differentiation induces increased 
C3aR and C5aR expression on the cell membrane (Burg et al., 1996; Klos et al., 1992).  
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2.5.2 RECEPTOR BINDING ASSAY ON PBMC CELLS  
Receptor binding was performed using [125I]-C3a, 80 pM (2200 Ci/mmol; Perkin Elmer, 
Torrance, CA, USA), PBMC cells (15x106 cells/mL and in the absence or presence of various 
concentrations of unlabeled C3a or C3a hexapeptide agonist for 60 min at room temperature with 
shaking in 50 mM Tris, 3 mM MgCl2, 0.1 mM CaCl2, 0.5% (w/v) Bovine serum albumin, pH 7.4.  
Unbound radioactivity was removed by filtration through glass microfiber filters GF/B (Whatman 
Iner. Ltd, England) which had been soaked in 0.6% polyethylenimine to reduce non-specific 
binding. The filter was washed 3 times with cold buffer (50 mM Tris-HCl) pH 7.4.  Bound [125I]-
C3a was then assessed by scintillation counting on a β-counter. Specific [125I]-C3a binding is 
defined as a difference between total binding and non-specific binding as determined in the 
presence of 1 µM unlabelled C3a. The IC50 value is the concentration of antagonist to inhibit the 
binding of labelled ligand by 50%. Nonlinear regression analysis (GraphPad Prism 5, USA) was 
performed on concentration response curves to determine IC50 and pIC50. The pIC50 for each 
compound was calculated for separate experiments and expressed as an arithmetic mean standard 
error (SE). IC50 values were expressed as a geometric mean. 
 
2.5.3 INTRACELLULAR CALCIUM RELEASE ASSAY (FOR SUSPENSION 
CELLS, dU937 CELLS) 
 Pretreated U937 cells and culture medium were centrifuged (2500 rpm, 5 mins). The supernatant 
was removed, and the cells were resuspended in 2 mL wash buffer (1X HBSS, 20 mM HEPES, 2.5 
mM Probenecid, pH 7.4) and cells were counted on a hemocytometer. One dye-loading buffer (12 
mL wash buffer, 1% FBS, 25 µL Fluo-3 (final concentration 4 µM), 25 µL 20% Pluronic acid) was 
added per 5-7 million cells. Cells were suspended in dye loading buffer, incubated in a covered 
culture flask for 1 h at 37 °C, then centrifuged (2500 rpm, 5 mins). The supernatant was removed, 
cells resuspended in 3 mL wash buffer, centrifuged (2500 rpm, 5 mins) and the process repeated for 
cell density of 2x106 cells/mL (or 100,000 cells per well). 50 µL of test compound or buffer or 
control/well was plated out on sterile black-wall, clear-bottom 96-well plates (Corning 
Incorporated, NY, USA). The Plate was then loaded into the FLUOstar instrument (BMG 
LabTechnologies, Offenburg, Germany), where fluorescence was measured over one minute with 
excitation at 485 nm and emission at 520 nm of Fluo-3 bound Ca2+ complex, at 28 °C. 
Differentiated U937 cells were administered in situ 10 sec into the one-minute reading. Agonist 
responses were expressed as a percentage of calcimycin (A23187) or control compound activity, 
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measured as the maximum change in fluorescence through emission from the Fluo-3 bound calcium 
complex.  
 
2.5.4  DATA ANALYSIS AND STATISTICS 
For both receptor binding and agonist assays, non-linear regression was performed using 
Prism 5 (GraphPad Software, San Diego, CA). The statistical analysis has been utilized for receptor 
binding assays and functional assays.  
In receptor binding assays, the pIC50 for each peptide was calculated for separate 
experiments and expressed as an arithmetic mean ± standard error (SE). A one-way ANOVA 
coupled with Tukey post test was performed on pIC50 values to compare compound affinities. P ≤ 
0.05 was considered to indicate a statistically significant difference between receptor affinities. 
In Functional Assays, the concentration curves were analysed by non-linear regression 
(GraphPad Prism 5, USA) and EC50 and pEC50 determined. A pEC50 for each compound was 
calculated from separate experiments and expressed as an arithmetic mean ± SE. A one-way 
ANOVA coupled with a Tukey post test was performed on pEC50 values to examine statistical 
significance between agonist potencies of C3a analogue peptides. P ≤ 0.05 was considered to 
indicate a statistically significant difference.  
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3.0 ABSTRACT 
In Chapter 2, peptides such as agonist FLTLAR and antagonist FLTChaAR were developed 
using competitive radio-ligand binding and structure-activity relationships to identify potent peptide 
agonists of human C3a receptor. However, C3a-derived peptides have significant disadvantages for 
use in biology and medicine in their poor bioavailability, poor stability to protease enzymes, high 
clearance rates, and poor membrane permeability. Therefore, it is highly desirable to develop 
nonpeptidic C3a ligands that are more suitable for use as pharmacological/physiological probes for 
interrogating the roles of hC3a in vivo. As a step towards this goal, Chapter 3 now summarizes the 
introduction of a heterocycle to restrict the conformational freedom of short peptides, in an attempt 
to mimic the receptor-binding conformation of the C-terminal activating domain of human C3a.  
A molecular modelling study (Figure 3.2) revealed structural similarity between the C3a 
carboxyl terminal residues (GLAR), modelled in a beta turn conformation, and the model of 
compound 56. This compound contains an oxazole heterocycle that acts as a beta turn-inducing 
constraint and mimics the conformation found for the C-terminus of C3a in its crystal structure. 
This result supports a large set of observations that GPCRs have a general tendency to recognise 
turn structural motifs in their protein and peptide ligands (Fairlie et al., 2005; Madala et al., 2010; 
Tyndall et al., 2005). 
In this study, multiple potent agonist compounds were discovered for C3aR. They competed 
strongly with 125I-labelled C3a in binding to, and activating intracellular calcium release in, human 
monocyte-derived macrophages (HMDM). Indeed, some of the compounds had equal or even 
greater affinity than C3a itself. Building on the discovery in Chapter 2 that hexapeptide agonists 
for C3aR agonist (e.g. FLTLAR) adopted a beta turn conformation at their C-terminus, it was 
decided to introduce an oxazole heterocycle into the LAR region to impart conformational rigidity 
to the agonist peptides (Figure 3.3). This modification produced new compounds with improved 
affinities for human C3aR. The oxazole has electronegative oxygen and nitrogen atoms that can 
function as hydrogen bond acceptors, while introducing a rigid turn-like conformation to the 
molecule. The most potent and selective compounds in this study were 56, 63 and 75 (EC50 = 19, 7 
and 17 nM, respectively) in HMDM cells. There was a linear correlation between the binding 
affinity of the compounds and their agonist potency.  
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3.1 INTRODUCTION 
C3a is a potent inflammatory mediator, which targets a wide range of immune and non-
immune cells. Release of C3a regulates vasodilation, increases vascular permeability and induces 
smooth muscle contraction (Ember et al., 1998). C3a can also trigger oxidative burst in 
macrophages (Murakami et al., 1993), neutrophils (Elsner et al., 1994b), and eosinophils (Elsner et 
al., 1994a). Stimulation of C3aR in basophils (Kretzschmar et al., 1993) and mast cells (Ellati et al., 
1994) causes the release of histamine. C3a also promotes the release of serotonin from guinea pig 
platelets (Fukuoka et al., 1988), modulates synthesis of IL-6 and TNF-α by B-lymphocytes and 
monocytes (Fischer et al., 1997; Fischer et al., 1999), and also stimulates the release of IL-1 from 
monocytes (Haeffnercavaillon et al., 1987). The functional receptor for C3a is C3aR, which binds 
C3a with Kd ~1 nM, but does not bind its desArg form or C5a (Crass et al., 1996; Wilken et al., 
1999). C3aR is a 54 kDa protein and is comprised of 482 amino acids. The binding of C3a to C3aR 
causes an increase in cytosolic calcium levels through activation of pertussis-toxin-sensitive G-
proteins (Norgauer et al., 1993; Zwirner et al., 1997). However, in endothelial cells, the signal 
transduction is through pertussis-toxin insensitive Gα12 and Gα13 (Schraufstatter et al., 2002). C3aR 
is also expressed on myeloid cell such as neutrophils, eosinophils, basophils, mast cells and 
monocytes/macrophages, dendritic cells (DC) and microglia (Ames et al., 1996; Crass et al., 1996; 
Daffern et al., 1995; Gutzmer et al., 2004; Hugli, 1986; Klos et al., 1992; Muller-Eberhard, 1988). 
C3aR also exists on non-myeloid cells such as astrocytes (Gasque et al., 1998), epithelial cells 
(Monsinjon et al., 2001), and endothelial cells (Monsinjon et al., 2003). 
C3a has been implicated in the pathogenesis and progression of numerous inflammatory 
conditions like asthma, allergies, arthritis, psoriasis, ischemia-reperfusion injury, sepsis, systemic 
lupus erythematosus, diabetes, nephropathy and others (Boos et al., 2004; Boos et al., 2005; Drouin 
et al., 2002; Drouin et al., 2001; Garrett et al., 2009; Humbles et al., 2000; Hutamekalin et al., 
2010; Kawamoto et al., 2004; Kildsgaard et al., 2000; Kirschfink, 2001; Mamane et al., 2009; 
Mizutani et al., 2009; Mocco et al., 2006; Mueller-Ortiz et al., 2006; Rahpeymai et al., 2006; 
Rynkowski et al., 2009; Tang et al., 2009; Wenderfer et al., 2009). In OVA-induced models of 
asthma in C3aR-/- mice (Drouin et al., 2002) and C3aR-/- guinea pigs (Bautsch et al., 2000), deletion 
of C3aR resulted in attenuation of asthma, as indicated by airway hyper-responsiveness, infiltration 
of eosinophils and decrease in levels of IL-5, IL-3 and IgE. Most studies indicate that C3a has a 
greater role in asthma progression than C5a. Therefore, the C3aR may be an important drug target 
for the development of anti-asthma drugs.  
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Human C3a is a highly cationic protein, which is comprised of 77 amino acids (human and 
porcine) and 78 (rat and mouse) with a molecular weight ca. 9000 (Hugli, 1975). The primary 
structure of C3a was reported in 1975 (Hugli, 1975). It was revealed to be highly cationic at the N-
terminus (amino acids 7-21) and C-terminus (amino acid 64-77)(Hugli et al., 1975b). There are 
several studies of the C3a structure with some conflicting results, which may be due to the 
utilisation of different techniques; for example X-ray crystallography (Figure 3.1) (Huber et al., 
1980; Paques et al., 1980), 1H NMR studies in aqueous solution from C3a desArg (Muto et al., 
1985), and circular dichroism of native C3a (Hugli, 1975; Hugli et al., 1975a; Lu et al., 1984). 
Despite differences in the techniques, there is a general consensus for the C3a structure in that it has 
a central globular helical core (residues 15-57), stabilised by three disulfide bonds with the C-
terminus extending from the helical core. Initial studies by CD suggested that the C3a molecule had 
regular helical structure with little beta-structure (Hugli et al., 1975a) and this was confirmed by 
crystallographic analysis; hC3a having 56% alpha-helicity (Huber et al., 1980).  Further study by 
2D NMR analysis of C3a by Nettesheim and colleagues (1988) identified the presence of three 
antiparallel helical regions in C3a at residues 17-28, 36-43 and 47-66. A transitional helix, from 67-
70, has also been reported (Chazin et al., 1988; Nettesheim et al., 1988). The N-terminus of C3a (1-
15) exhibits a high degree of flexibility. The C-terminus or effector region of C3a (69-77) has no 
well defined structure, which suggests either it remains flexible or folds back in a helical portion 
with a pseudo-beta turn conformation (Chazin et al., 1988). It has been postulated that the turn 
structure of the C-terminus of C3a may be important for the biological activity of C3a (Hoeprich et 
al., 1986). 
Circular dichroism techniques were used to study three truncated C-terminal sequences of 
native human C3a: C3a(57-77), C3a(65-77) and C3a(73-77) and it was indicated that these peptides 
have random coil conformations in aqueous solution(Lu et al., 1984). The 21-residue C-terminus 
(C3a 57-77) of C3a has been synthesised and shown by two groups (Huey et al., 1984; Lu et al., 
1984) that this peptide is nearly equivalent in potency as the 77 amino acids of native human C3a. 
CD data for C3a(57-77) indicated that the 21-residue peptide adopts an alpha-helical conformation 
(~ 41% of content) after addition of 25% (v/v) trifluoroethanol (TFE). Furthermore, a 21-residue 
analogue of native C3a, incorporating helix-promoting residues 2-aminobutyric acid and 2-
aminoisobutyric acid, showed a 250-fold increase in biological activity over both native C3a and 
C3a (57-77) (Hoeprich et al., 1986). In contrast, the incorporation of proline residues, which can 
disrupt helices, was shown to significantly reduce activity for C3a (57-77)(Hoeprich et al., 1986). 
This indicated a relationship between a preference for a turn conformation and the biological 
activity of the C-terminal sequence of C3a and derived short peptides.  
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The NMR and crystallographic studies of C3a were unable to assign the secondary structure 
of the C-terminal pentapeptide (C3a 73-77), which was shown to be highly flexible in aqueous 
media (Hoeprich et al., 1986). It has been suggested (Hoeprich et al., 1986; Lu et al., 1984) that the 
C-terminal pentapeptide may form a helical conformation under hydrophobic conditions such as in 
the membrane environment prior to binding and subsequent activation of C3aR.  
Parallel to these physicochemical approaches to characterise the C3a conformation, there are 
also many studies reported for biological activity of C3a and synthetic C3a peptide analogues. The 
synthetic C3a analogues and substituted peptides have been used to determine the important amino 
acids and structural requirements for C3a biological activity. 
LGLAR (C3a 73-77) was found to be the minimum sequence of C3a in the C3a mediated 
C3a-C3aR interaction to have anaphylatoxin-like activity (Caporale et al., 1980). LGLAR is highly 
conserved in many species e.g. human, bovine, rat, mouse and guinea pig (Corbin et al., 1976; 
Hugli, 1975; Hugli et al., 1975b). The activity of LGLAR is lower than the native C3a by 
approximately 1000 fold (Hugli et al., 1977). There are many studies of synthetic peptides that have 
shown that the activity is dependent on the peptide length. The C-terminal arginine was found to be 
essential for biological activity. The cleavage of the arginine residue by carboxypeptidease N 
(serum inactivator of the anaphylatoxin peptides)(Bokisch et al., 1970) abrogates the biological 
acitivities of C3a but not C5a. However, Hugli (1975) reported on the basis of a CD study that C3a 
and C3a desArg retain the same structure and this was also consistent with the results of  an NMR 
study (Muto et al., 1985). Furthermore, there was a study showing the relationship between the 
tertiary structure of C3a and its biological activity by using high temperature or denaturing 
chemicals which causes extensive and irreversible unfolding of structure and results in loss of 
biological activity of C3a (Hugli et al., 1978).  
A shorter C3a peptide analogue was found with more potency in biological assays. This 
enhanced activity was achieved by incorporating a hydrophobic fluorenyl-methoxycarbonyl (Fmoc) 
or 2-nitro-4-azidophenyl (Nap) or 6-aminohexanoyl (Ahx) group at the N-terminus of 5 to 13 
residues of C-terminal C3a analogue peptides (Ember et al., 1991; Gerardyschahn et al., 1988; Kohl 
et al., 1990) and even the C3a analogue peptide can be further shortened to the minimal sequence 
LAR with addition of hydrophobicity linked with a spacer (eg. Fmoc and Ahx)(Kohl et al., 1990). 
A two to ten fold increase in the biological potency was observed in a guinea pig platelet ATP-
release assay for the various 5 to 13 residue analogues of C3a which incorporated either Fmoc or 
Nap groups. It was hypothesised that the hydrophobic group was inserted into the membrane and 
helped to increase the effective concentration of the peptide for receptor activation (Ember et al., 
1991).  
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A C3a “superagonist” was reported by Ember and colleagues (1991) in which the natural 
amino acid tryptophan was used as an N-terminal hydrophobic residue (analogous to Fmoc and 
Map C3a analogues) and greater potency than C3a was reported. This 15-residue peptide 
(WWGKKYRASKLGLAR) was approximately 12-15 times more potent than C3a in a guinea pig 
platelet aggregation, vascular permeability and ileum contraction assay (Ember et al., 1991). 
However, there are many other studies suggesting that the C3a superagonist has lower affinity and 
less potency than hC3a in a calcium mobilisation assay on human C3aR transfected cells (Ames et 
al., 1996; Ames et al., 1997; Chao et al., 1999), human neutrophils (Ames et al., 1997), rat 
astrocytes (Ischenko et al., 1998) and guinea pig peritoneal macrophage cells (Takahashi et al., 
1996).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 The 3D Crystal structure of C3a (77 amino acid residue). It has a central globular 
helical core and is stabilised by three disulfide linkages (Cys: 22-49, 23-56, 36-57) with the C-
terminus extending from the helical core and adopting a dynamic random coil conformation 
(Huber et al., 1980).  
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3.2 AIMS/OBJECTIVES 
The objective was to investigate the activity of new ligands designed from the most potent 
and selective hexapeptide C3a agonist (FLTLAR) from Chapter 2, since that peptide showed a 
significant preference for a beta turn conformation in DMSO. 
 The aim of this study was to explore new compounds containing an oxazole ring that can 
potentially impart and stabilise a turn structural motif. By replacing the amino acids and the R 
group at the N-terminus of this scaffold, it was predicted that enhanced ligand affinity for C3aR 
might be obtained. Because the arginine residue at the C-terminus of the native agonist C3a is 
important for the biology of C3a, this residue was not changed. Structure-activity relationships 
(SAR) of these compounds were obtained through radioligand binding assays using [125I]-C3a and 
[125I]-C5a and an intracellular Ca2+ release assay for monitoring agonist/antagonist function.  
 
 
3.3 RESULTS 
The previous chapter reported the most potent and selective C3aR hexapeptide agonist 
known, FLTLAR. This had high affinity for human C3aR (IC50 42 nM vs 80 pM of iodine labelled 
human C3a) in a competitive binding assay on PBMCs and had full agonist activity (EC50 320 nM) 
in an intracellular calcium release assay on dU937 cells. The 1H NMR spectrum of FLTLAR in the 
aprotic solvent DMSO-d6 showed a beta-turn like conformation. The C-terminus of human C3a also 
showed a turn conformation in its crystal structure (Huber et al., 1980). By using molecular 
modelling of the last four C-terminal residues of native C3a (-GLAR) in a beta turn conformation 
and superimposing it upon a model of an oxazole-containing compound (56) which was synthesised 
by a chemist in the Fairlie group, we found a high degree of similarity in their turn conformations 
(Figure 3.2). This suggested that an oxazole might be useful for generating active compounds that 
bind tightly to human C3aR and give greater potency and selectivity for C3aR than the peptides in 
Chapter 2.  
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Figure 3.2 Superimposition of an oxazole scaffold compound (56, cyan) and tetrapeptide C-
terminal residues of hC3a (-GLAR, green) in a type II beta turn conformation. The oxygen 
atoms are represented in red and nitrogens are shown in blue (Courtesy of Dr. Robert Reid).  	  	  
3.3.1 Series I: N-Acyl Amino Acid Oxazole Arginine Derivatives. 
Denonne et al. (2007) have reported an analogue of SB290157 containing a furan ring as 
linker between the arginine residue and the ether moiety and showed higher affinity for C3aR than 
SB290157. This compound (144, in Chapter 4 Table 4.11) was prepared and tested by us but was 
found to bind with lower affinity than SB290157 and also displayed partial agonist effects.  In our 
binding affinity study we used a competitive binding assay against 80 pM [125I]-C3a on HMDM 
cells whilst Denonne et al.(2007) used a different concentration of [125I]-C3a on HMC-1 cell 
membranes. We rationalised that the furan oxygen and the oxygen atom of the ether group may 
both function as hydrogen bond acceptors with a H-bond donor from the receptor, but that the furan 
was less effective. Therefore replacement of the furan by better H-bond acceptors might afford 
greater affinity, as the nitrogen is a much better hydrogen bond acceptor.  There are other 
advantages from incorporating oxazole in the linker region, as the ring can introduce rigidity to the 
molecule and it also potentially introduces a turn conformation. It is known that over one hundred 
peptide-activated G-protein coupled receptors have a tendency to recognise protein and peptide 
ligands with turn-like conformations (Fairlie et al., 2005; Madala et al., 2010; Tyndall et al., 2005). 
Together these features could generate potent C3a agonists and antagonists. 
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A library of compounds was synthesised by the chemists in our group and they were assayed 
by me to determine the binding affinity for C3aR and functionality in the calcium mobilisation 
assay. Structure activity relationship (SAR) information was then used to identify molecular 
features that contribute to potency and agonist or antagonist function. It quickly became apparent 
from the screening at single point concentrations that the presence of the oxazole moiety afforded 
compounds with high affinity. 
Initial optimization of the generic structure drawn in Figure 3.3 was performed on the 
substituent denoted as AA by systematic substitution of the amino acid linked between the oxazole 
moiety and the acyl group, leaving the R substituent as a t-butoxy group (compounds 56, 57, 58, 59, 
and 60). The results of the binding affinity study in a concentration-dependent manner for these 
compounds showed that either leucine (56) or isoleucine (57) was the optimal amino acid in the 
linker region of the molecule. In contrast, the substitution of phenylalanine (58) or tryptophan (59) 
in the linker dramatically reduced the affinity of the molecule for the receptor (Table 3.1 and 
Figure 3.8).  
 
O
NH N
O
HN CO2H
NH
NH2HN
O
AA
R
ArginineOxazoleN-AcylAmino acid
 
Figure 3.3 N-Acyl amino acid-oxazole-arginine scaffold. 
 
 Cyclohexyalanine (compound 60) has also been explored due to the previous antagonist 
results obtained for hexapeptide FLTChaAR (Chapter 2). However, the calcium mobilisation assay 
showed that all the compounds had agonist activity, while SB290157 did not exert any agonist 
activity under the same assay conditions. Surprisingly, compounds 56 and 57 became more potent 
agonists than hC3a (EC50 65 nM) with EC50 19 and 27 nM, respectively (Table 3.1). There was a 
linear correlation between the competitive binding and calcium release assay data in this study.  In 
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addition, compounds 56 and 57 bound to C3a receptor more tightly than SB290157 (IC50 20, 30 vs 
38 nM respectively in competitive assays with 80 pM [125I]-C3a) (Table 3.1).  
These molecules were modified to two new series of compounds that retain the oxazole 
linker substituted with either of the amino acids leucine or isoleucine, and replacing the t-butoxy 
(Boc) group at the hydrophobic cap (N-terminus) with different fragments as shown in Figure 3.4, 
3.5 and 3.6. The compounds were then assayed to investigate structure activity relationships (SAR). 
Compounds 57, 61, 62, 64, 65, 66, 67, 68, 71, 73, 74, 75, 76, 77 and 78 include the side chain of 
isoleucine, while the molecules 56, 63, 69, 70, 72 and 79 contain the side chain of leucine (Figure 
3.6). 
Compounds 65 and 71 with the isoleucine side chain show high affinity for C3aR: 65 (IC50 
= 123 nM) and 71 (IC50 = 155 nM). Compound 65 has an isoquinoline ring in its structure, while 71 
has a 4-biphenyl aromatic group. Both of these compounds were potent agonists with EC50 
approximately 41 and 8 nM respectively. Interestingly, there was no correlation between the 
binding affinity and functional activity of these compounds. This could be due to the lack of 
selectivity of the compounds which led to stimulation of the intracellular calcium release through 
other receptors as well as C3a receptor. Further modifications to the structure of these new lead 
compounds have generated some better compounds, such as 75 and 73. Compound 75 has a 
bromine substituent on the pyridine ring. This significantly improved the binding affinity of the 
compound with an IC50 = 5 nM and became one of the most potent agonist compounds in this study 
(EC50 = 17 nM).  Conversely, substitution of the hydrophobic region with a phenoxyphenyl group 
(compound 73) gave lower binding affinity to the receptor (IC50= 55 nM), but had full agonist 
activity in calcium mobilisation assays tested on HMDM cells (EC50 = 54 nM). 
On the other hand, two molecules 56 and 63 incorporating the leucine side chain have 
shown tight binding to the C3aR. Compound 56 is similar to 57 (with the Boc group at the 
hydrophobic region). The only difference concerns the side chain of the amino acid substitution 
(isoleucine versus leucine). This alteration gives a slight improvement in both binding affinity and 
agonist potency to compound 56. The substitution of 56 with the indole ring (compound 63) at the 
hydrophobic region gave the greatest improvement in affinity. 63 had IC50 approximately 9 nM and 
was the most potent compound in the calcium mobilisation assay in HMDM cells (EC50 = 7 nM). 
These two compounds bind more tightly to the receptor than SB290157 (2 and 4-fold higher). They 
also have agonist potency 3 to 9 fold greater than native hC3a itself.  Interestingly, compound 79, 
which contains a fluoro substituted phenyl ring binds to the C3a receptor with IC50 = 102 nM. 
However, it shows less agonist activity (EC50 = 527 nM), suggesting that modification of this 
compound could eventually lead to C3aR antagonists.  
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Figure 3.4 N-Acyl-modifications. The hydrophobic/aromatic region of the oxazole-arginine 
scaffold was substituted with these different fragments. 	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Table 3.1 Competitive binding with [125I]-C3a and functional activity (Ca2+ mobilisation) of 
compounds on isolated human monocyte-derived macrophages (HMDM). 
 [125I]-C3a Binding assay Ca2+ release assay 
Compound  R AA n pIC50 ±  SE 
IC50 
(nM) %a
 n pEC50±SE 
EC50 
(nM) %b
 
hC3a   12 9.64 ± 0.04 0.23 0 3 7.19 ± 0.06 65  - 
SB290157   11 7.42 ± 0.06 38 6 7 5.52 ± 0.08 3050(IC50) 53 
56 a Leu 3 7.71 ± 0.08« 20 21 4 7.72 ± 0.27 19  - 
57 a Ile 3 7.53 ± 0.10Ï 30 18 4 7.57 ± 0.11 27  - 
58 a Phe 2 6.29 ± 0.14Ï«* 509 34† - - - - 
59 a Trp 2 5.64 ± 0.31Ï«* 2286 76† - - - - 
60 a Cha 3 7.09 ± 0.11Ï«* 82  2 6.87 ± 0.18Ï* 135 - 
61 b Ile 2 7.58 ± 0.07Ï 26 59 2 5.30 ± 0.18Ï* 5000 - 
62 c Ile 2 6.86 ± 0.08Ï«* 137 33 2 5.25 ± 0.31Ï* 5600 - 
63 d Leu 3 8.03 ± 0.05« 9.3 7 3 8.15 ± 0.10 7.2  - 
64 e Ile 4 6.82 ± 0.10Ï«* 152 19 3 7.14 ± 0.19Ï 73  - 
65 f Ile 3 6.91 ± 0.09Ï«* 123 10 7 7.39 ± 0.12Ï 41  - 
66 g Ile 2 6.10 ± 0.16Ï«* 800 68 - - - 73 
67 h Ile 2 6.80 ± 0.15Ï«* 157 42 - - - 83 
68 i Ile 2 7.14 ± 0.19Ï* 72 76 2 6.30 ± 0.90Ï* 498  - 
69 j Leu 2 5.99 ± 0.25Ï«* 1031  27 - - - 83 
70 k Leu 2 6.35 ± 0.17Ï«* 451 19 - - - 68 
71 l Ile 3 6.81 ± 0.07Ï«* 155 13 7 8.12 ± 0.21 8  - 
72 m Leu 2 6.85 ± 0.15Ï«* 142 49 - - - 100 
73 n Ile 3 7.26 ± 0.09Ï* 55 11 3 7.26 ± 0.08Ï 54  - 
74 o Ile 2 6.12 ± 0.13Ï«* 754 19 3 6.13 ± 0.11Ï* 744 - 
75 p Ile 3 8.30 ± 0.10«* 5 14 3 7.76 ± 0.36 17 - 
76 q Ile 5 6.98 ± 0.11Ï«* 104 17 3 6.62 ± 0.28Ï* 240 - 
77 r Ile 5 6.15 ± 0.14Ï«* 712 25 2 ∞ ∞ - 
78 s Ile 5 6.06 ± 0.13Ï«* 872 23 2 6.07 ± 0.13Ï* 849 - 
79 t Leu 6 6.99 ± 0.10Ï«* 102 15 3 6.28 ± 0.16Ï* 527 - 
a = % binding of [125I]-C3a at compound concentration of 20 µM ( or † = [10 µM]); compared to the binding of [125I]-
C3a with cells in the absence of compound (or Buffer) as 100% ; b = % Response to 100 nM C3a activity. The 
compounds tested at [10 µM]. Buffer at 100%; pIC50 and pEC50 expressed as mean ± SE; n represents the number of 
separate experiments performed..;    « p < 0.05 vs. SB290157; * p <0.05 vs. 56  and  Ï p < 0.05 vs. 63.  
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3.3.1.1 Affinity of Non-Peptide Agonists for C3aR on HMDM. 
 
Competitive Radioligand Binding Assay: [125I]-C3a Binding  
The evaluation of twenty non-peptidic compounds, at a single concentration (20 µM) in a 
competitive radioligand binding assay against human C3a is shown in Figure 3.5. 
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Figure 3.5 Competitive binding between [125I]-C3a and C3a non-peptide ligands in human 
monocyte derived macrophages. Human monocyte derived macrophage cells (HMDM) 
(1.5x106 cells/mL) were incubated for 1 h at room temperature with constant concentration  (80 
pM) of 125I-C3a and non-peptide ligands and SB290157 at concentrations of 20 µM. The buffer 
represents the total binding of [125I]-C3a to HMDM.  Data is expressed as mean [125I]-C3a 
binding ± S.E.M. with n=2. 
The non-peptidic ligands were screened for selectivity towards C3aR using a [125I]-C3a competitive 
binding assay.  From the results shown in Figure 3.7 and 3.8, there are some compounds (eg. 57, 
64, 65, 71 and 63 to 79) that bind to C3aR on human monocyte derived macrophage cells. A full 
concentration response curve has been obtained for these compounds in the same assay.  
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A. Isoleucine-oxazole Arginine Derivative  
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B.  Leucine-oxazole Arginine Derivative  
Figure 3.6 Structure activity relationship studies of C3a non-peptidic agonists by substitution 
of AA with either isoleucine (A) or leucine (B) to oxazole scaffold. The affinities of the ligands 
were tested using a competitive binding assay to compete between [125I]-C3a (80 pM) and C3a non-
peptide ligands at concentration of 20 µM in human monocytes derived macrophages.  
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3.3.1.2  Affinities of C3a Non-Peptide Ligands  
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Figure 3.7 Competitive [125I]-C3a binding of hC3a (l , n=12), SB290157 (n , n=11) and C3a 
non-peptide ligands (57(), 65(·), 71(), 64(£), 63(r), 56(s), 75(¯), 73(*), 79(é), 76 (+), 
77(Î), 78(), 70(), 58(£), 74(¯), 69(«), 61(*), 62(«), 68(¯), 67(¯), 66(+), 72(·), n≥3) on 
human monocyte derived macrophages. Human monocyte derived macrophage cells (1.5x106 
cells/mL) were incubated for 1 h at room temperature with 80 pM of 125I-C3a and increasing 
concentrations of non-labelled C3a (concentration 1 pM to 1 µM) or non-labelled non-peptidic 
ligands (concentration 0.1 nM to 100 µM). Each point represented the mean percentage specific 
binding ± S.E.M. 
 
The Binding Affinity Studies - Concentration Dependent Curves of Boc-oxazole Scaffold 
Ligands with the Variation of Amino acid Substituents. 
 
Figure 3.8 The comparisons in binding affinity of non-peptidic ligands 57 (p , n=3), 56 (· , 
n=3), 58 (Æ , n=1), 59 (Î , n=1) and 60 (q , n=3). These compounds have a Boc group at the 
hydrophobic/aromatic region and substituted with difference amino acids at the linker region of 
oxazole-arginine scaffold. It shows that leucine or isoleucine is the optimal amino acid in this 
scaffold. hC3a (l, n=12) and SB290157 (n, n=11). 
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3.3.2 Series II: Incorporation of a Methyl Group on the 5-Position on the 
Oxazole Ring.  
Molecular modelling studies of the tetrapeptide GLAR from the C-terminus of the hC3a 
sequence and 56 (N-acyl-leucine-oxazole-arginine scaffold, Figure 3.9) have suggested that the 5-
position of the oxazole ring might mimic the location of the side chain methyl group of the alanine-
76 residue in C3a, and could lead to a more potent and selective ligand for C3aR. Therefore, 
compound 80 was synthesized by Dr Reid. This molecule contains a methyl group at the 5-position 
of the oxazole scaffold (Figure 3.10). Binding studies of the new molecule designed through 
modelling suggestion (80) showed no improvement in the affinity for C3aR and decreased the 
potency two fold in the calcium mobilisation experiments compared to compound 56 (Table 3.2). 	  	  
(a.)
	  
(b.)	  
	  	  	  	  	  	  	  
Figure 3.9 The fifth position of oxazole was potentially a position for substitution with a 
methyl group which could mimic the side chain methyl of the alanine residue in C3a. (a.) 
Superimposition of an oxazole scaffold compound (56, cyan) and tetrapeptide C-terminal 
residues of hC3a, GLAR (green) (b.) chemdraw structure of compound 56 with the 5-position 
indicated. (courtesy of Dr Reid). 
 
Further investigation has been performed on compound 80. Structural modifications include 
different hydrophobic groups linked to the oxazole scaffold by replacing the Boc group at the 
hydrophobic region with aromatic substituents (Table 3.3).  
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    56      80 
 
Figure 3.10 Acyl-leucine-5-methyl-oxazole-arginine (compound 80).  Compound 80 mediated 
intracellular calcium mobilisation from HMDM cells with EC50 = 45 nM (n=3). 
 
Table 3.2 Activity of acyl-leucine-5-methyl-oxazole-arginine (80) on competitive binding 
with [125I]-C3a and Ca2+ mobilisation from isolated human monocyte derived macrophage 
cells (HMDM). 
 [125I]-C3a Binding assay Ca2+ release assay 
Compound  R1 R AA n pIC50 ±SE 
IC50 
(nM) n pEC50±SE  
EC50 
 (nM) 
 
56 - O
 
Leu 3 7.71± 0.08 20 4 7.72 ± 0.27 19 
80 Me O
 
Leu 3 7.86 ± 0.08 14 3 7.35 ± 0.18 45 
     pIC50 and pEC50 expressed as mean ± SE, n represents the number of separate experiments performed. 
 
ACYL-LEUCINE-5-METHYL-OXAZOLE-ARGININE 
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Table 3.3 SAR data for series II: Acyl-leucine-5-Methyl-Oxazole-Arginine scaffolds. 	  
compound R 
%[125I]-
C3a 
binding 
% 
agonist compound R 
%[125I]-
C3a 
binding 
% 
agonist 
81 
O O
 
19 84 93 
MeO
O
 
41 87 
82 
S O
 
14 62 94 
MeO
O
 
40 26 
83 
H
N O
 
26 56 95 S
O
O
 
44 103 
84 
N
O
 
31 77 96 
MeO
O
 
44 44 
85 
N
O
 
29 68 97 
MeO
O  
N/A 134 
86 
N
O
 
N/A 109 98 
MeO
MeO
O
 
65 67 
87 
O
 
39 107 99 
MeO
OMe
O
 
42 69 
88 
O  
26 69 100 
N
H
O
 
N/A 64 
89 
O
 
44 70 101 
H
N
O  
61 50 
90 
O
 
N/A 95 102 
N
N O
 
49 48 
91 
F3C
O
 
61 50 103 
O
O  
32 68 
92 
OMe
O
 
43 81 104 
N
Br
O
 
N/A 105 
 
%[125I]-C3a binding = % binding of [125I]-C3a at compound concentration of 20 µM; compared to the binding of 
[125I]-C3a with cells in the absence of compound (or Buffer) as 100% . The percentage binding of [125I]-C3a of 
SB290157 = 12. 
% agonist = % Response to 100 nM C3a activity . The compounds tested at [10 µM]. Buffer at 100% 
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A small library of compounds where the oxazole moiety has been functionalised at the 5th-
position with a methyl group, and the acyl fragment includes various hydrophobic groups, was 
investigated in binding assays and calcium mobilisation in HMDM cells. The binding studies 
suggest that compounds 81, 82, 83, 84, 85, 103 and 88 have some affinity similar to SB290157 
(percentage of [125I]-C3a binding = 12) (Table 3.3). Compounds 91, 98 and 101 have less affinity 
for C3aR in the competitive binding assay (Figure 3.11 A and 3.12).  
 The first three compounds in this series, 81, 82 and 83, with benzofused heterocyclic rings 
at the hydrophobic region gave the highest affinity (compound 82 (with a sulphur atom) > 81 (with 
an oxygen atom) > 83 (with a nitrogen atom)). Compound 82 with a benzothiophene in its structure 
has shown two-fold higher affinity compared to compound 83 bearing an indole ring. This indicates 
that there must be some space at this region of the receptor, which could be large enough for the 
bulky groups to fit into it. Compounds 87 and 88 have cyclohexyl and cyclohexylmethyl groups and 
show some affinity to C3aR. In addition, the cyclohexylmethyl group at this position seems to be 
more optimal than the cyclohexyl group. This suggests that the pocket of the receptor in this region 
is deep therefore a larger compound can fit better into the pocket. The presence of a bulkier group, 
such as in compound 91, showed less affinity and potency. Moreover, the presence of oxygen on 
the methoxy group in compounds 92, 93, 94, 95, 96, 97, 98 and 99 did not give any improvement in 
binding affinity. On the other hand, compound 98 showed lower binding affinity. 
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Figure 3.11 A. Competitive binding between [125I]-C3a and non-peptide ligands in human 
monocyte derived macrophages. Human monocyte derived macrophage cells (HMDM) 
(1.5x106 cells/mL) were incubated for 1 h at room temperature with constant concentration (80 
pM) of 125I-C3a and non-peptide ligands and SB290157 at a concentration of 20 µM. The buffer 
represents the total binding of [125I]-C3a to HMDM.  B. Non-peptide agonism screening in 
Ca2+ release assay in human derived macrophage cells at a concentration of 10 µM. 
Induction of calcium efflux from HMDM cells by compounds expressed as a percentage of 
cytosolic calcium efflux induced by 100 nM C3a ± S.E.M. with n ≥ 2.  
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Figure 3.12 Competitive [125I]-C3a binding of hC3a (l , n=12), SB290157 (n , n=11), 80 ( , 
n=3) and 81 (r , n=3) on human monocyte derived macrophage cells.  80 pM of [125I]-C3a 
was competed with increasing concentration of non-labelled hC3a (concentration 1 pM to 1 
µM), SB290157, 80 (concentration 0.1 nM to 100 µM) and 81 (concentration 0.01 nM to 10 
µM). It shows that 80 binds with high affinity to C3aR ((IC50 ± 95% CI) = 14.7 ± 5.4 nM). Each 
point represents the mean percentage of specific binding ± S.E.M. 
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3.3.3 Selectivity of C3a Non-Peptide Ligands for C5aR 
3.3.3.1 Competitive Radio-ligand Binding Assays: [125I]-C5a Binding 
The competitive radiolabelled C5a assay was used to evaluate whether the compounds 
bound selectively to C3aR over C5aR. A single concentration screen (ligands at 20 µM) for C5aR 
binding affinity shows none of these compounds have affinity for C5aR on human macrophages 
(HMDM)(Figure 3.13). The binding result of all compounds was compared to a control compound 
3D53, which is a known as a selective C5aR antagonist with no cross reactivity to C3aR (Chapter 
2). This result suggests that all non-peptide ligands are selective for C3aR over C5aR (Figure 
3.13).. 	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Figure 3.13 Competitive binding between [125I]-C5a and C3a non-peptide ligands in human 
monocyte derived macrophages. Human monocyte derived macrophage cells (1.5x106 
cells/mL) were incubated for 1 h at room temperature with constant concentration (20 pM) of 
[125I]-C5a and non-peptide ligands and 3D53 at a concentration of 20 µM. The buffer represents 
the total binding of [125I]-C5a to HMDM (~ 4000 cpm). Data is expressed as mean [125I]-C5a 
binding ± S.E.M. with n=2. 
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3.3.3.2 The Affinity to C5aR of Non-Peptide C3a Ligands: Studies in 
Concentration Dependent Manner. 
To confirm this result, the most potent oxazole analogues have been studied in a full 
concentration response curve in the same assay as shown in Figure 3.14. 	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Figure 3.14 Competitive [125I]-C5a binding of hC5a (l , n=3), 3D53 (n , n= 3) and C3a non-
peptide ligands 63 (w), 57 (q), 75 (p), 80 (n), 81 (l), n=3 on human monocyte derived 
macrophage cells. Human monocyte derived macrophage cells (1.5x106 cells/mL) were 
incubated for 1 h at room temperature with 20 pM of [125I]-C5a and increasing concentrations of 
non-labelled C3a (concentration 1 pM to 0.3 µM) and non-peptidic ligands (concentration 0.1 
nM to 100 µM). Each point represents the mean percentage specific binding ± S.E.M. 
 
 
3.3.4 Selectivity Test: Desensitisation Experiments 
Desensitisation experiments were used to measure the selectivity of various ligands for 
C3aR, since this can help to clarify whether the non-peptidic ligands bind selectively to C3aR over 
other GPCRs that signal through intracellular calcium release.  
The hC3a (3 µM) was administered to human monocyte derived macrophage cells, which 
produces an efflux of intracellular Ca2+ that dissipates after 4-5 mins (Figure 3.15). A second 
addition of 3 µM hC3a after 5 mins has no effect, and this effect is attributed to desensitisation of 
the receptor through either receptor (C3aR) phosphorylation or receptor internalisation from the cell 
surface. Figure 3.15 shows how compound 73 caused a second efflux of intracellular Ca2+. This 
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suggests that this non-peptidic ligand is not purely selective for C3aR.  In contrast, compounds 57, 
65, 71 and 56 (EC50= 27, 41, 8 and 19 nM, respectively) appear to be selective for C3aR as a 
second addition of 1 µM of these compounds, following desensitisation with C3a, did not produce 
calcium efflux from macrophage cells.  
The possibility that these compounds (63, 73 and 80) may bind to C5aR has already been 
discounted by the competitive [125I]-C5a binding studies that showed no binding to C5aR (Figure 
3.13 and 3.14). This suggests that the second efflux of calcium induced by these compounds is 
caused by a calcium-associated GPCR other than C3aR or C5aR. 
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Figure 3.15 C3a receptor desensitisation calcium mobilisation plots performed on human 
monocyte derived macrophages (HMDM) for non-peptidic agonists. HMDM were first 
treated with 3 µM of hC3a, which induced a calcium response that was allowed to dissipate over 
250 (A) or 280 (B) seconds prior to a second agonist injection. 
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3.3.5 Effect of C3a Non-Peptide Agonists/Antagonists on Calcium Release from 
Human Monocyte Derived Macrophages. 
 C3a non-peptidic ligands were also examined in the calcium mobilisation experiment for 
antagonism, using SB290157 as a control compound (Figure 3.16). Compounds with greater 
antagonist activity than SB290157 were examined further for calcium mobilisation in a dose 
dependent manner. The antagonist screening was used to test all compounds at a single 
concentration of non-peptidic compound, which can provide a quick result and allow the relative 
activities of multiple compounds to be compared in a single experiment. However it also can give a 
false positive if compounds display any partial agonism activity for the receptor. For example, if an 
agonist ligand is present, it can cause desensitisation/internalisation of the receptor and therefore 
inhibit the ability of the cell to mobilise calcium in response to stimulation with C3a. So 
compounds must first be shown not to cause Ca2+ release before they can be tested for antagonism. 
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Figure 3.16 Non-peptide antagonism screening in Ca2+ release assay in human derived 
macrophage cells at a concentration of 10 µM. Intracellular calcium release caused by 100 
nM hC3a.  Inhibition expressed as a percentage of maximum change in fluorescence induced by 
100 nM C3a. Error bars represented S.E.M. with n=2. 	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3.3.5.1 C3aR Non-Peptide Agonists 
 
From the results of calcium mobilisation experiments, the concentration response curve for 
C3a non-peptide agonists on human monocyte derived macrophage cells (Figure 3.17 and 3.18), 
the most potent non-peptidic agonists in this study were compounds 75 (EC50 = 17 nM, pEC50 = 
7.76 ± 0.36, n=3), 56 (EC50= 19 nM, pEC50 7.72 ± 0.27, n = 4 and 63 (EC50= 7.2 nM; pEC50 8.15 ± 
0.10, n=3) and 71 (EC50 = 8 nM, pEC50 8.12 ± 0.21, n=7).  
The competitive binding studies (Figure 3.7 and Table 3.1) also show that 75, 56, 63 have 
high affinity for C3aR on HMDM (IC50 < 20 nM), while compound 71 has lower affinity than those 
compounds. It still can stimulate calcium release from cells at very low concentrations. This 
observation indicates that this compound, though having limited binding affinity, still has good 
potency in terms of calcium release from cells, similar to those compounds having better binding. 
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Figure 3.17 Intracellular Ca2+ mobilisation dose response induction by hC3a (l , n=11), 
SB290157 (« , n=6) and variable concentration of C3a non-peptide agonists. 71 ( , n=7), 
65 (£ , n=7), 56 (£ , n=4), 57 (s , n=4), 80 (« , n=4), 75 (r , n=3), 63 (p , n=3), 74 (q , n=3), 
64 ( , n=3), 73 (Î , n=3), 62 (¯ , n=2), 68 (r , n=2), 79 (® , n=3), 77 ( , n=3), 76 (p , n=3). 
The results are expressed as a percentage of maximum change in fluorescence induced by hC3a 
(100 nM) ± S.E.M. 
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Figure 3.18 Intracellular calcium release in HMDM cells induced by hC3a (s , n=11), 71 
(l , n=7), 65 (n , n=7), 63 (p , n=), 56 (q , n=4), 75 (® , n=3), 57 ( , n=4), 73 (r , n=3). The 
results are expressed as a percentage of maximum change in fluorescence ± S.E.M. 
 
 
3.4 DISCUSSION AND CONCLUSIONS 
C3a peptides have many disadvantages for use as pharmacological/physiological tools for in 
vivo studies. For example, they have low bioavailability, poor stability to protease enzymes, high 
clearance rates from serum, and also low membrane permeability. Therefore, the development of 
non-peptidic C3a ligands that presumably will have improved bioavailability and stability are 
needed to interrogate the roles of C3a in vitro and in vivo and to serve as leads to new 
pharmaceuticals.  
C3a is involved in the pathogenesis and progression of numerous inflammatory conditions, 
including asthma, allergies, arthritis, psoriasis, ischemia-reperfusion injury, sepsis, systemic lupus 
erythematosus, diabetes, nephropathy and others. It may be a very attractive target for therapeutic 
intervention, however as yet there has been no successful development of a small potent and 
selective C3aR agonist or antagonist that can be used as a pharmacological/physiological probe in 
studying the roles of C3a in vivo. 
 The first and most studied non-peptidic antagonist of C3aR was the compound SB290157, 
which was reported by Smithkline Beecham in 2001 (Ames et al., 2001). It binds to C3aR with IC50 
= 200 nM in a competitive radioligand binding assay in RBL cells and showed antagonist activities 
in both in vitro and in vivo studies (Ames et al., 2001). However, the study by Mathieu and 
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colleagues (2005) showed that it has potent agonist activities in a variety of assays e.g. calcium 
mobilisation assay in transfected RBL cells, a beta-lactamase assay in CHO-NFAT-bla-Gα16 
(chinese hamster ovary cells) and an enzyme release assay in dU937 cells. It has been suggested 
that SB290157 is a partial agonist, which shows its agonist activity when there is a high level of 
C3aR expression on the cells. 
We chose FLTLAR as a peptidic lead compound and modified the N-terminus, incorporated 
a turn-inducing oxazole scaffold but retained the arginine, to produce new compounds for these 
studies. From the new series of C3aR non-peptidic agonists obtained by modification of FLTLAR, 
we found that the incorporation of an oxazole ring leads to improved binding affinity and potency 
for many of the new compounds generated. The incorporation of oxazole was also a dramatic 
improvement on the previous report by Denonne et al. (2007) where replacing the ether group with 
a more rigid furan was claimed to give improved affinity for C3aR. We found that the optimal 
amino acid side chain for attachment to the oxazole scaffold was leucine (56) or isoleucine (57), 
with only a slight difference in the binding affinity and potency of the respective compounds. 
Compounds 75, 63, 56 and 80 have the highest affinity for HMDM (IC50 = 5, 9.3, 20 and 14 
nM respectively in competitive binding studies), show selectivity for C3aR in competitive 
radioligand binding assays (both 125I labelled C3a and C5a) and also in a desensitisation assay, 
which confirmed the selectivity of the ligands by their inability to induce calcium release after 
desensitisation of the cells with C3a.  
In Figure 3.19 there was a pseudolinear correlation between agonist potency (intracellular 
release of calcium in human monocyte derived macrophage cells) and the binding affinity for C3aR 
(measured by competition with [125I] labelled C3a on HMDM). From these data, we found that all 
of these compounds have agonist activities. Surprisingly some of the compounds show even more 
potent agonist activity in calcium mobilisation assay than does hC3a.  
Molecular modelling (Figure 3.2) showed the overlay of the C3a carboxyl terminal 
residues, G73LAR76, modelled in a beta turn conformation, with compound 56 displaying structural 
similarity. The oxazole at the linker region could assist the compound to adopt a beta-turn 
conformation that mimics the conformation of the C-terminus of C3a. This result also supports the 
theory that GPCRs have a tendency to recognise protein and peptide ligands with turn structure 
(Fairlie et al., 2005; Madala et al., 2010; Tyndall et al., 2005). 
In conclusion, we can say that the introduction of a rigid turn-like conformation by using an 
oxazole heterocycle has led us to the discovery of multiple potent and selective C3aR non-peptidic 
agonists (63, 75 and 56, EC50 < 20 nM in HMDM cells).  These compounds could be useful for 
probing the physiological/pharmacological roles of C3a in vitro studies however these compounds 
retained the C-terminus arginine that could have poor bioavailability (Denonne et al., 2007) for     
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in vivo studies therefore the need for further modification to improve these compounds by using 
arginine mimetics have been suggested. 
 
 
 
 
 
 
Figure 3.19 Correlation between binding affinity (pIC50) and agonist activity (pEC50) of 
non-peptide agonists (56, 57, 60, 61, 62, 63, 64, 65, 68, 71, 73, 74, 75, 80), nonpeptide 
antagonist (SB290157) and hC3a. 
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3.5 MATERIALS AND METHODS   
3.5.1 Macrophage Cell Culture and Differentiation. 
Human monocyte-derived macrophage (HMDM) cells were kept in complete media, 
consisting of IMDM with 10% FBS, 10 U/mL penicillin, 10 U/mL streptomycin and 2 mM L-
glutamine (Invitrogen). Cells were cultured at 37°C, with 5% CO2. For HMDM, peripheral blood 
mononuclear cells were isolated from buffy coat (obtained from Australian Red Cross Blood 
Service, Kelvin Grove) using Ficoll-paque density centrifugation (GE Healthcare Bio-Science, 
Uppsala, Sweden). CD14+ monocytes were positively selected using CD14+ MACS magnetic beads 
(Miltenyi Biotech, Auburn, CA, USA). Monocytes were differentiated to HMDM in complete 
media containing 104 U/mL (100 ng/mL) recombinant human macrophage colony stimulating 
factor (M-CSF) (PeptroTech Inc, Rocky Hill, New Jersey, USA) at 1.5 x 106 monocytes/mL. 
HMDM were supplemented with 50% fresh complete medium containing CSF-1 on Day 5 after 
seeding. Cells were harvested by gentle scraping in saline solution and replated for use on Day 7. 
3.5.2 Calcium Mobilization Assay on HMDM (Adhesion cells) 
In this experiment the concept is the same as for the calcium mobilisation assay as described 
in Chapter 2. However, the protocol in preparation of the HMDM cells (adhesion cells) for the 
assays is different from the dU937 cells (suspension cells).  
Harvested HMDM cells were washed with 0.9% NaCl solution by centrifugation at 2500 
rpm for 5 min, followed by resuspension of the cell pellet with complete media. Cells were seeded 
at 5 x 104 cells/well in a 96-well black-wall, clear bottom plate (DKSH, Zurich), and left overnight 
to adhere at 37°C. On the day of the experiment, supernatant was removed and cells were incubated 
in dye loading buffer (Hank’s Balanced Salt Solution (HBSS) with 4µM Fluo-3, 25 µL pluronic 
acid, 1% fetal bovine serum (FBS) and 2.5 mM probenecid) for one hour at 37°C. Cells were then 
washed twice with HBSS and transferred to a Fluorostar spectrofluorimeter (BMG, Durham NC) 
for agonist injection and fluorescence measurements.  
3.5.3 Receptor Binding Assay of HMDM 
Receptor binding assays were performed using [125I]-C3a 80 pM (2200 Ci/mmol; Perkin 
Elmer, Torrance, CA, USA), HMDM cells (1.5x106 cells/mL) and in the absence or presence of 
various concentrations of unlabelled C3a or C3a hexapeptide agonist for 60 mins at room 
temperature with shaking in 50 mM Tris, 3 mM MgCl2, 0.1 mM CaCl2, 0.5% (w/v) Bovine serum 
albumin, pH 7.4.  Unbound radioactivity was removed by filtration through glass microfiber filters 
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GF/B (Whatman Iner. Ltd, England) which had been soaked in 0.6% polyethylenimine to reduce 
non-specific binding. The filter was washed 3 times with cold buffer (50 mM Tris-HCl) pH 7.4.  
Bound [125I]-C3a will then be assessed by scintillation counting on a β-counter. Specific [125I]-C3a 
binding is defined as a difference between total binding and non-specific binding as determined in 
the presence of 1 µM unlabeled C3a. The IC50 value is the concentration of antagonist to inhibit the 
binding of labelled ligand by 50 percent. 
3.5.4 Data analysis and statistics 
Receptor binding data was expressed as specific binding (i.e. total binding – non-specific 
binding and non-specific binding = binding with 1 µM C3a). Functional activity data is expressed 
as a percentage of the maximum response induced by C3a (100 nM). Nonlinear regression analysis 
(GraphPad Prism 5, USA) will be performed on concentration response curves to determine EC50 or 
IC50 and pEC50 or pIC50.The statistical analysis has been utilized for both receptor binding assays 
and functional assays.  
In receptor binding assays, pIC50 for each compound will be calculated for separate 
experiments and express as an arithmetic mean standard error (SE). IC50 values will be expressed as 
a geometric mean. A one-way ANOVA coupled with Tukey post test was performed on pIC50 
values to compare compound affinities. P ≤ 0.05 was considered to indicate a statistically 
significant difference between receptor affinities. 
In Functional Assays, the concentration curves were analysed by non-linear regression 
(GraphPad Prism 5, USA) and EC50 and pEC50 determined. A pEC50 for each compound was 
calculated from separate experiments and expressed as an arithmetic mean ± SE. A one-way 
ANOVA coupled with a Tukey post test was performed on pEC50 values to examine statistical 
significance between agonist potencies of C3a analogue peptides/non-peptides. P ≤ 0.05 was 
considered to indicate a statistically significant difference.  
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4.0  ABSTRACT 
C3a has been implicated in many physiological processes and in the pathogenesis of many 
disease conditions. Therefore, effective antagonists of C3aR are predicted to have therapeutic 
potential for treating inflammatory diseases such as anaphylaxis, adult respiratory distress 
syndrome (ARDS), acute transplant rejection, ischemia reperfusion injury, sepsis (Drouin, 2001), 
brain inflammation and many other autoimmune diseases for example psoriasis, rheumatoid 
arthritis, and systemic lupus erythematosus (SLE)(Clancy, 2000; Volanakis et al., 1998).  
 In the previous chapter, agonists were developed by using a molecular modelling study, 
which suggested that the oxazole–arginine dipeptide surrogate might have a similar turn 
conformation to that for the last four C-terminal residues of C3a, namely GLAR. The turn 
conformation has been observed for ligands that bind to many other GPCRs (Madala et al., 2010; 
Tyndall et al., 2005). By modification of the oxazole scaffold with different hydrophobic groups 
(Figure 4.1 A), we found a more potent C3aR agonist (56) that we used in this study. The 
incorporation of a phenyl group at the 5-position of the oxazole ring gave an improvement in 
binding affinity and eventually led to the novel and potent nonpeptidic C3aR antagonist compound 
(105). Further study by modification of the Boc group at the N-terminus of compound 105 also 
generated another potent C3aR antagonist compound (109).  
A second approach to developing C3aR antagonists was to use the known, albeit weak,  
antagonist compound SB290157 as a lead compound for further modifications (Figure 4.1 B). 
SB290157 was the first reported “potent” C3a receptor antagonist in several in vitro assays and two 
in vivo models. In 2005, SB290157 was reported to also have “potent” agonist activities in a variety 
of in vitro and in vivo assays. We proposed to develop new non-peptidic antagonists using 
SB290157 as a lead compound, because it binds tightly to C3aR and, in our hands, it showed no 
agonist activity in the Ca2+ assay on human monocyte derived macrophages. Moreover, it also 
showed no cross reactivity at, or binding to, C5aR. The SB290157 molecule can be considered to 
comprise three different regions (a hydrophobic N-terminus, a linker, and an arginine at the C-
terminus). Our development of new antagonists focussed on modifying each of these components 
separately.   
We discovered several potent C3aR antagonists, which bind tightly to C3aR and are 
equipotent with C3a itself in calcium mobilisation assays in HMDM cells. These compounds 
feature a 5-phenyl oxazole ring or derivations of SB290157 with linker region replaced by a furan 
ring. The heterocycle was modified with varying hydrogen bond acceptors. The most potent and 
selective compounds in this study were 105, 109 and 145 and 146 (IC50 17, 14, 460 and 534 nM 
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respectively) in the calcium mobilisation assays in HMDM cells. Binding affinity correlated with 
antagonist potency, and our compounds are by far the most potent C3aR antagonists known.  
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4.1 INTRODUCTION   
In 2001, N2-[(2,2-diphenylethoxy)acetyl]-L-arginine or SB290157 (Figure 4.2 A) was 
developed as a C3aR antagonist (Ames et al., 2001). SB290157 had IC50 = 200 nM in competitive 
radioligand binding assays in rat basophilic leukemia cells (RBL), and it was also able to inhibit 
C3a-induced calcium mobilization in C3aR expressing RBL cells and human neutrophils (IC50 28 
nM), C3a-induced receptor internalization in human neutrophils, C3a-mediated ATP release from 
guinea pig platelets, and C3a-induced potentiation of the contractile response to field stimulation of 
perfuse rat caudal artery.  There were a number of in vivo studies reported in which SB290157 was 
used, such as guinea pig LPS-induced lung neutrophilia (Ames et al., 2001) and a rat adjuvant-
induced arthritis model (Ames et al., 2001). Another C3aR antagonist was reported in 2001 - a 1,3-
diiminoisoindoline (Figure 4.2 B) with an IC50 of 1.7 µM in the binding assay and an IC50 of 2.0 
µM in the calcium mobilisation functional assay (Grant et al., 2001). 
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(A) N-Acyl amino acid-oxazole-
arginine  
 
(B) SB290157 (R=H) 
Figure 4.1 (A) oxazole-containing C3aR modulators. (B) SB290157 is N2-[(2,2-
diphenylethoxy)acetyl]-L-arginine which has three different regions: (i) a hydrophobic cap  
(ii) a linker region and (iii) an N-terminal arginine. 
 
In 2005, (Mathieu et al.) it was reported that SB290157 had potent agonist activities in a 
variety of assays involving different cell types that overexpressed C3aR; for example, transfected 
rat basophilic leukemia (RBL) cells, CHO-NFAT-bla-Gα16 (chinese hamster ovary cells) and 
differentiated human U937 cells. These agonist activities were reduced in guinea pig platelets, cells 
which are known to express low levels of C3aR (albeit as two receptor sub-types). It was suggested 
that SB290157 was a partial agonist. In another pharmacological study in rat intestinal 
ischemia/reperfusion injury, the effects of SB290157 could also not be attributed to antagonism of 
C3aR (Proctor et al., 2004). 
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The pharmacology Nobel laureate James Black (1989) stated that partial agonists can often 
be partial antagonists and may contain the same structural components that can be modified to give 
full antagonists without any agonist activity. Thus, we chose SB290157 as a lead compound and 
modified its hydrophobic and linker regions while retaining the C-terminal arginine to produce new 
compounds for these studies. 
Denonne and colleagues (2007a) conducted a study of different non-peptidic compounds 
incorporating either a pyridine moiety or an amino-piperidine linker in place of the arginine residue 
(Figure 4.2 C pIC50 = 7.5), which was suspected to cause the poor bioavailability associated with 
SB290157. Numerous analogues were prepared to improve the binding affinity, however all 
analogues were found to have full agonist activity in functional assays.  
In the same year, another study (Denonne et al., 2007b) reported a new compound (pIC50 7.5 
vs 20 pM [125I]-C3a) with higher affinity for C3aR than SB290157. This new compound was a 
constrained analogue of SB290157 with a rigid furan ring and an arginine residue (Figure 4.2 D). 
The compound was evaluated for DMPK (drug metabolism and pharmacokinetics) properties in rats 
and showed low bioavailability (< 1%) attributed to poor intestinal absorption.   In vivo studies 
using a model of airway inflammatory disease found that the compound (30 mg/kg ip) reduced 
levels of eosinophils in broncho-alveolar fluid and also decreased concentrations of IL-13. 
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(A) SB290157  
N2-[(2,2-diphenylethoxy)acetyl]-L-arginine 
(Ames et al., 2001) 
(B) 1,3 diiminoisoindoline IC50 = 1.7 µM in 
binding assay (Grant et al., 2001). 
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(C) Amino-piperidines without an arginine 
moiety   pIC50= 5.8 (Denonne et al., 2007a) 
(D) Optimized derivative of SB290157 by 
using 2,5- furyl with arginine moiety 
(Binding pIC50 = 7.2 vs 20 pM 125I-C3a) 
(Denonne et al., 2007b) 
Figure 4.2 Structures for non-peptidic “antagonists” of C3aR reported in the literature.  
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One of the difficulties in evaluating the physiological/pharmacological roles of C3a is the 
lack of potency and selectivity of C3aR agonists and/or antagonists. We proposed to develop new 
non-peptidic antagonists based either on (a) the potent agonist oxazole-containing compound (56) 
from Chapter 3, or (b) the SB290157 compound, which has antagonist activity at least in the Ca2+ 
assay against C3aR.  
 
 
4.2 AIMS/OBJECTIVES 
The objectives of this Chapter were to investigate the activity of new ligands designed from 
(a) the potent oxazole-containing agonist (56) described in Chapter 3, and (b) the known C3aR 
antagonist SB290157. The competitive radioligand binding assay with 125I-C3a showed that 
SB290157 binds tightly to C3aR without any detectable cross reactivity with C5aR (Chapter 2). It 
also demonstrated no agonist activity in functional (Ca2+ release) assays on human PBMCs.  
The oxazole-containing compound (56) was modified by incorporating 5-phenyl substituted 
oxazole derivatives and different hydrophobic groups at the N-terminus. The SB290157 compound 
can be described in terms of three different regions: (i) an N-terminal hydrophobic/aromatic cap, (ii) 
a linker region and (iii) a C-terminal arginine. Because the arginine residue at the C-terminal 
position of the native peptide agonist C3a is important for activating C3aR (although probably a 
binding residue), only the first two regions were modified in this chapter. New antagonists were 
designed from SB290157 by modifying the N-terminal hydrophobic cap or by using differently 
constrained heterocyclic linkers incorporating different hydrogen-bond acceptors. All compounds 
were supplied by chemists in the Fairlie Group, especially Mr Anthony Reed (Hons 2009), Ms 
Peifei Chu (Hons 2010) and Dr. Robert Reid. Structure-activity relationships (SAR) for these 
compounds were determined by me using radioligand binding and a functional assay. [125I]-C3a and 
[125I]-C5a were used to measure receptor binding affinity of new ligands on whole human 
monocyte-derived macrophages, and an intracellular calcium mobilisation assay was used to probe 
function.  
 
 
4.3 RESULTS  
4.3.1 Structural Modifications of Oxazole-Containing C3aR Agonists 
In Chapter 3, a new series of potent C3a receptor agonists were derived by using the 
oxazole scaffold that showed a turn conformation in molecular modelling of compound 56 (N-acyl-
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leucine-oxazole-arginine scaffold). This is shown (Chapter 3, Figure 3.2) superimposed on the C-
terminal four residues of hC3a, namely GLAR.  Further investigation in this present chapter has 
been concentrated initially on a small library of compounds (80-104), in which the fifth position of 
the oxazole ring incorporated a methyl substituent to mimic the location of the side chain methyl 
group of the alanine residue in the second last C-terminal position of C3a (Figure 4.3 and 4.4). 
However, there was no improvement in the binding affinity, and only a decrease in potency in the 
calcium mobilisation assay (Table 3.2 and Table 3.3). 	  
	  
Figure 4.3 Overlay of 56 (cyan) and GLAR (sequence corresponding to the C-terminus of 
C3a, namely C3a73-76, green) reveals the possibility of incorporation the functional group 
into the 5th position of oxazole ring. The location of the side chain methyl group of the alanine 
residue in C3a is boxed in red (courtesy of Dr. Robert Reid).  
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Figure 4.4 Modification of the oxazole scaffold by incorporating a 5-methyl substituent. 
Boc-leucine-oxazole-arginine (56) and Acyl-leucine-5-methyl-oxazole-arginine (80). 
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We therefore next decided to add bulk at the fifth position by incorporating a 5-phenyl 
substituent on the oxazole ring of 56 to see if that increased or decreased receptor binding affinity 
or function (Figure 4.5). That analogue of 56, namely compound 105, was tested in the competitive 
binding assay and in calcium mobilisation in human monocyte-derived macrophages.  
 
4.3.1.1 Incorporation of a Phenyl Group at the Fifth Position of the Oxazole 
Ring. 
The first compound in this study (105, Figure 4.5) was modified from the potent compound 
56 (Boc-leucine-oxazole-arginine) in Chapter 3.  
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Figure 4.5 Modification of the oxazole scaffold by incorporating a 5-phenyl substituent. 
Boc-leucine-oxazole-arginine (56) and Boc-leucine-5-phenyl-oxazole-arginine (105). 
 	  	  
From the results for binding affinity, compound 105 was shown to bind tightly to hC3aR 
with IC50 ± 95% = 37 ± 16 nM (Table 4.1, Figure 4.6). However, there was no improvement in 
binding affinity over the methyl-substituted compound (80)(Figure 4.4), which had IC50 ± 95% = 
15 ± 5 nM, indicating that the 5-phenyl substituent is not more effective in filling out space in the 
receptor that the methyl group is projecting into. This suggests that even larger substituents might 
be accommodated at this position with improved receptor affinity.  
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Table 4.1 SAR of acyl-leucine-5-phenyl-oxazole-arginine (105) comparison to boc-leucine-
oxazole-arginine (56) and acyl-leucine-5-methyl-oxazole-arginine (80) on competitive 
binding with [125I]-C3a and Ca2+ mobilisation from HMDM cells. 
 	   	   Receptor	  Binding	  	  
Affinity	  
	   	   Apparent	  Agonist	  
Activity	  
	   	   Apparent	  
Antagonist	  
Activity	   	  
Agonist/	  
Antagonist	  
n	   pIC50	  ±	  SE	   IC50	  (nM)	   n	   pEC50	  ±	  SE	   EC50	  	  (nM)	   n	   pIC50	  ±	  SE	   IC50	  (nM)	  
hC3a	   12	   9.64	  ±	  0.04	   0.23	   3	   7.2	  ±	  0.06	   65	   -­‐	   -­‐	   -­‐	  
SB290157	   11	   7.42	  ±	  0.06	   38	   4	   *	   *	   9	   5.6	  ±	  0.09	   2700	  
56	   3	   7.71±	  0.06é	   20	   4	   7.7	  ±	  0.27Ê	   19	   -­‐	   -­‐	   -­‐	  
80	   3	   7.86±	  0.08é	   15	   2	   7.4	  ±	  0.18	   45	   -­‐	   -­‐	   -­‐	  
105	   4	   7.43±	  0.10Î#	   37	   4	   *	   *	   4	   7.8	  ±	  0.17é	   16.5	  
The compounds show no agonist activity in calcium mobilisation assay up to 100 µM. 
é p < 0.05 vs. SB290157; Î p < 0.05 vs. 56; # p < 0.05 vs. 80 and * p < 0.05 vs. hC3a. 
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Figure 4.6 Competition with [125I]-C3a for binding to human monocyte-derived 
macrophages: hC3a (l), SB290157 (n), 56 (u), 80 (q) and 105 (p); n≥3. Human 
monocyte-derived macrophages (1.5x106 cell/mL) were incubated for 1 h at room temperature 
(22°C) with 80 pM of [125I]-C3a and increasing concentrations of unlabelled C3a (concentration 
1 pM to 1 µM) or non-peptides (concentration = 0.1 nM to 100 µM). Each point represented the 
mean percentage specific binding ± S.E.M. 
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A new series of compounds was next investigated in which a phenyl group was maintained 
at the 5-position of the oxazole ring and coupled with a hydrophobic group in place of the Boc 
group. Similar to the previous study in Chapter 3 (Acyl-leucine-5-methyl-oxazole-arginine 
compounds), the replacement of the Boc group with different hydrophobic groups in compound 105 
was thought to be potentially capable of improving binding affinities of the compounds for the 
human C3a receptor.  
 
 
Table 4.2 SAR data of Acyl-Leucine-5-Phenyl-Oxazole-Arginine series. 	  
O
NH N
O
HN COOH
NH
NH2HN
O
R
	  	  	  
Compound	  	   R	   %[125I]-­‐C3a	  
bindinga	  
	  
%	  
Agonistb	  
	   	   200	  nM	   20	  µM	   	  
106	  
N
Br
	   65	   25	   78	  
107	  
F 	   58	   66	   N/A	  
108	  
S
	   74	   50	   N/A	  
109	  
MeO 	   50	   31	   18	  
110	   	   61	   45	   23	  
 
a: % Binding of [125I]-C3a at compound concentrations  of 200 nM and 20 µM; compared to  
the binding of [125I]-C3a with cells in the absence of compound (or Buffer) as 100%; n = 2. 
b: % Response to 100 nM C3a activity. The compounds tested at [10 µM] and the response  
of 100 nM hC3a is equal to 100% response. n= 2. 
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From this study of competitive binding on HMDM cells, we found that compounds 106 and 
109 bound most tightly to the receptor in this series (Table 4.2). In the single point assay, at 200 
nM 109 had an affinity for the receptor of approximately 50% compared to SB290157 which had an 
affinity of 39%. At the concentration 20 µM, 109 had an affinity around two fold lower than for 
SB290157 (12%).  
Compounds 108 and 110 have benzothianaphthene and cyclohexane groups respectively, 
which were also used in Chapter 3 to study 5-methyl-oxazole-arginine agonists and led to better 
affinity for the receptor in the series of 5-phenyl-oxazole-arginines here. In addition compound 107, 
which has a para fluoro substituted aromatic ring, that can act as a hydrogen bond acceptor, has 
poor affinity for the receptor. 
Compound 106, which has the bulkier substituent (Br), binds tightly to the receptor at the 
higher concentration, however in the calcium mobilisation assay the compound caused stimulation 
(78%) of calcium release from HMDM cells. In contrast, compounds 109 and 110, which have 
oxygen on the methoxy (4-methoxybenzoyl substituent) and a cyclohexane group respectively, 
showed higher affinity and lower agonist activity in the calcium release assay.  
Compound 109 was chosen for further study in the full dose response in the competitive 
binding assay (Figure 4.7) and calcium mobilisation assay because of the higher binding affinity to 
the receptor and the lowest agonist activity of the compound. 
109 showed high affinity for the receptor with IC50 ± 95% = 18 ± 7 nM (Table 4.3) while 
the compound 105 had IC50 ± 95% = 38 ± 16 nM. This result suggests that replacement of the Boc 
group in compound 105 with the hydrophobic ring, and an oxygen to act as a hydrogen bond 
acceptor, leads to improved binding affinity for the human C3a receptor on HMDMs.  
 
Table 4.3 Competitive binding of 109 with [125I]-C3a and Ca2+ mobilisation from human 
derived macrophage cells.  	  	   	   Receptor	  Binding	  	  
Affinity	  
	   	   Apparent	  
Agonist	  
Activity	  
	   	   Apparent	  
Antagonist	  
Activity	   	  
Agonist/	  
Antagonist	  
n	   pIC50	  ±	  SE	   IC50	  	  (nM)	   n	   pEC50	  ±	  SE	   EC50	  	  (nM)	   n	  	   pIC50	  ±	  SE	  	   IC50	  	  (nM)	  	  
hC3a	   12	   9.64	  ±	  0.04	   0.23	   3	   7.2	  ±	  0.06	   65	   -­‐	   	  	  	  	  	  	  -­‐	   -­‐	  
SB290157	   11	   7.42	  ±	  0.06	   38	   7	   *	   *	   9	   5.6	  ±	  0.09	   2700	  
109	   3	   7.75	  ±	  0.09é	   18	   4	   *	   *	   4	   7.9	  ±	  0.14é	   14	  
*The compounds show no agonist activity in calcium mobilisation assay up to 100 µM. é	  p	  <	  0.05	  compare	  with	  SB290157. 
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Figure 4.7 Receptor affinities for C3aR measured by displacement of 80 pM [125I]-C3a 
from HMDM cells: hC3a (l), SB290157 (n), 109 (l) and 105 (p) n≥3. Human monocyte-
derived macrophage cells (1.5x106 cell/mL) were incubated for 1 h at room temperature with 80 
pM of [125I]-C3a and increasing concentration of non-labelled C3a (concentration 1 pM to 1 µM) 
and non-labelled of 105 and 109 (concentration 0.1 nM to 100 µM). Each point represented the 
mean percentage specific binding ± S.E.M.(n ≥ 3). 	  	  
4.3.1.2 Receptor Selectivity: Competitive Binding with [125I]-C5a. 
A limited receptor selectivity study was performed by using [125I]-C5a radioligand 
competitive binding to evaluate whether compounds bound selectively to C3aR over C5aR. Firstly, 
all the compounds in this series were tested at a single concentration (20 µM) for competition with 
radioligand labelled C5a (20 pM) for human monocyte-derived macrophages. The binding of all 
compounds was compared with 3D53, which has been shown to selectively bind C5aR but not 
C3aR on HMDMs (Chapter 3). From the single concentration screening results shown (Figure 4.8 
A), none of the compounds bind to C5aR, which suggests that all agonist/antagonist ligands tested 
were selective for C3aR over C5aR (Figure 4.8 A). The two compounds with highest affinity in the 
C3aR binding assay, 105 and 109, were chosen for further study in a full concentration-response 
curve in the same assay (Figure 4.8 B).   
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Figure 4.8 A. Competitive binding versus [125I]-C5a (20 pM) for C3aR-binding non-peptide 
ligands  (20 µM) in human monocyte-derived macrophages. B. Competitive concentration-
dependent binding of hC5a (l), 3D53 (n), 105 (p) and 109 (q) versus [125I]-C5a binding 
affinity on HMDM. This shows that 105 and 109 have no binding for C5aR. Each point 
represented the mean percentage specific binding ± S.E.M. with n≥ 3. 	  	  
4.3.1.3 Receptor Selectivity: Desensitisation  
Another method for qualitatively estimating receptor selectivity is based on receptor 
desensitisation. Administration of 3 µM hC3a to isolated human macrophages produces an efflux of 
intracellular calcium release from cells. The basic concept of the calcium mobilisation is to detect 
the change in fluorescence that occurs when the cells release intracellular calcium from the 
endoplasmic reticulum after stimulation of the cells with an agonist. Fluo-3AM was used as a cell-
permeable calcium indicator and it needs to pass through the cell membrane with the aid of a mild 
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detergent, pluoronic acid, then esterase enzymes in cells cleave the Fluo-3AM into Fluo-3. Fluo-3 
will bind to the intracellular calcium to become the Fluo-3 calcium complex and it can be detected 
when excited by 485 nm light and emits 520 nm light.  
After stimulating the HMDM cells using 3 µM hC3a, which causes efflux of calcium that 
dissipates after 5-6 mins, then a second addition of 3 µM C3a has no effect due to the 
desensitisation of cell surface C3aR (Figure 4.9 A). A similar result was found when the second 
addition was either compound 105 (Figure 4.9 B) or 109 (Figure 4.9 C) at 10 µM instead of 3 µM 
C3a, which suggests that these compounds are selective for C3aR and do not activate some other 
receptor linked to intracellular Ca2+ release in HMDMs. 
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Figure 4.9 C3a receptor desensitisation in the calcium mobilisation assay on HMDM for 
105 (B) and 109 (C). HMDM were first treated with 3 µM C3a, which induced intracellular 
calcium release that was allowed to dissipate over 310 seconds prior to a second agonist 
injection. 
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4.3.1.4  Structure-Activity Relationships (SAR) 
All the compounds in this series were tested for agonist activity in a single point assay using 
the intracellular calcium mobilisation assay. In leukocytes such as eosinophils, neutrophils and 
basophils, C3a is known to induce calcium mobilisation and degranulation (Elsner et al., 1994; 
Nagata et al., 1987; Norgauer et al., 1993; Takafuji et al., 1994). These effects are mediated by 
coupling to pertussis toxin sensitive G-protein (Gαi) (Norgauer et al., 1993).  
Here our new compounds were tested at 10 µM and the results of the agonist response are 
compared to 100 nM hC3a responses under the same conditions (Figure 4.10). From Table 4.2, 
compound 106 showed good agonist activity comparable to that of hC3a. In contrast, compound 
109 and 110 showed less agonist activity when tested at 10 µM. These compounds have lower 
binding affinities for C3aR than 106 at 20 µM.   
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B. Antagonism 
 
 
 
Figure 4.10 Single point calcium release induced by Acyl-Leucine-5-Phenyl-Oxazole-
Arginine compounds. A. 105, 106, 109 and 110 were tested at 10 µM in calcium 
mobilisation assay for agonist activity. hC3a (100 nM) and SB290157 (10 µM) were used as 
reference compounds. B. compound 107, 108, 110 and 109 were tested at 1 µM and 10 µM 
for antagonist activity. hC3a was used to induce calcium release after incubating HMDM cells 
with compounds for 15 mins. Inhibition expressed as a percentage of maximum change in 
fluorescence induced by 100 nM hC3a. Error bars represented S.E.M. with n≥ 2. 
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The single point calcium mobilisation data provided quick results for comparison. 
Compound 109 had the best antagonist activity, better than for the reference compound SB290157 
(Figure 4.10 B). Moreover, 109 also gave the least agonist activity in the agonist activity screening 
results (Figure 4.10 A). Additionally, concentration dependence studies of calcium mobilisation 
were performed for compounds 105 and 109.  
The antagonist activity of SB290157 in this study was IC50 = 2.9 ± 1.1 µM against 100 nM 
hC3a on isolated human derived macrophage cells, while compound 105 had IC50 22 ± 15 nM and 
compound 109 had IC50 17 ± 10 nM (Figure 4.11). These results suggest that compounds 105 and 
109 are potent antagonists for C3aR, much more potent than SB290157 in inhibiting C3a induced 
calcium release from HMDM cells. 
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Figure 4.11 Concentration dependent inhibition of SB290157 (l), 105 (n) and 109 (p). 
Various concentrations of SB290157, 105 and 109 were incubated with HMDMs 15 mins 
prior to the experiment. The cells were then challenged by 100 nM hC3a. Differences in 
fluorescence induced by intracellular calcium mobilisation were measured and expressed as 
percentage of response induced by 100 nM hC3a on untreated HMDMs ± S.E.M. Results were 
plotted to corresponding concentrations by using prism 5.0. All the compounds were tested with 
n ≥ 3.  
 	  
In conclusion, substitution by a phenyl group at the fifth position of the oxazole ring has 
turned C3aR agonists into antagonists, and bulkier substitution at the N-terminus also improved 
potency. From this study, we discovered two potent new C3aR antagonists with potency at 
nanomolar concentrations, about 100 fold more potent as antagonists than SB290157. In addition, 
there was a correlation between the binding affinity and calcium mobilisation assay of the 
compounds in this study (Figure 4.7 and 4.11). Compound 109 (IC50 18 nM) bound tightly to 
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C3aR, possibly more tightly than 105 (37 nM) and SB290157 (38 nM), and it also showed the 
highest agonist potency for inhibiting calcium release after stimulating cells with 100 nM hC3a.  
The next approach will be the modification of SB290157, the first non-peptidic ligand that 
was reported as a C3aR antagonist and showed some affinity for C3aR but not C5aR. 	  
4.3.2 Structural Modification of C3aR Antagonist: SB290157 
SB290157 was first reported by Ames et al. (2001) as a potent C3a receptor antagonist, 
which showed antagonist activity in several in vitro assays and in vivo studies, including calcium 
mobilisation in RBL and neutrophils, LPS-induced lung neutrophilia model in guinea pig and an 
adjuvant–induced arthritis rat model. This study also showed that SB290157 binds tightly to C3aR, 
with IC50 200 nM in a competitive radioligand binding assay using RBL-2H3 cells. The results of 
Chapter 2 also showed that SB290157 had no cross reactivity with C5a in competitive radioligand 
binding and desensitisation assays. Taking these considerations in mind, we decided to use 
SB290157 as a lead compound and focussed on optimising the different components of SB290157. 
SB290157 can be regarded as having three different regions: (i) a hydrophobic diphenylmethane 
moiety, (ii) an aliphatic linker region and (iii) a C-terminal arginine residue (Figure 4.12). 
The C-terminal arginine of new ligands was retained to maintain the potency of the ligands. 
It has been shown that the arginine at the C-terminus is important for recognition (binding) and 
thereby maintaining high agonist activity for C3a and all potent C3a peptide agonists. Furthermore, 
the cleavage of C3a at the arginine position by carboxypeptidases N leads to the complete loss of 
biological activity because C3a-des Arg does not bind to C3aR (Wetsel et al., 2000). The 
modification of the arginine residue by replacing with arginine mimetics may improve 
bioavailability, solubility and, metabolic stability of the compounds (Denonne et al., 2007b) and 
might be part of future studies.  
The structure of SB290157 has been modified in five different ways: (1) the modification of 
the linker region while leaving unchanged the diphenylmethylene rings and arginine moieties, (2) 
the modification of the aromatic and linker regions where the ether bond and the linker are replaced 
by an amide functional group (R-glycine-arginine scaffold), (3) the aromatic region can also be 
replaced by cinnamic acids and derivatives while the ether bond and the linker region are replaced 
with an amide group (cinnamic acids-glycine-arginine), (4) the linker region has also been 
investigated by introducing a tryptophan residue and analogues with different substituents at the 
aromatic region, and finally (5) the linker has been replaced by furan moieties, including 
functionalised analogues.  
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Figure 4.12 C3aR antagonist SB290157.  	  
4.3.2.1 Series I:  Linker Alkylated SB290157 Analogues. 
 
Initially, the methylene group located in the linker component of SB290157 was 
functionalised with different alkyl groups to explore whether the substitution of the space filling 
group might improve the affinity or the potency of the new family of the compounds generated 
(Table 4.4).  
Competitive radio-ligand binding assays have been used for affinity measurement and the 
calcium mobilisation assay for a functional test, both using human monocyte-derived macrophages 
to derive the structure-activity relationships.  
In the competitive radioligand binding assay the new agonist candidates were tested in 
competition with 80 pM of [125I]-C3a (2200 Ci/mmol, Perkin Elmer) or 20 pM of [125I]-C5a (2200 
Ci/mmol, Perkin Elmer) for C3aR or C5aR binding on HMDM cells. Unlabelled compounds with 
high affinity for C3aR compete with labelled C3a for binding to C3aR, and this was determined by 
scintillation counting on a Wallac Beta scintillation counter. The non-specific binding for C3aR  
was determined by using at 1 µM C3a in competitive binding of compounds against [125I]-C3a or  at 
300 nM of C5a in competitive binding of compounds against [125I]-C5a . 
The calcium mobilisation assay was performed on HMDM cells using Fluo-3 as a calcium 
indicator. C3aR on myeloid cells is coupled to Gαi2/3 (Mousli et al., 1992). The activation of C3aR 
induces the release of calcium from the endoplasmic reticulum through phospholipase C(β). The 
calcium released into the cytoplasm was detected by the cell-permeable calcium binding 
fluorophore (e.g. Fluo-3). The fluorescence is then measured with a spectrofluorimeter. 
CHAPTER	  4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Towards C3a receptor antagonists 
	   175 
The results of affinity and functional assays of the compounds have been compared to 
SB290157 as a control. 
 
Table 4.4 SAR data for series I: Alkylated SB290157 analogues.  	  
	  
[125I]-­‐C3a	  Binding	  	  
	  
	  
Ca2+	  release	  assay	  
	  
Com	  
-­‐pound	  	  
	  
	  
Structure	  
n	   pIC50	  ± 	  SE	   IC50	  
(nM)	  
%a	   n	   pIC50	  ±SE	   IC50	  
(nM)	  
%b	  SB	  290157	   O HN
O
CO2H
NH
NH2HN 	  
11	   7.42	  ±	  0.06	   38	   6	   7	   5.52	  ±	  0.08	   3050	  	   53	  
111	  
O
H
N
O
CO2H
NH
NH2HN 	  
	   -­‐	   	   50	  	   	   -­‐	   	   86	  
112	  
O
H
N
O
CO2H
NH
NH2HN 	  
	   -­‐	   	   57	  	   	   -­‐	   	   100	  	  
113	  
O
H
N
O
CO2H
NH
NH2HN 	  
2	   5.39	  ±	  0.35	   4000	  	   21	  	   2	   5.27	  ±	  0.17	  	   5320	  	   87	  
 
a = % of binding of [125I]-C3a at compound concentration of 20 µM; compared to the binding of [125I]-C3a (80 pM) 
with cells in the absence of the compound (or Buffer) is 100% or in the presence of hC3a (1 µM) is 0%. Thus 
SB290157 had the best binding affinity to C3aR in this series. 
b = % of response to 100 nM hC3a activity (Antagonism test) . The compounds were tested at [10 µM] which were 
incubated with the cells and then tested with 100 nM of hC3a, giving a buffer response of 100%.  Thus SB compound 
was the best antagonist. 
 
All the compounds were tested in a C3a binding assay first. The results suggest that the 
substitution of the methylene moiety between the ether and the carbonyl groups of SB290157 leads 
to decreased affinity for C3aR binding (-hydrogen > -butyl > -methyl ≈ -ethyl).   
As for the affinity assay, the compounds were tested for function at just one concentration 
(10 µM) and reported as a percentage of the calcium release observed for hC3a at 100 nM. The 
results show that 112 is not an antagonist, while 111 and 113 show some inhibition of calcium 
efflux, which was stimulated by 100 nM of hC3a. Further examination of 113 in a full 
concentration response range gave IC50 5.3 µM that is higher than for SB290157 (IC50 ∼3 µM). 
Affinity of 113 at the single point concentration of 20 µM was similar to that found for SB290157 
(Figure 4.16 A).  
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4.3.2.2 Series II: R-Glycine-Arginine Tripeptide/Dipeptide Surrogates.  
Previous studies conducted by Dr. Jade Blakeney (PhD dissertation, University of 
Queensland, 2007) showed that substitution of the ether group in SB290157 with a planar amide 
lead to active C3aR ligands. In that series, the compounds were developed as tripeptides and 
dipeptide surrogates. The replacement of the ether group in SB290157 by an amide bond, which has 
partial double bond character and hence imparts a more rigid conformation to the compounds 
(Figure 4.13), could potentially lead to improved binding affinity of new analogues. 
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Figure 4.13 R-glycine-arginine tripeptide/dipeptide surrogates. The ether bond was 
substituted by an amide functional group, which gave more rigidity to the molecule. 	  	  
Table 4.5 SAR data for series II: R-Glycine-arginine tripeptide/dipeptide surrogates. 	  
	  
[125I]-­‐C3a	  Binding	  
assay	  
	  
Ca2+	  release	  assay	  
	  
Compound	  
	  
	  
R	  
%a	   %b	  
114	  
	  
68	   83	  
115	  
	  
100	  	   75	  
116	   	   100	   64	  
117	   	   100	   78	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118	  
	  
98	   72	  
119	   	   88	   84	  
120	  
	  
100	   96	  
121	   	   77	   97	  
122	  
	   	   59	   N/A	  
123	  
	   	   53	   N/A	  
124	  
	   	   100	   N/A	  
125	  
	   	   100	   N/A	  
126	  
	   	   88	   N/A	  
127	  
	   	   100	   N/A	  
128	  
	   	   71	   N/A	  
129	  
	   	   	   65	   	   N/A	  
130	  
	   	   93	   N/A	  
131	  
	   	   46	   N/A	  
 
a = % of binding of [125I]-C3a at compound concentration of 20 µM; compared to the binding of [125I]-C3a (80 pM) 
with cells in the absence of the compound (or Buffer) is 100% or in the presence of hC3a (1 µM) is 0%. Thus 
compound 131 was the best binding affinity to C3aR on the cells in this series. 
b = % of response to 100 nM hC3a activity (Antagonism test) . The compounds were tested at [10 µM] which were 
incubated with the cells and then tested with 100 nM of hC3a, giving a buffer response of 100%.  Thus compound 116 
was the best antagonist in this series.  N/A not tested.	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Table 4.6  R-Glycine-arginine tripeptide surrogates as candidate C3aR ligand. 	  
	  
[125I]-­‐C3a	  Binding	  assay	  
	  
	  
Ca2+	  release	  assay	  
	  
Com-­‐	  
pound	  	  
	  
R	  
n	   pIC50±SE	   IC50	  
(nM)	  
%a	   n	   pEC50± 	  SE	   EC50	  
(nM)	  
%b	  
	  
132	  	   	   2	   5.65	  ±	  0.35	   2200	   55	   -­‐	   -­‐	   -­‐	   -­‐	  
 
a = % of binding of [125I]-C3a at compound concentration of 20 µM; compared to the binding of [125I]-C3a (80 pM) 
with cells in the absence of the compound (or Buffer) is 100% or in the presence of hC3a (1 µM) is 0%.  
b = % of response to 100 nM hC3a activity (Antagonism test) . The compounds were tested at [10 µM] which were 
incubated with the cells and then tested with 100 nM of hC3a, giving a buffer response of 100%.   
 
 
Compounds 114 – 132, having the glycine-arginine unit and other functional groups R in the 
hydrophobic region, showed significantly lower binding affinity for C3aR compared to SB290157 
(Table 4.5 and 4.6). Compound 122 is the amide analogue of SB290157, which bound poorly 
indicating that replacement of the ether bond with an amide reduced the binding affinity of the 
compound to C3aR. Compound 123, with the 2-naphthoic acid substituent and no glycine residue, 
showed a slight improvement in binding affinity compared to 122. Compound 131, with a 4-
biphenylacetyl fragment connected to the amide bond had the best affinity of this series of 
analogues. This could be attributed to the lack of the glycine moiety as linker fragment and amide 
bond at the aromatic region of the molecule.   
 
4.3.2.3 Series III : Cinnamoyl-Glycine-Arginine Tripeptide Surrogates. 
 
Substitution of the hydrophobic fragment R on R-glycine-arginine by cinnamoyl and 
derivatives has been investigated. The cinnamic acids were coupled to glycine-arginine in this 
series (Figure 4.14). The new family of compounds generated showed less affinity for C3a receptor 
in the competitive radioligand binding assay (Figure 4.16 B) and also less antagonist potency in the 
calcium mobilisation assay compared to SB290157 (Table 4.7). The benzophenone derivative 137 
was completely inactive. The low affinity of the cinnamoyl-glycine-arginine tripeptide surrogate 
compounds for C3aR can be attributed to the lower flexibility of the carbon-carbon double bond 
linking the aromatic ring, making it difficult to correctly position large hydrophobic groups in the 
pocket of the receptor. 
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Figure 4.14 Cinnamoyl-glycine-arginine tripeptide surrogates. 	  	  	  
Table 4.7 SAR data of Series III: Cinnamoyl-glycine-arginine tripeptide surrogates. 	  
	  
[125I]-­‐C3a	  Binding	  assay	  
	  
	  
Ca2+	  release	  assay	  
	  
Compound	  	   	  R	  
%a	   %b	  
133	   	   93	   100	  
134	   	   67	   99	  
135	   	   70	   89	  
136	   	   74	   85	  
137	   	   100	   100	  
 
a = % of binding of [125I]-C3a at compound concentration of 20 µM; compared to the binding of [125I]-C3a (80 pM) 
with cells in the absence of the compound (or Buffer) is 100% or in the presence of hC3a (1 µM) is 0%. Thus 
compound 134 had the best binding affinity to C3aR on the cells in this series. 
b = % of response to 100 nM hC3a activity (Antagonism test) . The compounds were tested at [10 µM] which were 
incubated with the cells and then tested with 100 nM of hC3a, giving a buffer response of 100%.  Thus compound 136 
was the best antagonist in this series. 
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4.3.2.4 Series IV:  R-Tryptophan-Arginine Tripeptide Surrogates. 
 
The fourth series of compounds was generated incorporating the tryptophan-arginine 
dipeptide unit and with various other functional groups “R” in the hydrophobic region (Figure 
4.15). The substitution of the linker region with a tryptophan residue provided a potential hydrogen 
bond donor on the indole ring and additionally, a bulky hydrophobic structure that could fill space 
that may be available in the receptor. Compounds 138 to 142 were designed and synthesized by 
chemists in our group.  
 Binding results of these compounds at 20 µM concentration showed that they increase their 
affinity for C3aR (Figure 4.16 C). However, none of these compounds was a potent antagonist in 
inhibiting calcium release from cells after challenge with 100 nM hC3a in the HMDM cells (Table 
4.8). 
Compound 138 demonstrated a partial agonist activity with an EC50 907 nM. This was the  
first compound to give a submicromolar agonist potency of the first four series, confirming a result 
reported by Blakeney in her PhD thesis (2007). The hydrophobic group R linked to the amide bond 
was phenylmandelic acid, consisting of a quaternary carbon with two phenyl rings and a hydroxyl 
group as substituents.  
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Figure 4.15 R-Tryptophan-arginine tripeptide surrogates. 	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Table 4.8 SAR data of Series IV: R-Tryptophan-arginine tripeptide surrogates. 	  
	  
[125I]-­‐C3a	  Binding	  assay	  
	  
	  
Ca2+	  release	  assay	  
	  
	  
Com	  
Pound	  
	  
	  
R	  
n	   pIC50±SE	   IC50	  
(nM)	  
%a	   n	   pEC50	  ±SE	   EC50	  
(nM)	  
%b	  
138	   	   	   -­‐	   -­‐	   42	   2	   6.04	  ±	  0.17	   907	  	   -­‐	  
139	   	   	   -­‐	   -­‐	   46	   	   -­‐	   -­‐	   90	  
140	   	   2	   5.93	  ±	  0.31	   1200	   35	   	   -­‐	   -­‐	   88	  
141	  
	  
	   -­‐	   -­‐	   100	  	   	   -­‐	   -­‐	   88	  
142	   	   	   -­‐	   -­‐	   57	  	   	   -­‐	   -­‐	   100	  
 
a = % of binding of [125I]-C3a at a compound concentration of 20 µM; compared to the binding of [125I]-C3a (80 pM) 
with cells in the absence of the compound (or Buffer) is 100% or in the presence of hC3a (1 µM) is 0%. Thus 
compound 140 was the best binding to C3aR on the cells in this series. 
b = % of response to 100 nM hC3a activity (Antagonism test) . The compounds were tested at [10 µM] which were 
incubated with the cells and then tested with 100 nM of hC3a, giving a buffer response of 100%. 
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B. Glycine-Arginine Derivative 
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C. Tryptophan-Arginine Derivative 
 
 
Figure 4.16 Structure activity relationship studies of C3a non-peptidic agonists by 
substitution of SB290157 in different regions. The affinities of the ligands were tested by 
competitive binding with [125I]-C3a (80 pM) using C3aR non-peptide ligands at concentrations 
of 20 µM in human monocyte-derived macrophages. Error bars represented S.E.M. with n≥ 2. 
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4.3.2.5 Series V: Substitution of Furan at the Linker Predominantly Gives 
Agonists 
Denonne and colleagues (2007b) reported a compound which had higher affinity for C3aR 
(pIC50 7.5 vs 20 pM [125I]-C3a) than SB290157 by optimising the structure of SB290157 with a 
rigid furan ring and retaining the arginine and ether oxygen that is assumed to contribute binding 
interactions because replacing furan at the linker with a benzene or thiophene rings which are not 
capable of acting as hydrogen bond acceptors showed less affinity for C3aR, with pIC50 4-6 and 5.2 
vs 20 pM [125I]-C3a respectively. However, in our hands this furan compound was a C3aR agonist 
with relatively poor affinity for C3aR. 
We were interested in modifying the linker region of SB290157 by incorporating other 5-
membered heterocycles but retaining the diphenylmethane unit and the arginine residue (Figure 
4.17). Structure-activity relationships from such a study could provide information about potential 
H-bond interactions between the compounds and the C3a receptor. 
Initially, SB290157 and the previously reported compound (144) from Denonne and 
colleagues (2007b) were synthesised by our group and I measured C3a receptor binding affinities 
and calcium mobilisation for agonism (induced calcium release) and antagonism (inhibition of 
calcium release by the induction of 100 nM hC3a) in human monocyte-derived macrophages. 	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Figure 4.17 (a) SB290157 (b) Substitution of different heterocycles in the linker region.  	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Table 4.9 C3aR binding and agonism: Effect of heterocycles in the linker region.  	  	   X	   Y	   Z	   	   Receptor	  
Binding	  	  
Affinity	  
	   	   Apparent	  
Agonist	  
Activity	  
	  
Agonist	   	   	   	   n	   pIC50	  ±	  SE	   IC50	  (nM)	   n	   pEC50	  ±	  SE	   EC50	  (nM)	  
143	   N	   O	   CH	   4	   7.43	  	  ±	  0.10	   37	   4	   8.2	  ±	  0.15	   6.6	  
144	   O	   CH	   CH	   3	   5.88	  	  ±	  0.11*	   1300	   2	   6.19	  ±	  0.2	   645	  
145	   O	   N	   C-Me	   3	   6.22	  	  ±	  0.15*é	   606	   2	   ϕ	   ϕ	  
146	   S	   N	   C-Me	   3	   7.04	  	  ±	  0.12*éÎ	   91	   2	   4.13	  ±	  2.7*	   74800	  
ϕ	  compound	  showed	  no	  agonist	  activity	  up	  to	  100	  µM.	  
* p < 0.05 vs. 143; é p < 0.05 vs. 144 and Î p < 0.05 vs. 145. 
 
The results of the competitive binding studies in HMDM cells showed that SB290157 had a 
higher binding affinity than 144 (IC50 38 nM vs 1.3 µM respectively)(Table 4.9 and Figure 4.18). 
The calcium mobilisation assay indicated that SB290157 (IC50 2.7 µM) was an antagonist without 
agonist activity, whereas 144 displayed partial agonist activity (EC50 645 nM) (Table 4.9).  
The other compounds in this series (143, 145 and 146) were synthesised by modified 
heterocycle ring to explore the possibility of improvement of the affinity of the compounds to the 
receptor by enhanced hydrogen bond acceptors. The compounds were tested in the C3a binding 
assay first. The results showed compound 143 had the highest affinity for C3aR, similar to 
SB290157 (IC50 38 versus 37 nM, respectively). As expected, the oxazole in 143 conferred greater 
affinity for C3aR than the furan in 144, and we attributed this to the fact that oxazole has a much 
stronger H-bond accepting nitrogen (at 3rd position) than the oxygen (at 1st position) of furan. 
Compound 145 had around 15-fold lower affinity for C3aR than 143, but 2 fold greater than for the 
furan-containing 144. A drop in the binding potency of 145 may be due to the weaker hydrogen 
bond interaction of oxygen (at 1st position). Compound thiazole 146 (IC50 91 nM), which had a 
sulfur atom at the 1st position, showed improved binding affinity compared with when an oxygen 
atom was at the same position (compound 145). This was surprisingly as a sulfur atom is not 
recognised as a good hydrogen bond acceptor, but it did improve the binding affinity of the 
compound, possibly because its lone pair orbitals project further into a pocket than those of oxygen.  
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Figure 4.18 Competitive [125I]-C3a binding of hC3a (l), SB290157 (n), and non-peptidic 
ligands with heterocycles in the linker region 143 (q), 144 (¡), 145 (£) and 146 (U) on 
human monocyte derived macrophage cells. Human monocyte derived macrophage cells (1.5 
x 106 cells/mL) were incubated for 1 h at room temperature with 80 pM of 125I-C3a and 
increasing concentration of non-labelled C3a (concentration 1 pM to 1 µM) and non-labelled 
non-peptidic ligands (concentration 0.1 nM to 100 µM). All compounds were tested with n ≥ 3. 
Each point represented the mean percentage specific binding ± S.E.M.  	  	  
4.3.2.5.1 C3aR Agonists Containing a Heterocycle in the Linker 
 The compounds were tested in the calcium mobilisation assay at different concentrations. 
Compound 143 and 144 displayed partial agonist activity with EC50 7 nM and 645 nM respectively, 
while compounds 145 and 146 showed negligible agonist activity (EC50 ≥ 50 µM)(Figure 4.19). 
From the results we also found that compound 143 (pEC50 = 8.12 ± 0.15) had greater agonist 
potency than hC3a (pEC50 = 7.2 ± 0.06), although the plots below should probably be viewed as 
just qualitatively indicating comparable agonist potency (see Table 4.9). 145 and 146 were chosen 
for further examination of their antagonist activity in the calcium mobilisation assay. 
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Figure 4.19 Intracellular calcium release from human monocyte derived macrophage cells 
induced by hC3a (), 143 (l), 144 (n), 145 (l), 146 (♦). Difference in fluorescence was 
measured and expressed as a percentage of maximum response induced by 100 nM hC3a ± 
S.E.M. Results were plotted against corresponding concentration in Prism 5.0. All compounds 
were tested with n ≥ 3.  
 
4.3.2.5.2 C3aR Antagonists Containing Heterocycles. 
In the calcium mobilisation assay, compounds 145 and 146 showed higher antagonist 
activity than SB290157 (Table 4.10) without agonist activity (Figure 4.20), which suggests that 
these compounds might provide clues for further C3aR antagonist development. However, the 
advantage of the heterocycle over the ether oxygen in SB290157 was not as great as it was for the 
agonist potency of the related compound 143. Perhaps the hydrogen bond acceptor power supplied 
by the heteroatom of the 5-membered ring is more important for agonist than antagonist function. 
 
Table 4.10 Comparison of results between Agonist and Antagonist activity of 145 and 146. 	  	   	   Apparent	  
Antagonist	  
Activity	  
	   	   Apparent	  Agonist	  
Activity	  
	  
Agonist/	  
Antagonist	   n	   pIC50	  ±	  SE	   IC50	  (nM)	   n	   pEC50	  ±	  SE	   EC50	  (nM)	  
145	   3	   6.34	  	  ±	  0.23	   460	   2	   ϕ	   ϕ	  
146	   3	   6.27	  	  ±	  0.22	   534	   2	   4.13	  ±	  2.7	   74800	  
ϕ	  	  compound	  showed	  no	  agonist	  activity	  up	  to	  100	  µM.	  
no statistic significant of pIC50 value between 145 and 146.  
The statistical differences between two compounds (145 and 146) were accessed using Student’s t-test between them. 
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Figure 4.20 Concentration dependent inhibition of C3a-inducd Ca2+ release in HMDM by 
SB290157 (l), 145 () and 146 (n). Various concentrations of SB290157, 145 and 146 were 
incubated with HMDMs 15 mins prior to the experiment. The cells were then challenged by        
100 nM hC3a. Differences in fluorescence induced by intracellular calcium mobilisation were 
measured and expressed as percentage of response induced by 100 nM hC3a on untreated 
HMDMs ± S.E.M. Results were plotted to corresponding concentrations by using Prism 5.0.  
Compound SB290157 (♦), 145 (q) and 146 (♦) were also tested for agonist activity in the same 
assay. All the compounds were tested with n ≥ 3. 	  	  	  
4.3.2.5.3 Selectivity of Heterocycle-Containing Ligands for C5aR 
Competitive Radioligand Binding Assays: [125I]-C5a Binding. 
 The compounds (143-146) were tested in the competitive binding assay to evaluate 
selectively for C3aR over C5aR. A single concentration screening (ligands at 20 µM) competition 
with radiolabelled C5a 20 pM was performed. The results showed that none of these compounds 
have affinity for C5aR on human macrophage cells (Figure 4.21). The results of binding were 
compared to 3D53, which was known as a C5aR antagonist with no cross reactivity with C3aR. It is 
therefore suggested that the compounds incorporating heterocycles are selective for C3aR over 
C5aR. 
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Figure 4.21 Competitive binding between [125I]-C5a and heterocycle-containing ligands in 
human monocyte derived macrophage cells. Human monocyte derived macrophages (1.5x106 
cells/mL) were incubated for 1 h at room temperature with constant concentration (20 pM) of 
[125I]-C5a and furan-incorporated ligands and 3D53 at a concentration of 20 µM. The buffer 
represents the total binding of [125I]-C5a to HMDM (approximately 4000 cpm). Error bars are 
means ± S.E.M. 	  	  	  
4.3.2.5.4 Receptor Selectivity: Desensitisation  
 The desensitisation experiments were used to measure the selectivity of ligands for C3aR 
which helped to clarify that the ligands have selectivity for C3aR over other GPCRs that signal 
through intracellular calcium release. The hC3a (3 µM) was administered to HMDMs which 
produces an efflux of intracellular calcium that dissipates after 5-6 mins (Figure 4.22). A second 
addition of 3 µM hC3a after 5 mins has no effect, and this effect is due to desensitisation of the 
receptor through desensitisation/ internalisation of the receptor from the cell surface. Figure 4.22 
shows all compounds in these series in the second addition after desensitised cells with hC3a did 
not cause release of calcium from HMDM cells which suggests these heterocyclic ligands are 
selective for C3aR. 
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Figure 4.22 C3a receptor desensitisation calcium release plots performed on HMDM for 
compounds with heterocycles at the linker region. HMDM were first treated with hC3a 3 µM 
that induced a calcium response that was then allowed to dissipate over 310 secs prior to a 
second agonist administration. 
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4.4 DISCUSSION 
From the previous study in Chapter 3, we found that the oxazole–containing compounds 
showed high similarity in their conformations to the last four C-terminal residues of C3a (GLAR in 
a beta turn conformation), suggesting that the oxazole scaffold favoured a conformation leading to  
potent C3aR agonists/antagonists. The compounds with an oxazole scaffold did indeed bind to 
C3aR with low nanomolar affinity and greater potency than hC3a itself. Next we incorporated a 
methyl group at the fifth position of the oxazole, but this did not improve the affinity for C3aR and 
showed only agonist activity. Further studies in this chapter involved incorporating a larger group 
(phenyl) at the fifth position, which led to higher affinity for C3aR. The first compound in this 
series (105) showed no improvement over the methyl-substituted analogue with respect to affinity 
for C3aR. However, the compound had no agonist activity up to 100 µM in the calcium 
mobilisation assay on HMDM. Moreover, 105 showed some potent antagonist activity, with IC50 17 
nM, which is much more potent than SB290157 (IC50 2.7 µM). Substituting the Boc group in 105 
by the 4-methoxybenzoyl substituent produced compound 109, which had greater affinity for C3aR 
and higher antagonist potency than SB290157 but similar activity to 105. 
The SAR study showed that modification of the oxazole compound at the 5-position with a 
phenyl group transformed C3aR agonists into antagonists. 
In another new series of C3aR non-peptidic agonists/antagonists obtained by modification of 
SB290157, we found that the substitution of the linker of SB290157 with an appropriate 
heterocyclic ring leads to improved binding affinity and potency of the new compounds in this 
series. The incorporation of oxazole (Figure 4.23) led to a dramatic improvement over a previous 
report by Denonne et al. (2007b), where replacing the ether oxygen with a furan oxygen was 
claimed to give improved affinity for C3aR. 
Compound 143 was the most potent (IC50 = 37 nM in competitive binding studies) however 
it showed agonist activity in the calcium mobilisation EC50 = 6.6 nM, whereas compounds 145 and 
146 had lower affinity for C3aR (IC50 606 and 91 nM) with less agonist activity. However, 
compound 144 (Figure 4.23) was the same compound reported by Denonne in 2007 (Denonne et 
al., 2007b). In our hands, 144 had affinity for C3aR with pIC50 = 5.88 ± 0.11 vs 80 pM in [125I]-C3a 
in whole HMDMs, while Denonne and colleagues reported pIC50 = 7.2 vs 20 pM [125I]-C3a in a cell 
membrane preparation from HMC-1 cells. The difference between these results may be due to 
differences between protocols, since isolated membrane receptors frequently show 10-100 fold 
higher affinities for ligands than whole cells (Monk et al., 2007). 
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All compounds showed selectivity for C3aR over C5aR in competitive radioligand binding 
assays using 125I labelled C3a and C5a, and also in a receptor desensitisation assay, which 
confirmed the selectivity of the ligands by their inability to induce calcium release after 
desensitisation of the cells with C3a.  
In conclusion, from these studies of structure-activity relationships (SAR) for potent and 
selective non-peptide C3aR antagonists, we found that the fifth position of the oxazole is the critical 
position for transforming an agonist to an antagonist. From another series, where substitution at the 
linker region of SB290157 with furan-like rings, the thiazole compound (146) improved the binding 
affinity and had antagonist activity with IC50 lower than for SB290157. 
 
 
 
 
Figure 4.23 Superimposition of SB290157 (green) and furan compound (144) showing the 
location of the hydrogen bond acceptor atom (arginine residue not shown) (courtesy of Dr. 
Reid). 
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5.0 ABSTRACT 
Potent and selective peptide antagonist 25 and non-peptide antagonist 146 have been 
compared in this chapter with SB290157 for their capacity to inhibit intracellular calcium release in 
HMDM stimulated by up to 100 µM of three different classes of C3aR agonists: human C3a, 
peptide agonists (17 and 20), and non-peptide agonists (63 and 80).  
The antagonists SB290157, 25 and 146 all displayed insurmountable and non-competitive 
antagonism against C3a for C3aR. This is attributed to either a possible allosteric binding site for 
the compounds on C3aR or possibly irreversible or pseudo-irreversible binding to the C3a receptor. 
By contrast, SB290157 was a surmountable and competitive antagonist against peptide agonists (17 
and 20) and non-peptide agonists (63 and 80).  Compound 25 was an insurmountable antagonist for 
all C3a agonists (hC3a, peptide and non-peptide agonists). Compound 146 behaved similarly to 
SB290157 in exhibiting surmountable and competitive antagonism of peptide and non-peptide 
C3aR agonists.  
These results point to a mechanism of insurmountable antagonism for compound 25 against 
all agonists (hC3a, 17, 20, 63 and 80) involving binding to C3aR that is unlikely to be at an 
allosteric site since it competed with [125I]-C3a in the competitive binding assay. It is more likely 
that compound 25 binds pseudo-irreversibly to C3aR. 
The competitive antagonism study of C3aRA (SB290157) against all peptide and non-
peptide agonists showed a concentration of C3aRA (SB290157) that caused a two-fold rightward 
shift of agonists in the following order: 20 (63 nM) < 17 (100 nM) < 63 (126 nM) < 80 (158 nM). 
This indicates that the non-peptide agonists (63 and 80) bind to C3aR more tightly than peptide 
agonists (17 and 20), thus requiring higher concentrations of C3aRA (SB290157) to shift the EC50 
value of agonists two-fold to the right.  
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5.1 INTRODUCTION   
The peptide inflammatory mediator C3a is released after activation of the complement 
system by the cleavage of Component 3 by C3 convertases in either of the three known complement 
activation pathways. C3a causes chemotaxis and degranulation of eosinophils (Daffern et al., 1995) 
basophils and mast cells (Hartmann et al., 1997), stimulates cytokines release from macrophages 
and monocytes (Fischer et al., 1999; Takabayashi et al., 1998; Takabayashi et al., 1996), induces 
smooth muscle contraction (Hugli, 1975) and increased vascular permeability (Vallota et al., 1973). 
C3a and its receptor have been implicated in various immuno-inflammatory and autoimmune 
diseases. Studies of C3a in vitro and in vivo show that C3a is involved in asthma (Humbles et al., 
2000), allergies (Drouin et al., 2002; Drouin et al., 2001), sepsis (Drouin, 2001; Kildsgaard et al., 
2000), allergic rhinitis (Andersson et al., 1994; Jun et al., 2008), systemic lupus erythematosus 
(Bao et al., 2005), diabetes (Mamane et al., 2009), arthritis (Hutamekalin et al., 2010), psoriasis 
(Kapp et al., 1985), nephropathy (Tang et al., 2009; Wenderfer et al., 2009) and ischemia 
reperfusion injury (Mocco et al., 2006; Proctor et al., 2004). C3a mediates its inflammatory 
functions by interacting with its receptor, C3aR that belongs to the rhodopsin family of 7-
transmembrane GPCR (Kretzschmar et al., 1993; Martin et al., 1997; Zwirner et al., 1997).  
Like C5a, the carboxy-terminal sequence of C3a (LGLAR) is important to activate its 
receptor (Caporale et al., 1980; Chazin et al., 1988; Hoeprich et al., 1986; Kawai et al., 1991; Kohl 
et al., 1990; Zhang et al., 1997). The minimum sequence is LAR which was reported by Kohl and 
colleagues (1990) is vital for biological activity of C3a. There are many groups that focus on 
developing the therapeutic potential of selective C3aR agonists/antagonists by modification of the 
C-terminal region of the native peptide C3a.  
From the results of chimeric and deletion mutagenesis of C3aR, a two-site binding model 
was proposed (Figure 5.1) for the C3a - C3aR interaction which was similar to that proposed for 
the C5a-C5aR interaction (Chao et al., 1999; Chenoweth et al., 1980; Ember et al., 1997). The 
“non-effector” site or “recognition” binding site (site 1) is hypothesized to involve an interaction 
between the anionic residues near the N and C-termini of extracellular loop two of C3aR and 
cationic residues in the C-terminal helical region of C3a. The second binding site, called the 
“effector” site (site 2), is thought to be responsible for activation of the receptor. The C-terminal 
sequence of C3a (LGLAR) interacts in a binding pocket, which is formed by the transmembrane 
domains of the receptor (Chao et al., 1999; Ember et al., 1997). Unlike C5aR, the C3aR does not 
have a highly anionic N-terminal region, which constitutes a non-effector or recognition site in 
C5aR for C5a-C5aR interaction. The replacement of the C3aR N-terminal sequence with that from 
the hC5aR, or truncated up to 16 amino acids, had minimal effect on C3a binding (Chao et al., 
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1999; Crass et al., 1999). Thus, the N-terminal region of C3aR has a minor role in the C3a - C3aR 
interaction while the substitution of the 2nd extracellular loop causes changes in its affinity and 
activity. 
 
 
 
 
 
 
 
Figure 5.1 Two-site model proposed for the interaction between C3a and its receptor. The 
proposed model for the C3a - C3aR interaction corresponds to a model originally proposed for 
multi-site binding of C5a-C5aR interaction (Chenoweth et al., 1980; Siciliano et al., 1994). The 
non-effector site (site 1) is hypothesized to involve the interaction of the negatively charged 
regions of the 2nd extracellular loop with the positively charged residues in the C3a molecule 
close to the C-terminal effector region (site 2) (Ember et al., 1997).  	  	  	  	  
 The crucial role of C3a in activation of complement pathways makes the C3a/C3aR 
interaction a highly desirable drug target. However, there are currently no drug-like molecules 
available that are potent and selective agonists or antagonists for C3aR.  
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Recently, our group (in Chapter 2) reported potent and selective hexapeptide C3aR agonists 
(17 and 20) and an antagonist (25)(Scully et al., 2010)(Figure 5.2). These compounds may bind to 
the receptor in a turn conformation. The hexapeptide agonists (17 and 20) had high affinities for the 
human C3aR (IC50 40 and 82 nM against 80 pM 125I-C3a) on peripheral blood monocytes, and were 
potent agonists of C3a-stimulated intracellular calcium release (EC50 0.32 µM, pEC50 = 6.50 ± 0.12; 
n=5 and 0.37 µM, pEC50 = 6.43 ± 0.09; n=6), respectively) in dU937 cells. The new hexapeptide 
antagonist (25) showed no agonist activity up to 100 µM, bound tightly to C3aR (IC50 238 nM 
against 80 pM 125I-C3a) on PBMCs, and exhibited similar antagonist potency to SB290157 (IC50 
=1.3 µM versus 100 nM of hC3a on dU937 cells.)  
Incorporation of a heterocycle into C-terminal tripeptide sequences resulted in Chapter 3 
and Chapter 4 reporting new ‘non-peptidic’ C3aR agonists (63, 80; Figure 5.2) and antagonists 
(105, 146; Figure 5.2), which bound with high affinity to C3aR (IC50 = 9 nM, 14 nM, 37 nM, 91 
nM respectively) on HMDMs, as revealed by radioligand competition assay using 125I-C3a (80 pM). 
Agonists 63 (EC50 = 7 nM, pEC50 = 8.15 ± 0.10; n=3) and 80 (EC50 = 45 nM, pEC50 = 7.35 ± 0.18; 
n=2) were of comparable potency to C3a in inducing intracellular calcium release in isolated 
HMDM. The substitution of oxazole in Chapter 4 by 5-phenyl oxazole transformed agonists into 
potent antagonists like 105 (IC50 = 16.5 nM against 100 nM hC3a) and by thiophene into antagonist 
146 (IC50 = 534 nM) on HMDM.  
In this Chapter, we now examine more closely the nature of the antagonism for three 
compounds (SB290157, peptide antagonist 25, non-peptide antagonist (146) against individual 
agonists of three classes: human C3a, potent peptide agonists (17, 20) and potent non-peptide 
agonists (63 and 80). The results from this study could lead us to a better understanding of the 
binding site of these compounds on C3aR and whether they are orthosteric or allosteric antagonists.  
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Figure 5.2 Structures of peptide agonists (17 and 20), peptide antagonist (25), non-peptide 
agonists (63 and 80) and non-peptide antagonists (105, 146 and SB290157). 	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5.2 AIMS/OBJECTIVES 
The objectives of this chapter were initially to study the most potent and selective currently 
available antagonists (peptide FLTChaAR (25), nonpeptide SB290157, and SB290157 analogue 
146) for their mechanism(s) of action against three different classes of agonists of C3aR (protein 
C3a, peptide 17 and 20, peptidomimetics 63 and 80). By identifying competitive/noncompetitive 
and surmountable/insurmountable behaviour in the Ca2+ release assay, we could potentially learn 
about the relative binding locations of the compounds and their different mechanisms of action.  
There have been no reports of human C3aR subtypes so far, with only one C3aR in the human 
genome having been described (Crass et al., 1996). This is in contrast to C3aR in guinea pigs for 
which there were 2 C3aR subtypes reported, but only after a great deal of research in the 1980s and 
1990s on guinea pig tissues (Fukuoka et al., 1998). This new study using a variety of new C3aR 
antagonists may give confidence to other researchers wanting to further classify the human C3aR 
and its pharmacology in vitro and in vivo. In this study we decided to compare the pharmacological 
profiles of SB290157 and the new peptide antagonist (25) and non-peptide antagonist (146) in the 
calcium mobilisation assay on human monocyte-derived macrophages. 	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5.3 RESULTS 
Results from the previous chapters can be plotted to examine any correlation between 
receptor binding affinity at human C3aR and receptor activation as defined by intracellular calcium 
release (Figure 5.3). The plot below shows a stark correlation that separates the agonists (17, 20, 
63, 80) from the antagonists (25, 105, 146, SB290157). At first, we thought that the higher than 
predicted agonist potencies for synthetic compounds might be reflecting off-target agonist action 
via some other receptor(s) that could be contributing to intracellular calcium release. However, our 
receptor desensitization experiments do not support that conclusion. It is more likely, in our 
opinion, that the reason our compounds 17, 20, 63, 80 are not precisely on the line defined by C3a 
is probably more to do with our data for C3a, which does tend to vary from batch to batch and 
depending upon the supplier. Currently, commercial source of C3a are isolated from serum and are 
supplied in a phosphate buffer solution. The batches of C3a show variability decrease in the ability 
to induce calcium release, which shows the change in EC50 and reduces the maximum response of 
calcium release at the EC100 of C3a. It may be a result of serum/ C3a variability at the source, 
concentration variations or freeze/thaw cycles. However, even the small amounts of C3a obtained 
from the source of variation showed its high potency with EC50 = 18.6 nM (pEC50 = 7.7 ± 0.08, 
n=4) for calcium release in HMDM. 
 
 
Figure 5.3 Correlation between binding affinity (pIC50) and agonist activity (pEC50) of 
hC3a, peptide C3a agonists (17, 20), non-peptidic C3a agonists (80, 63) and C3a antagonists 
(SB290157, 25, 105, 146).  There were no agonist activities for SB290157, 25, 105 and 146 in 
the calcium mobilisation assay test on HMDM cells. Error bars represented S.E. 
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5.3.1 Competition of Non-peptide Antagonist SB290157 with C3aR Agonists  
5.3.1.1  SB290157 is a Non-competitive and Insurmountable Antagonist of hC3a 
C3a stimulated calcium release in a concentration-dependent manner in HMDM derived 
from differentiating monocytes that isolated from fresh, whole, human blood. It was found that 
human C3a mediated calcium release that was non-competitively and insurmountably inhibited by 
the C3aR antagonist, SB290157. This was indicated by a vertical reduction in the C3a-induced 
response without any shift of IC50, even at the higher concentrations of agonist. This means that 
human C3a was not able to attain full receptor activation in the presence of SB290157 which was 
unable to be completely displaced from C3aR. This is consistent with irreversible or pseudo-
irreversible binding or with it binding at an allosteric site on the receptor.  
The maximal hC3a (1 µM) mediated Ca2+ release was inhibited to 97.6 ± 5.0 %,              
84.2 ± 3.0 %, 85.8 ± 2.5 %, 72.0 ± 2.2 % by C3aR antagonist (SB290157) at concentration of 200 
nM, 1, 2 and 8 µM, respectively (Figure 5.4).  The EC50 of hC3a in the absence of C3a antagonist 
(SB290157) was 18.6 nM (pEC50 = 7.7 ± 0.08, n = 4) and EC50 was higher in the presence of 
increasing concentrations of SB290157. EC50 (pEC50) was 31.0 nM (7.5 ± 0.07), 40.8 nM (7.4 ± 
0.06), 53.5 nM (7.3 ± 0.05) and 75.7 nM (7.1 ± 0.04) in the presence of 0.2, 1, 2 and 8 µM of 
SB290157. Schild plot for C3a antagonist SB290157 against hC3a (slope <1). 
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Figure 5.4 Antagonism by SB290157 against hC3a. (A) SB290157 is a non-competitive and 
insurmountable antagonist against hC3a, showing concentration-dependent (zero (l), 200 
nM (n), 1 µM (), 2 µM (), 8 µM (®) SB290157) inhibition of iCa2+ release in human 
monocyte derive macrophage cells (HMDM) induced by varying concentrations (0.01 nM to 1 
µM) of hC3a. Data is expressed as % of maximal change in fluorescence induced by hC3a (1 µM) 
mediated iCa2+ mobilisation ± S.E.M. (B) Schild plot for C3a antagonist SB290157 against hC3a 
(slope <1).  
 
5.3.1.2  SB290157 is a Competitive and Surmountable Antagonist of Agonists 17 
and 20 
The peptidic C3a agonists 17 and 20 were the first two potent and selective C3a agonists 
reported from our group in 2010 (Scully et al., 2010). 17 and 20 at 100 µM showed full agonist 
efficacy on human C3aR like hC3a at 100 nM in stimulating the release of intracellular calcium in 
dU937 cells (Chapter 2).  
Concentration response curves for 17 and 20 were generated on HMDM cells in the absence 
of SB290157 and presence of 200 nM, 300 nM, 1, 2, 4, 8 and 10 µM that pre-treated cells 15 mins 
before the calcium mobilisation assays were performed. These curves were then compared with the 
control curve (in the absence of SB290157) as shown in Figure 5.5 A and 5.6 A. 
SB290157 is a competitive and surmountable antagonist against compound 17 
SB290157 or C3aR antagonist inhibited the concentration response of 17 and 20 in the 
calcium mobilisation assay (Figure 5.5 A and 5.6 A) by shifting the concentration-response curves 
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to the right or horizontally. However, the maximal response for agonist activities of these 
compounds can be achieved by increasing the concentration of agonist compounds. These are 
characteristics of a competitive and surmountable antagonist. The EC50 of 17 in the absence of C3a 
antagonist (SB290157) was 435 nM (pEC50 = 6.4 ± 0.11, n=4) and EC50 was higher in the presence 
of increasing concentrations of SB290157. EC50 was 1.3 µM (5.9 ± 0.08), 2.5 µM (5.6 ± 0.07), 8.6 
µM (5.1 ± 0.07), 33 µM (4.5 ± 0.25) and 17.4 µM (4.8 ± 0.02) in the presence of 300 nM, 1, 2, 8 
and      10 µM of SB290157 on HMDM. 
The results (Figure 5.5 A) were converted to a Schild plot (Figure 5.5 B) to calculate the 
Schild slope factor and pA2 value of SB290157 against 17. The Schild slope is an indication of the 
competitive relationship between agonist and antagonist. The pA2 value for the antagonist 
represents a negative logarithm of the concentration of antagonist (SB290157) required to cause a 
two-fold rightward shift of agonist EC50 (17 or 20). 
The Schild plot suggests that SB290157 is a competitive and surmountable antagonist of 
C3aR against compound 17. The slope factor of approximately 1.0 (0.9 ± 0.1) suggests a fully 
competitive relationship between these two compounds (i.e. ratio of 1:1). The calculated pA2 value 
indicates that the concentration of SB290157 required to shift the compound 17 curve by two fold is 
~158 nM (pA2 = 6.8, Figure 5.5 B). We conclude that SB290157 likely binds at the orthosteric site 
for agonist 17; in other words they bind at the same site on human C3aR on HMDMs. 
 
(A). 
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  (B). 
 
 
 
 
 
Figure 5.5 SB290157 is a competitive antagonist against 17 on human monocyte derived 
macrophages, (A) indicated by shifting of EC50 values due to competition at various 
concentrations of SB290157 (zero (l), 0.3 (o), 1 (r), 2(), 8 (®), 10 () µM) as measured 
by the inhibition of iCa2+ release in HMDM which was induced by varying concentrations 
of C3a peptide agonist 17 (3 nM to 100 µM). Data is expressed as % of maximal change in 
fluorescence induced by 17 (100 µM) mediated iCa2+ mobilisation ± S.E.M. (B) Schild plot for 
SB290157 against 17 (slope = 0.9 ±  0.1). Calculated pA2 value for SB290157 against 17 was 
6.80 (or A2  = 158 nM). 
 
 
SB290157 is a competitive and surmountable antagonist against compound 20 
SB290157 is also a competitive antagonist (reversible and surmountable) against C3a peptidic 
agonist, 20. Increasing concentrations of SB290157 resulted in a horizontal shift in the agonist 
concentration-response curves (Figure 5.6 A). SB290157 is a surmountable antagonist of 20, which 
can be fully displaced by 20 at high concentrations. In Figure 5.6 A, the EC50 of 20 in the absence 
of C3a antagonist (SB290157) was 11.7 nM (pEC50 = 7.9 ± 0.6, n=4) and EC50 was higher in the 
presence of increasing concentrations of SB290157. EC50 was 48.9 nM (7.3 ± 0.29), 289.5 nM (6.5 
± 0.14), 627.3 nM (6.2 ± 0.22), and 1.4 µM (5.9 ± 0.12) in the presence of 200 nM, 2, 4 and 8 µM 
of SB290157 on HMDM. The data reveal that SB290157 and agonist 20 likely bind at the same site 
on human C3aR on HMDMs since the Schild plot has a slope of very close to 1.0. 
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Figure 5.6 SB290157 is a competitive antagonist against 20 on human monocyte-derived 
macrophages, which (A) showing shifting of EC50 values due to competition at varies 
concentrations of SB290157 (zero (l), 0.2 (n), 2 (), 4 (), 8 (®) µM) as measured by the 
inhibition of iCa2+ release in HMDM which was induced by varying concentrations of C3a 
peptide agonist FWTLAR (1 nM to 100 µM). Data is expressed as % of maximal change in 
fluorescence induced by 20 (100 µM) mediated iCa2+ mobilisation ± S.E.M. (B) Schild plot for 
SB290157 against 20 (slope = 1). Calculated pA2 value for SB290157 against 20 was 7.2. 
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The Schild plot suggests that SB290157 is a surmountable antagonist of C3aR against 20. 
The slope factor of approximately 1.0 (0.97 ± 0.05), suggests the competitive relationship between 
these two compounds is equal to 1:1. The calculated pA2 value indicates that the concentration of 
SB290157 required to shift the compound 20 curve by two fold is ~ 63 nM (pA2 = 7.2, Figure 5.6 
B). 
 
 
5.3.1.3  SB290157 is a Competitive and Surmountable Antagonist of Agonists 63 
and 80 
SB290157 is a competitive and surmountable antagonist against compound 63 
Compound 63 is an oxazole-containing compound that shows a beta-turn structure from the 
molecular modelling and may potentially mimic the receptor bound conformation of the C-terminal 
tetrapeptide sequence (GLAR) of human C3a. From Chapter 3 in competitive binding studies, 63 
binds tightly to C3aR with IC50 = 9.3 nM (pIC50 = 8.03 ± 0.05) and in the functional assay of 
calcium release it showed high potency in stimulating calcium from macrophage cells comparable 
to human C3a (EC50 = 7.2 nM, pEC50 = 8.15 ± 0.10). In selectivity studies by using competitive 
radioligand of C5a, 63 had no binding affinity to C5aR. Desensitisation assays also confirmed the 
selectivity of the non-peptidic ligand in stimulation of calcium release through C3aR only. 
The mechanism of antagonism of SB290157 against 63 study showed that SB290157 
(C3aRA) is a surmountable and reversible antagonist against non-peptide agonist (63).  
Results were plotted for concentration-dependent response curves in Figure 5.7 A, the EC50 
of 63 in the absence of C3a antagonist (SB290157) was 8.4 nM (pEC50 = 8.08 ± 0.16, n=4) and 
EC50 was higher in the presence of increasing concentrations of SB290157. EC50 was 23 nM (pEC50 
= 7.64 ± 0.13), 162 nM (6.79 ± 0.2), 501 nM (6.3 ± 0.18), and 767 nM (6.12 ± 0.11) in the presence 
of 200 nM, 2, 4 and 8 µM of SB290157 respectively. This clearly showed that increasing 
concentrations of SB290157 cause significantly increased EC50 values for 63 in a concentration-
dependent manner, while having no significant reduction effect on the maximal response of the 
compound (Figure 5.7 A). This is further supported by a Schild plot (Figure 5.7 B) with a linear 
slope of 1.1± 0.08 (slope ~1), which indicates the relationship between agonist and antagonist as 
competitive. The pA2 value is the concentration of SB290157 required to shift the agonist curve of 
63 by two-fold, and is ~ 126 nM (or pA2 = 6.9). 
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Figure 5.7 SB290157 is a competitive and surmountable antagonist against non-peptide 
C3a agonist (63), (A) shows concentration - dependent (zero (l), 200 nM (n), 1 µM (), 2 
µM (), 8 µM (®), n≥4) inhibition of iCa2+ release in human monocyte derived 
macrophage cells (HMDM) induced by varying concentrations (0.1 nM to 10 µM) of 63. 
Data is expressed as % of maximal change in fluorescence induced by 63 (10 µM) mediated 
iCa2+ mobilisation ± S.E.M. (B) Schild plot for C3a antagonist SB290157 against 63 (slope = 
1). Calculated pA2 value for SB290157 against 63 was 6.9. 
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SB290157 is a competitive and surmountable antagonist against compound 80 
 Compound 80 is the acyl-leucine-5-methyl-oxazole-arginine compound. It binds tightly to 
C3aR with IC50 = 14 nM (pIC50 = 7.86 ± 0.08, n=3, Chapter 4). However it had lower agonist 
potency than 63 (EC50 = 45 nM versus 7 nM respectively). It also has selectivity for C3aR, which 
was shown in the results of a competitive binding assay of [125I]-C5a and in the C3aR 
desensitisation experiment.  
 The effect of SB290157 was determined in HMDM cells using 80 as the stimulus to release 
calcium inside cells. Concentration response curves of 80 were measured following incubation of 
the HMDMs with increasing concentrations of C3aR antagonist (SB290157). The results showed 
that SB290157 inhibited compound 80 in a competitive and surmountable fashion, since increasing 
concentrations of SB290157 increased the EC50 value of 80 and also made the dose response curve 
for the agonist shift rightward. However, the curves of 80 in presence and absence of antagonist did 
not show a clear result and the number of experiments need to be increased (Figure 5.8 A). 
Results were plotted in a dose-dependent response curve in Figure 5.8 A, the EC50 of 80 in 
the absence of C3a antagonist (SB290157) was 59.4 nM (pEC50 = 7.23 ± 0.08, n=6) and EC50 was 
higher in the presence of increasing concentrations of SB290157. EC50 was 76.1 nM (7.12 ± 0.16), 
285.6 nM (6.54 ± 0.11), 375.9 nM (6.43 ± 0.08), and 2.75 µM (5.56 ± 0.05) in the presence of 200 
nM, 1, 2 and 8 µM of SB290157 (n=2) respectively.  
The results from dose response curve of SB290157 against 80 is further supported by Schild 
plot (Figure 5.8 B) with a linear slope of 0.95 ± 0.10 (slope ~1). The Schild plot suggests that 
SB290157 is a competitive and surmountable antagonist of C3aR against 80. The pA2 value is the 
concentration of SB290157 that is required to shift the agonist curve of 80 by two-fold is ~ 158 nM 
(or pA2 = 6.8). 
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Figure 5.8 SB290157 is a competitive and surmountable antagonist against non-peptide 
C3a agonist (80). (A) showing concentration - dependent (zero (l), 200 nM (n), 1 µM (), 
2 µM (), 8 µM (®)) inhibition of iCa2+ release in human monocyte derived macrophage 
cells (HMDM) induced by varying concentrations (10 nM to 100 µM) of 80. Data is 
expressed as % of maximal change in fluorescence induced by 80 (100 µM) mediated iCa2+ 
mobilisation ± S.E.M. (B) Schild plot for SB290157 against 80 (slope = 1). Calculated pA2 
value for SB290157 against 80 was 6.8. 
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5.3.2 Competition of Peptide Antagonist 25 (FLTChaAR) with C3aR Agonists 
5.3.2.1  Compound 25 is a Non-competitive and Insurmountable Antagonist of 
hC3a 
Compound 25 was first reported by our group as a peptide antagonist (Scully et al., 2010). It 
binds to C3aR with IC50 = 238 nM (pIC50 = 6.62 ± 1.59, n=2) and has no agonist activity at the 
concentration up to 100 µM in dU937 cells. It was an equipotent antagonist of C3a-induced 
intracellular calcium release with IC50 = 1.5 µM vs 100 nM of hC3a in dU937) compared to 
SB290157 (IC50 = 1.3 µM) (Chapter 2). It was selective for C3aR over C5aR in competitive [125I]-
C5a binding assays. 
The antagonist effect of 25 was then determined in HMDMs by using human C3a to 
stimulate intracellular calcium release from cells. Concentration response curves of C3a were 
performed after preincubation of macrophage cells with increasing concentrations of 25. 
Interestingly, the results showed that 25 inhibited C3a in an insurmountable manner because 
increasing concentrations of 25 reduced the maximal response achievable in a dose-dependent 
manner of C3a.  
The maximal hC3a (10 µM) mediated Ca2+ release was inhibited to 56.1 ± 9.5 % and 15.2 ± 
3.3 % by peptide C3aR antagonist (25) concentration at 4 and 8 µM, respectively (Figure 5.9A). 
The EC50 of hC3a in the absence of peptide C3a antagonist (25) was 48 nM (pEC50 = 7.3 ± 0.09, n 
= 6) and EC50 was higher in the presence of increasing concentration of 25.  EC50 was 131 nM (6.88 
± 0.11), 137 nM (6.87 ± 0.11), 153 nM (6.82 ± 0.09) and 232 nM (6.63 ± 0.28) and 42 nM (7.38 ± 
0.58) in the presence of 500 nM, 1, 2, 4 and 8 µM of compound 25. A Schild plot (Figure 5.9B) 
suggests that compound 25 is a non-competitive and insurmountable antagonist of human C3a as 
shown by a linear slope of 0.37 (much less than 1.0). 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER	  5	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Antagonism of C3aR Agonists	  
213 	  
 (A). 
-10 -9 -8 -7 -6 -5
0
50
100
+ 0.5µM FLTChaAR
+ 1µM FLTChaAR
+ 2µM FLTChaAR
+ 4µM FLTChaAR
+ 8µM FLTChaAR
hC3a
Log [C3a] (M)
%
 
 F
lu
o
re
s
c
e
n
c
e
 (
E
M
5
2
0
)
in
d
u
c
e
d
 b
y
 C
3
a
 (
1
0
 µ
M
) 
 
 
 (B). 
!"#$ !%#& !%#$ !&#& !&#$
$#$
$#'
$#(
$#%
$#)
*+,-.'&/-012
*+
,-
03
+4
5-
67
89+
-!:
2
!"#$%&'(
)*+!,%$%-'./%(%-'0&
1#$%-'(.
 
 
Figure 5.9 Mechanism of C3aR antagonism. (A) Compound 25 is a non-competitive and 
insurmountable antagonist against hC3a, showing concentration - dependent (zero (r), 
500 nM (l), 1 µM (n), 2 µM () 4 µM () and 8 µM (®)) inhibition of iCa2+ release in 
human monocyte derived macrophage cells (HMDM) induced by varying concentrations 
(0.1 nM to 3 µM) of hC3a. Data is expressed as % of maximal change in fluorescence induced 
by C3a (10 µM) mediated iCa2+ mobilisation ± S.E.M. (B) Schild plot for C3a antagonist 25 
against hC3a (slope <1). 
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5.3.2.2  Compound 25 is a Non-competitive and Insurmountable Antagonist of 
Agonists 17 and 20 
Compound 25 is a non-competitive and insurmountable antagonist against 
compound 17 
The peptide antagonist 25 also inhibited 17 in an insurmountable fashion as increasing 
concentrations of 25 reduced the maximal response achievable in a dose-dependent manner of 17 
similar to the results for hC3a.  
The maximal response of compound 17 mediated Ca2+ release (100 µM) was inhibited to 
94.0 ± 6.6 %, 93.1 ± 5.2 %, 86.6 ± 6.1 %, 73.1 ± 4.2 %, 66.9 ± 4.4 % and 39.9 ± 2.7 %, by peptide 
C3aR antagonist 25 at concentrations of 200 nM, 2, 4, 6, 8 and 10 µM, respectively (Figure 5.10 
A).  Compound 25 had a Kb value of  ~100 nM on HMDM cells. 
The EC50 of 17 in the absence of peptide C3a antagonist (25) was 48 nM (pEC50 = 7.3 ± 0.2, 
n = 4) and EC50 was higher in the present of increasing concentration of 25. EC50 was 138 nM (6.9 
± 0.3), 419 nM (6.4 ± 0.1), 640 nM (6.2 ± 0.1) and 549 nM (6.3 ± 0.1), 1.2 uM (5.9 ± 0.1) and 2.2 
µM (5.7 ± 0.1) in the presence of 200 nM, 2, 4, 6, 8 and 10 µM of compound 25. A Schild plot 
(Figure 5.10 B) supports the compound 25 being a non-competitive and insurmountable antagonist 
of 17, since there is a linear slope of 0.7 ± 0.13 (slope <1.0).  
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Figure 5.10 Compound 25 is a non-competitive and insurmountable antagonist against 17, 
(A) shows concentration - dependent (zero (l), 200 nM (n), 2 µM () 4 µM (®), 6 µM 
(), 8 µM (£) and 10 µM (r) inhibition of iCa2+ release in HMDM induced by varying 
concentrations (3 nM to 100 µM) of 17. Data is expressed as % of maximal change in 
fluorescence induced by 17 (100 µM) mediated iCa2+ mobilisation ± S.E.M. (B) Schild plot for 
C3a antagonist 25 against 17 (slope <1) (n≥3). 
 
 Compound 25 is a non-competitive and insurmountable antagonist against 
compound 20 
Similar results were found for 25 against agonist 20 as against 17. Compound 25 inhibited 
20 in an insurmountable fashion. The increasing concentration of peptide antagonist 25 reduced the 
agonist response without a shift in the EC50 value. The maximal Ca2+ release (100 µM) mediated by 
agonist 20 was inhibited to 95.9 ± 7.6 %, 82.6 ± 4.8 %, 85.2 ± 9.6 %, 75.3 ± 28.7 % and 28.8 ± 8.9 
% by peptide C3aR antagonist (25) at concentrations increasing from 500 nM to 1, 2, 4 and 8 µM, 
respectively (Figure 5.11 A). The Schild plot (Figure 5.11 B) from these results is in contrast to the 
results obtained for 17. A Schild plot for antagonism by 25 against peptide agonist 20 showed a 
linear slope of 1.9 ± 0.3 (slope >1) which may indicate positive cooperativity in the binding of 25, 
depletion of a potent antagonist from the medium by receptor binding or non-specific binding or 
lack of antagonist equilibrium (Kenakin, 1997). 
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Figure 5.11 Compound 25 is a non-competitive and insurmountable antagonist against 20, 
(A) shows concentration - dependent (zero (n), 500 nM (l), 1 µM (n), 2 µM () 4 µM 
() and 8 µM (®)) inhibition of iCa2+ release in human dU937 cells induced by varying 
concentrations (10 nM to 300 µM) of 20. Data is expressed as % of maximal change in 
fluorescence induced by 20 (1 mM) mediated iCa2+ mobilisation ± S.E.M. (B) Schild plot for 
C3aR peptide antagonist 25 against 20 (slope >1). 
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5.3.2.3  Compound 25 is a Non-competitive and Insurmountable Antagonist of 
Agonists 63 and 80 
 Compound 25 is a non-competitive and insurmountable antagonist of compound 
63 
Compound 25 inhibited 63 in an insurmountable fashion as increasing concentrations of 25 
reduced the maximal response achievable in a dose-dependent manner of 63. At the higher 
concentrations of compound 25, 63 was not able to achieve full receptor activation because it was 
not able to displace compound 25 bound to C3aR. The maximal response of compound 63 mediated 
Ca2+ release (100 µM) was inhibited to 83.6 ± 3.2 %, 73.1 ± 0.06 %, 54.3 ± 3.7 % and 24.2 ± 2.2 % 
by peptide C3aR antagonist (25) concentration at 500 nM, 2, 4 and 8 µM, respectively (Figure 5.12 
A).  The EC50 of 63 in the presence and absence of 25 is not significantly changed (EC50 =10 -18 
nM). Kb value = 398 nM. A Schild plot (Figure 5.12 B) reinforces the conclusion that compound 
25 is a non-competitive and insurmountable antagonist of C3aR agonist 63.  
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Figure 5.12 Compound 25 is a non-competitive and insurmountable antagonist against 
non-peptide agonist (63). (A) showing concentration-dependent (zero (l), 500 nM (n), 2 
µM (), 4 µM (), 8 µM (®)) inhibition of iCa2+ release in human monocyte derived 
macrophage cells (HMDM) induced by varying concentrations (0.1 nM to 10 µM) of 63. 
Data is expressed as % of maximal change in fluorescence induced by 63 (10 µM) mediated 
iCa2+ mobilisation ± S.E.M.  (B) Schild plot for C3a peptide antagonist 25 against 63     
(slope <1). 
 	  	  	  
Compound 25 is a non-competitive and insurmountable antagonist of agonist 80 
Similar results were found for compound 80 which inhibited stimulation of calcium release 
by 25 in an insurmountable manner, with the increasing concentration of antagonist reducing the 
maximal response in a dose dependent manner. The maximal Ca2+ release mediated by 80 (100 µM) 
was inhibited to 84.4 ± 3.3 %, 66.1 ± 2.3 %, 71.1 ± 3.1 % and 40.8 ± 3.1 % by peptide C3aR 
antagonist (25) at concentrations 1, 2, 4 and 8 µM, respectively (Figure 5.13 A). A Schild plot 
(Figure 5.13 B) suggests that compound 25 is a non-competitive and insurmountable antagonist of 
C3aR agonist 80.  	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Figure 5.13 Compound 25 is a non-competitive and insurmountable antagonist against 
non-peptide agonist (80). (A) shows concentration - dependent antagonism by 25 (zero (l), 
1 µM (), 4 µM (®), 8 µM () of iCa2+ release in human monocyte-derived macrophage 
cells (HMDM) induced by varying concentrations (10 nM to 100 µM) of 80 (n ≥3). Data is 
expressed as % of maximal change in fluorescence induced by 80 (100 µM) mediated iCa2+ 
mobilisation ± S.E.M. (B) Schild plot for C3a peptide antagonist 25 against agonist 80  
(slope <1). 
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5.3.3 Competition of Non-peptide Antagonist 146 with C3aR Agonists  
5.3.3.1 Compound 146 is a Non-competitive and Insurmountable Antagonist of 
hC3a  
From the studies of antagonist mechanisms, we found that human C3a mediated calcium 
release was non-competitive and insurmountably inhibited by C3aR antagonist, SB290157 analogue 
(146). This was indicated by a vertical reduction in the agonist (hC3a) induced response without 
any shift of EC50 even at the higher concentrations of agonist. This means that the human C3a was 
not able to achieve full receptor activation due to it being unable to compete with 146 binding to 
C3aR. These results could be because 146 binds to C3aR in an irreversible or pseudo-irreversible 
binding pattern or it binds at an allosteric binding site on the receptor.  
The maximal response of hC3a (1 µM) mediated Ca2+ release was inhibited to 55.1 ± 6.4 %, 
51.8 ± 8.6 %, 59.1 ± 62.8 %, 23.0 ± 4.7 % and 18 ± 3.5 % by C3aR antagonist (146) concentration 
at 100 nM, 300 nM, 1, 3 and 10 µM, respectively (Figure 5.14 A). 
The EC50 of hC3a in the absence of C3a antagonist (146) was 28.2 nM (pEC50 = 7.5 ± 0.07, 
n = 4) and EC50 was higher in the present of increasing concentrations of antagonist 146. EC50 was 
124 nM (6.9 ± 0.14), 129 nM (6.9 ± 0.17), 440 nM (6.36 ± 0.44), 235 nM (6.6 ± 0.24) and 313 nM 
(6.5 ± 0.1) in the presence of 100 and 300 nM, 1, 3 and 10 µM of compound 146. 
 
  (A). 
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A schild plot (Figure 5.14 B) supports the compound 146 being a non-competitive and 
insurmountable antagonist of human C3a, since there is a linear slope of 0.25 ± 0.03 (slope < 1.0). 
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Figure 5.14 Compound 146 is a non-competitive and insurmountable antagonist against 
hC3a on human monocyte derived macrophages. (A) shows concentration -dependence of 
146 (zero (l), 0.1 (¾), 0.3 (p), 1 (), 3(®), 10 () µM) measured by the inhibition of 
iCa2+ release in HMDM which was induced by varying concentrations of human C3a (0.01 
nM to 1 µM) (n ≥3). Data is expressed as % of maximal change in fluorescence induced by 
hC3a (1 µM) mediated iCa2+ mobilisation ± S.E.M.  (B) Schild plot for 146 against hC3a 
(slope < 1).  	  	  
5.3.3.2 Compound 146 is a Competitive and Surmountable Antagonist of Agonist 
17 
Compound 146 or C3aR non-peptidic antagonist inhibited the dose response of 17 in the 
calcium mobilisation assay by shifting the dose response curves to the right (horizontal shift). 
However, the maximal agonist response of these compounds could be restored by increasing the 
concentration of agonist compounds. These are characteristics of a competitive and surmountable 
antagonist. The EC50 of 17 in the absence of 146 was 87 nM (pEC50 = 7.06 ± 0.42, n=4) and EC50 
was higher in the presence of increasing concentrations of 146. EC50 was 301.8 nM (6.52 ± 0.12), 
1.6 µM (5.79 ± 0.12), 12.2 µM (4.92 ± 0.15), 23.4 µM (4.63 ± 0.11) and   18.7 µM (4.73 ± 0.08) in 
the presence of 300 nM, 1, 4, 8, 10 µM of 146. 
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The results (Figure 5.15 A) were converted to a Schild plot (Figure 5.15 B) to calculate the 
Schild slope factor and pA2 value of 146 against 17. The Schild slope is an indication of the 
competitive relationship between agonist and antagonist. pA2 value of antagonist represents the 
negative logarithm of the concentration of antagonist compound 146 required to cause a two-fold 
rightward shift of agonist (17). 
 (A). 
!" !# !$ !%
!%&
&
%&
$&
#&
"&
'&&
'%&
!"#$%&'($)*+,
$
$-
./
"0
12
31
43
1$
)5
6
78
9+
$
01
2:
"4
21
$;"
$&
99
$+
*
$$"
<$&
'
 	   	  (B).  
!"#$ !%#& !%#$ !&#& !&#$ !'#&
$
(
)
*
!"
#$
%&
"'
($
)*
+,"
$-.
/
!"#$0.123$%4/
+,)-.%#/
012+3.-.(#*.(.$#(
4).-.$#/5
	  
Figure 5.15 Compound 146 is a competitive antagonist against 17 on human monocyte 
derived macrophages. (A) showing shifting of EC50 values due to competition at various 
concentrations of 146 (zero (l), 0.3 (¾), 1 (p), 4 (), 8 (®), 10 () µM) as measured by 
the inhibition of iCa2+ release in HMDM which was induced by varying concentrations of 
C3a peptide agonist 17 (3 nM to 100 µM)(n ≥3). Data is expressed as % of maximal change in 
fluorescence induced by. 17 (100 µM) mediated iCa2+ mobilisation ± S.E.M. (B) Schild plot for 
146 against 17  (slope ≥  1). Calculated pA2 value for 146 against 17 was 6.9 (~126 nM). 
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The Schild plot suggests that 146 is a surmountable antagonist of C3aR against 17. The 
slope factor of approximately 1.0 (1.3 ± 0.1), suggesting a competitive relationship between these 
two compounds is equal to 1:1. The calculated pA2 value indicates that the concentration of 
SB290157 required to shift the 17 curve by two fold is ~126 nM (pA2 = 6.9, Figure 5.15 B). 	  
5.3.3.3 Compound 146 is a Competitive and Surmountable Antagonist of Non-
Peptide Agonist 63 
Compound 146 is also a competitive antagonist (reversible and surmountable) against  non-
peptidic agonist 63. Increasing concentrations of 146 resulted in a horizontal shift in the agonist 
concentration-response curves (Figure 5.16 A). 146 was also a surmountable antagonist of 63, 
since it could be fully displaced by 63 at high concentrations. 
The EC50 of 63 in the absence of 146 was 8.9 nM (pEC50 = 8.05 ± 0.24, n=3) and EC50 was 
higher in the present of increasing concentrations of 146. EC50 was 38 nM (7.42 ± 0.30), 74.5 nM 
(7.13 ± 0.15), 418.7 nM (6.38 ± 0.16), 985 nM (6.01 ± 0.1) and 2.52 µM (5.6 ± 0.19) in the 
presence of 100 nM, 300 nM, 1, 3, 10 µM of compound 146. 
The Schild plot suggested that 146 was a surmountable antagonist of C3aR against 63. The 
slope factor of approximately 1.0 (1.01 ± 0.08), suggesting a competitive relationship between these 
two compounds is equal to 1:1. The calculated pA2 value indicates that the concentration of 146 
required to shift the 63 curve by two fold is ~ 32 nM (pA2 = 7.5, Figure 5.16 B). 
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Figure 5.16 Compound 146 is a competitive antagonist against 63 on human monocyte 
derived macrophages, (A) showing shifting of EC50 values due to competition at various 
concentrations of compound 146 (zero (n), 0.1 (), 0.3 (), 1 (®), 3 (), 10 (£) µM) as 
measured by the inhibition of iCa2+ release in HMDM induced by varying concentrations 
of C3a peptide agonist 63 (0.3 nM to 10 µM)(n ≥3). Data is expressed as % of maximal 
change in fluorescence induced by 63 (100 µM) mediated iCa2+ mobilisation ± S.E.M. (B) 
Schild plot for 146 against 63  (slope =1). Calculated pA2 value for 146 against 63 was 7.5     
(~ 32 nM). 
 
 
 
 
5.4 DISCUSSION 
C3a is proposed to interact with C3aR in a similar manner to how C5a is thought to interact 
with C5aR. This may involve two major sites of C3a interacting with the receptor in a two-site 
binding model, involving a high affinity recognition binding site and a low affinity activation site 
on the receptor (Chao et al., 1999; Ember et al., 1997). Human C3aR was cloned in 1996 (Ames et 
al., 1996; Crass et al., 1996; Roglic et al., 1996) revealing an extraordinarily large second 
extracellular loop between transmembrane domain 4 and 5. This 2nd extracellular loop is thought to 
be involved in the recognition and binding site of C3a (Chao et al., 1999). The activation site of 
C3aR responsible for triggering cell function is thought to be bound by C-terminal residues of C3a 
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in a site on C3aR that may be in the seven transmembrane helices in the membrane of the cell 
(Figure 5.1). 
The C-terminal octapeptide region of C3a, implicated as the effector region required for 
activation of C3aR, has been used as a template for analogue development of C3aR agonists and 
antagonists. However, until this thesis there was no truly potent or selective small molecule agonist 
or antagonist reported for C3aR and so there have been limited tools available for probing the 
pharmacological roles of human C3a in physiology or diseases. 
The main C3aR antagonist known is SB290157 but, while it has been used to study in vitro 
and vivo the roles of C3a and its receptor, it is not a particularly potent antagonist (IC50 2 µM, Ca2+) 
and has also shown agonist properties in some assays (Mathieu et al., 2005).  In our hands, 
SB290157 had no agonist activity in the calcium mobilisation assay on HMDM and other cells.  We 
have examined the nature of the antagonism for SB290157 and new, more potent, C3aR antagonists 
recently developed in our laboratories in the functional assay or calcium mobilisation assay.  
SB290157 displayed non-competitive and insurmountable antagonism against human C3a. 
In contrast, it was a competitive and surmountable antagonist against both potent peptide agonists 
of C3aR (17 and 20) and potent non-peptidic agonists (63 and 80). Insurmountable antagonism is 
an inhibition that has showed a significant reduction in the maximum response attained by the 
agonist in the presence of increasing antagonist concentrations. This may involve different 
processes such as physiological antagonism (two drugs with opposing actions in the body), 
allosteric binding of the receptor, irreversible or pseudo-irreversible binding to the receptor, 
receptor internalisation (decreased number of receptors available on the cell surface) and the 
activation states of the receptor (Kenakin, 1997). Pseudo-irreversible or irreversible antagonism is a 
competitive antagonism that occurs when the antagonist dissociates very slowly, or not at all, from 
the receptors, with the result that no change in the antagonist occupancy takes place when the 
agonist is applied.  
The mechanism of insurmountable antagonism of SB290157 against hC3a from this study is 
likely to be due to it binding pseudo-irreversibly to C3aR or it may have caused receptor 
internalisation that reduced the number of receptors at the cell surface. However, it is unlikely that 
SB290157 binds at an allosteric site on the receptor as it showed that it could compete with iodine 
labelled C3a in competitive binding assays. In contrast, the antagonism of SB290157 against 
peptide agonists and non-peptide agonists it is a competitive and surmountable antagonism of these 
agonists. The results could explain that SB290157 binds at the same site as peptide agonists and 
non-peptide agonists. 
A peptide antagonist (25) of C3aR, derived from the C-terminal region of C3a, was reported 
in Chapter 2 and is now published (Scully et al., 2010). From figure 5.17 A showed the overlayed 
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of 25 on the oxazole compound (88) which showed that the last four residues of 25 form a beta-turn 
comformation which preferred recognised of ligands for GPCRs. This would explain the high 
affinity of this compound for C3aR (IC50 = 238 nM). This compound inhibited the C3a (100 nM) 
induced response in dU937 with IC50 =1.5 µM which were equipotent to SB290157 (IC50 = 1.3 
µM). The hexapeptide antagonist 25 has showed non-competitive and insurmountable antagonism 
against (1) hC3a, (2) peptide agonists (17 and 20) and (3) a non-peptide agonist (63) (Figure 5.17 
B), since depression of agonist response by varying concentrations of any of these agonists did not 
change the IC50 of compound 25. This insurmountable antagonism has several possible alternative 
explanations. The antagonist may interact at the allosteric site on the receptor (i.e. not the 
orthosteric site where the agonist binds) or it may bind pseudo-irreversibly. 
However, the mechanism of insurmountable antagonism of 25 against all agonists (hC3a, 
17, 20, 63 and 80) from this study is unlikely to be due to an allosteric interaction on the receptor as 
in the previous study it showed that it could compete with [125I]-C3a in competitive binding assay. 
It is more likely that 25 binds tightly and pseudo-irreversibly to C3aR, in other words with a slow 
off rate leading to a long residence time on the receptor.  
Compound 146, an analogue of SB290157, is a new antagonist that has been discovered in 
our studies (Figure 5.17 C). Figure 5.17 C demonstrated the superimposed of the furan compound 
(144) with SB290157 showed that the ether oxygen atom of SB290157 align with the oxygen, 
nitrogen or sulfur atom of furan. These atoms (oxygen, nitrogen or sulfur) are hydrogen bond 
acceptors which contribute to the receptor binding potency of the compounds. It had affinity for 
C3aR (IC50 = 91 nM against 80 pM [125I]-C3a) in HMDMs, but it had no agonist activity up to 100 
µM in calcium mobilisation on HMDM. It inhibited the native human C3a (100 nM) response with 
IC50 = 534 nM. Interestingly, the results of antagonism of 146 against hC3a and peptide and non-
peptide agonists are similar to those of SB290157, consistent with their structural similarity. 
Compound 146 is a non-competitive and insurmountable antagonist of hC3a (Schild plot slope < 
1.0), but it is a competitive and surmountable antagonist of peptide (17) and non-peptide (63) 
agonists. It could be that compound 146 binds to the receptor at the same site as SB290157, while 
25 binds to a different site from these two antagonists. Thus the component of the antagonists that 
appears to govern the finer differences in where all these compounds are binding on C3aR appears 
not to be the common arginine, or similar linker (ether oxygen or heterocylic hydrogen-bonding 
acceptor), but rather the different hydrophobic component at the N-terminus of our tripeptide-like 
surrogates (Figure 5.17).  
In conclusion, the antagonists (SB290157 and SB analogue 146) are suggested to bind to 
C3aR at the same site as the peptide agonists (17 and 20) and non-peptide agonists (63 and 80) 
which are all shown to be competitive ligands for C3aR. In contrast, peptide antagonist (25) binds 
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pseudo-irreversibly (rather than allosterically) to C3aR. In competition studies, SB290157 has pA2 
values (pA2 value of antagonist represents the negative logarithm of the concentration of antagonist 
required to cause a two-fold rightward shift of agonist) against all agonists is in following order: 20 
(63 nM) < 17 (100 nM) < 63 (126 nM) < 80 (158 nM). This reveals that the non-peptide agonists 
(63 and 80) bind to C3aR more tightly than peptide agonists, thus they require more concentration 
of SB290157 to shift the EC50 value of agonist two-fold and concentration-dependent agonist 
curves to the right. In contrast, the value of pA2 in the competitive studies with 146 found that the 
concentrations required to cause a two-fold rightward shift are lower with compound 63 (pA2= 32 
nM) compared to peptide agonist (17), which has pA2 = 126 nM.  These results need further study 
by testing more compounds, conducting molecular modelling studies, and chimeric and deletion 
mutagenesis of C3aR. 
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Figure 5.17 A. Superimposition of the oxazole (green) (Boc-Leu-oxazole-Arg, 88) with the 
last four C-terminal residues of FLTChaAR (25) (cyan, NMR structure). B. SB290157 
(grey) aligned with energy minimised compound 63 (green) C. Alignment of furan (cyan) 
and SB290157 (green) Arg residue not shown (courtesy of Dr. Reid). 
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5.5 MATERIALS AND METHODS 
5.5.1 Calcium mobilization assay on HMDM cells 
Harvested HMDM cells were washed with 0.9% NaCl solution by centrifugation at 2500 
rpm for 5 min, followed by resuspension of the cell pellet with complete media. Cells were seeded 
at 5 x 104 cells/well in a 96-well black-wall, clear bottom plate (DKSH, Zurich), and left overnight 
to adhere at 37°C. On the day of the experiment, supernatant was removed and cells were incubated 
in dye loading buffer. Dye-loading buffer was prepared by using 12 mL of wash buffer (Hank’s 
Balanced Salt Solution (1x HBSS, 20 mM HEPES, 2.5 mM probenecid, pH 7.4) with 25 µL Fluo-3 
(final concentration 4 µM), 25 µL 20% pluronic acid, 1% fetal bovine serum (FBS) and incubated 
in a cover plate for one hour at 37°C. The supernatant was removed and cells were then washed 
once with HBSS. Then 100 µL of test compound or buffer or control/well was plated out on sterile 
black-wall, clear-bottom 96-well plates (Corning Incorporated, NY). Plate was then transferred to a 
Fluorostar spectrofluorimeter (BMG LabTechnologies, Offenburg, Germany), where fluorescence 
was measured over 1 min with excitation at 485 nm and emission at 520 nM of Fluo-3 bound Ca2+ 
complex, at 28 oC. Agonist responses were expressed as a percentage of native human C3a at 100 
nM (or calcimycin) as the maximum change in fluorescence through emission from the Fluo-3 
bound calcium complex. 
5.5.1.1 Antagonist Surmountability/Insurmountability:  
Cells were prepared as for the calcium mobilisation assay after incubation with dye loading 
buffer for 1 h, cells were incubated with different concentrations of antagonist for 15 mins before 
starting the experiment. The plate was then transferred to a Fluorostar spectrofluorimeter (BMG 
LabTechnologies, Offenburg, Germany), and examined for concentration-dependent effects on the 
activity of agonists in the absence and presence of different concentrations of antagonist. 
5.5.1.2 Data Analysis 
In Functional Assays, the concentration curves were analysed by non-linear regression 
(GraphPad Prism 5, USA) and EC50 and pEC50 determined. A pEC50 for each compound was 
calculated from separate experiments and expressed as an arithmetic mean ± SEM.  Functional 
activity is expressed as a percentage of the maximal response induced by hC3a (100 nM) or 100 
µM of agonist compounds for calcium mobilisation of human derived macrophage cells. 
Non-linear regression was performed. SB290157 (C3aR antagonist) has been shown to 
insurmountably antagonise the C3aR which might be attributed to pseudo-irreversible antagonism.  
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The Kb was calculated from the equation Kb=[antagonist]/slope-1 (Kenakin, 1997) This was 
obtained from the linear regression of 1/[A] versus 1/[A’] where A is the agonist concentration and 
A’ is the equi-active concentration of agonist in the presence of antagonist. The more accurate 
estimates of Kb are derived from experiments in which the maximal response to the agonist is 
depressed by the antagonist to less than 50% of the maximal response, so this calculation was 
performed using a concentration of antagonist which gave at least 50% inhibition. 	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CHAPTER 6 
SUMMARY 
Complement activation is one of the body’s most important responses against antigens and 
other foreign materials. The complement system includes more than 30 different proteins, some of 
which combine together to form the membrane attack complex, which can causes lysis of bacteria, 
virus-infected or damaged cells. Two products of complement activation are the small proteins, C3a 
and C5a, also known as ‘anaphylatoxins’.  Anaphylatoxins play major roles in inflammation, 
priming and amplifying the immune response through chemoattraction of immune cells to 
inflammatory sites and promoting the secretion of proinflammatory agents, lysosomal enzymes, and 
reactive oxygen species (ROS). C3a is a 77 amino acid protein that binds to its functional receptor, 
C3aR, which is a G protein–coupled receptor predominantly coupled to Gi. C3aR is found in both 
myeloid and non-myeloid cells. C3a and its receptor have been implicated in the pathogenesis of 
various autoimmune diseases and inflammatory conditions (e.g. asthma, sepsis, allergies, lupus 
erythematosus (SLE), diabetes, psoriasis, arthritis, nephropathy, ischemia-reperfusion injury and 
others). Potent and selective agonists or antagonists that selectively act on C3aR have enormous 
potential as physiological probes, anti-inflammatory and perhaps other classes of drugs.  
The agonist activity of C3a is due to the octapeptide fragment at the C-terminus, which 
triggers C3a receptor activation. The truncated and modified 15 residue C-terminal end of C3a, with 
addition of two tryptophans to it’s N-terminus, was reported to be 15-fold more potent than C3a in a 
guinea pig platelet aggregation assay. This superagonist activity has been disputed in the literature 
(Ames et al., 1997; Chao et al., 1999; Ischenko et al., 1998; Sun et al., 1999) and by our group in a 
previous study (Blakeney, 2007) since the compound showed less potency and no selectivity for 
C3aR. In any case, there is no potent agonist of C3aR composed of less than eight amino acids.  
 The first chapter of our study focused on the development of C3a peptide derived ligands by 
studying both selectivity and potency of compounds. Firstly, we studied the affinity and selectivity 
of compounds using a competitive radioligand binding assay with [125I]-labelled C3a and [125I]-
labelled C5a on peripheral blood mononuclear cells (PBMCs), which were isolated from human 
plasma. The general selectivity was also determined by a C3a-induced receptor desensitisation 
experiment which shows effects other than those mediated through C3aR. Finally, we determined 
the functional potency of the compounds by using an intracellular calcium release or mobilisation 
assay, which detected intracellular calcium trafficking by binding calcium to a cell permeable 
fluorophore. 
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 We found that previously reported compounds, including the C3a “superagonist”  
(WWGKKYRASKLGLAR), were not selective for C3aR in a receptor desensitisation experiment. 
Four decapeptides, originally reported as C5aR agonists, also bound tightly to C3aR in PBMC cells. 
Two reported oryzatensin pentapeptide derivatives, WPLPR and YPLPR, also showed no 
selectivity for C3aR over C5aR in the competitive radioligand binding assay. A new series of 
hexapeptides based on the C-terminus of human C3a was designed and studied using structure-
activity relationships (SAR). Two small peptide agonists were identify to be highly potent agonists 
and selective for C3aR.  FLTLAR and FWTLAR bound to C3aR tightly with IC50 ~ 40 and 80 nM, 
respectively on PBMC cells and in the calcium mobilisation assay had EC50  = 0.32 and 0.37 µM, 
respectively. Structure activity relationships and competitive binding results	   have led to a new 
C3aR peptide antagonist, F1LTChaAR6. Changing leucine at position 4 to a bulkier amino acid such 
as cyclohexylalanine (Cha) showed no agonist activity (>100 µM) in a calcium mobilisation assay 
in dU937 cells, but did bind tightly to C3aR and displayed antagonist activity (IC50 1.5 µM). 
However, C3a-derived peptides have significant disadvantages for uses in biology and 
medicine because of the poor bioavailability of peptides in general, as well as poor stability to 
protease enzymes, high clearance rates, and poor membrane permeability. Therefore, it is highly 
desirable to develop nonpeptidic C3a ligands that are more suitable for use as 
pharmacological/physiological probes for interrogating the roles of hC3a in vivo. As a step towards 
this goal, we introduced a heterocycle to restrict the conformational freedom of short peptides, in an 
attempt to mimic the receptor-binding conformation of the C-terminal activating domain of human 
C3a.  
A molecular modelling study (Figure 3.2) revealed structural similarity between the C3a 
carboxyl terminal residues (GLAR), modelled in a beta turn conformation, and the model of 
compound 56. This compound contains an oxazole heterocycle that acts as a beta turn-inducing 
constraint and mimics the conformation found for the C-terminus of C3a in its crystal structure. 
This result supports a large set of observations that GPCRs have a general tendency to recognise 
turn structural motifs in their protein and peptide ligands (Fairlie et al., 2005; Madala et al., 2010; 
Tyndall et al., 2005). In this study, multiple potent agonist compounds were discovered for C3aR. 
They competed strongly with 125I-labelled C3a in binding to, and activating intracellular calcium 
release in, human monocyte-derived macrophages (HMDM). Indeed, some of the compounds had 
equal or even greater affinity than C3a itself. Building on the discovery in Chapter 2 that 
hexapeptide agonists for C3aR agonist (e.g. FLTLAR) adopted a beta turn conformation at their C-
terminus, it was decided to introduce an oxazole heterocycle into the LAR region to impart 
conformational rigidity to the agonist peptides (Figure 3.3). This modification produced new 
compounds with improved affinities for human C3aR. The oxazole has electronegative oxygen and 
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nitrogen atoms that can function as hydrogen bond acceptors, while introducing a rigid turn-like 
conformation to the molecule. The most potent and selective compounds in this study were 56, 63 
and 75 (EC50 = 19, 7 and 17 nM, respectively) in HMDM cells. There was a linear correlation 
between the binding affinity of the compounds and their agonist potency. 
A potent C3aR agonist (56) was chosen for further study in Chapter 4. The incorporation of 
a phenyl group at the 5-position of the oxazole ring of compound 56 gave an improvement in 
binding affinity and eventually led to the novel and potent nonpeptidic C3aR antagonist compound 
(105). Further study by modification of the Boc group at the N-terminus of compound 105 also 
generated another potent C3aR antagonist compound (109), which suggested that the fifth position 
of the oxazole is the critical position for transforming an agonist to an antagonist. In addition, 
substitution at the fifth position of the oxazole ring and at the N-terminus with a bulkier group gave 
improvement in binding affinity and antagonist potency of the compound. 
A second approach to developing C3aR antagonists in Chapter 4 was to use the known, 
albeit weak, antagonist compound SB290157 as a lead compound for further modifications (Figure 
4.1 B). SB290157 was the first reported “potent” C3a receptor antagonist in several in vitro assays 
and two in vivo models. In 2005, SB290157 was reported to also have “potent” agonist activities in 
a variety of in vitro and in vivo assays. We proposed to develop new non-peptidic antagonists using 
SB290157 as a lead compound, because it binds tightly to C3aR and, in our hands, it showed no 
agonist activity in the Ca2+ assay on human monocyte derived macrophages. Moreover, it also 
showed no cross reactivity at, or binding to, C5aR. The structure of SB290157 was modified in five 
different ways: (i) modifications to the linker region, while leaving unchanged the 
diphenylmethylene rings and arginine moieties, (ii) modifications to the aromatic and linker 
regions, where the ether bond and the linker were replaced by an amide functional group (R-
glycine-arginine scaffold), (iii) replacement of the aromatic region by cinnamic acids and 
derivatives, while the ether bond and the linker region were replaced with an amide group 
(cinnamic acid-glycine-arginine), (iv) introduction to the linker region of a tryptophan residue and 
analogues with different substituents at the aromatic region, and (v) replacement of the linker by 
furan moieties, including functionalised analogues.   
We discovered two potent C3aR antagonists, which bound tightly to C3aR in HMDM cells. 
These compounds feature derivations of SB290157 with linker region replaced by a furan ring. The 
heterocycle was modified with varying hydrogen bond acceptors. The most potent and selective 
compounds in this study were 145 and 146 (IC50 460 and 534 nM, respectively) in the calcium 
mobilisation assays in HMDM cells. Binding affinity correlated with antagonist potency, and these 
compounds were by far the most potent C3aR antagonists reported to date. 
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To better understanding the binding site, the new potent and selective peptide antagonist 25 
and non-peptide antagonist 146 have been compared in this chapter with SB290157 for their 
capacity to inhibit intracellular calcium release in HMDM stimulated by up to 100 µM of three 
different classes of C3aR agonists: human C3a, peptide agonists (17 and 20), and non-peptide 
agonists (63 and 80).  
The antagonists SB290157, 25 and 146 all displayed insurmountable and non-competitive 
antagonism against C3a for C3aR. This is attributed to either a possible allosteric binding site for 
the compounds on C3aR or possibly irreversible or pseudo-irreversible binding to the C3a receptor. 
By contrast, SB290157 was a surmountable and competitive antagonist against peptide agonists (17 
and 20) and non-peptide agonists (63 and 80).  Compound 25 was an insurmountable antagonist for 
all C3a agonists (hC3a, peptide and non-peptide agonists). Compound 146 behaved similarly to 
SB290157 in exhibiting surmountable and competitive antagonism of peptide and non-peptide 
C3aR agonists.  
These results point to a mechanism of insurmountable antagonism for compound 25 against 
all agonists (hC3a, 17, 20, 63 and 80) involving binding to C3aR that is unlikely to be at an 
allosteric site, since it competed with [125I]-C3a in the competitive binding assay. It is more likely 
that compound 25 binds pseudo-irreversibly to C3aR. The competitive antagonism study of C3aR 
antagonist C3aRA (SB290157) against all peptide and non-peptide agonists showed a concentration 
of C3aRA (SB290157) that caused a two-fold rightward shift of agonists in the following order: 20 
(63 nM) < 17 (100 nM) < 63 (126 nM) < 80 (158 nM). This indicated that the non-peptide agonists 
(63 and 80) bound to C3aR more tightly than peptide agonists (17 and 20), thus requiring higher 
concentrations of C3aRA (SB290157) to shift the EC50 value of agonists two-fold to the right. 
The work presented in this thesis has extensively studied the discovery and development of 
C3aR-selective, small molecule agonists/antagonists with high affinity and potency for human 
C3aR. These could serve as chemical probes for revealing the roles of C3a and C3aR in immune 
and inflammatory physiology and pathophysiology. They might also provide some clues to drive 
the development of specific drugs to target C3aR and are produce benefits for the treatment of 
immune-deficiency or immunosuppression (C3aR agonist) or autoimmune, inflammatory, 
metabolic diseases (C3aR antagonist). 
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Human anaphylatoxin C3a, formed through cleavage of complement protein C3, is a potent effector of
innate immunity via activation of its G protein coupled receptor, human C3aR. Previously reported
short peptide ligands for this receptor either have low potency or lack receptor selectivity. Here we
report the first small peptide agonists that are both potent and selective for human C3aR, derived from
structure-activity relationships of peptides based on the C-terminus of C3a. Affinity for C3aR was
examined by competitive binding with 125I-labeled C3a to human macrophages, agonist versus anta-
gonist activity measured using fluorescence detection of intracellular calcium, and general selectivity
monitored by C3a-induced receptor desensitization. An NMR structure for an agonist in DMSO
showed aβ-turnmotif thatmay be important forC3aRbinding and activation.Derivatization produced
a noncompetitive and insurmountable antagonist of C3aR. Small molecule C3a agonists and antago-
nists may be valuable probes of immunity and inflammatory diseases.
Introduction
Human complement is a complex network1-3 of plasma
proteins that initiates inflammatory and cellular immune
responses to stimuli like infectious organisms (bacteria/
viruses/parasites), chemical/physical injury, radiation, and
cancer. Complement activation is an important proteolytic
signaling cascade in the immune response to infection and
tissue injury, its proteins cooperatively effecting recognition,
opsonization, lysis, and removal of pathogens and infected or
damaged cells and cellular debris. Among complement acti-
vation products are the anaphylatoxins C3a and C5a, which
prime and amplify the immune response through chemoat-
traction of immune cells to inflammatory sites andby promot-
ing secretion of proinflammatory agents, lysosomal enzymes,
and reactive oxygen species.1-3 Unlike C5a, which is almost
undetectable in healthy individuals, there is considerable C3a
(>100 nM) present due to continuous degradation of C3.
While the pharmacology of C5a and its receptor4a,b has been
strongly implicated in the pathogenesis of inflammatory dis-
eases through effects of gene deletion, genetic deficiency, anti-
bodies, and a synthetic antagonist, C3a or its receptor C3aRa
has only more recently been implicated in the pathogenesis
and progression of inflammatory diseases such as asthma,
allergies, sepsis, lupus erythematosus, diabetes, arthritis, psor-
iasis, nephropathy, ischemia-reperfusion injury, andothers.5-7
Antimicrobial and antifungal properties have also been re-
ported for C3a derived peptides.8 The 21-residue C-terminus
of C3a and the 20-residue C-terminus of C3adesArg are also
antibacterial against E. faecalis and P. aeruginosa,9 Escherichia
coli, and Staphylococcus aureus10 and antifungal againstCandi-
da albicans.11 Two nonapeptide derivatives of the C3a C-termi-
nus interfere with intracellular Ca2þ release and ERK 1/2
phosphorylation by binding to andpromoting phosphorylation
of type 1 Fc ε receptor in mast cells.12 As more C3a-C3aR
pharmacology has become established, interest has been re-
newed in C3a and there is a realization of the need for synthetic
C3a agonists and antagonists for interrogating and potentially
treating human C3a-mediated conditions.5-7
Human complement component C3a is a 76 residue protein
that binds to a single known seven-transmembrane domain
receptor C3aR, a rhodopsin-like GPCR that is expressed
ubiquitously on the surface of many cells (particularly
*To whom correspondence should be addressed. Phone: þ61 7
33462989. Fax: þ61 7 33462990. E-mail: d.fairlie@imb.uq.edu.au.
aAbbreviations: 3D53, C5aR antagonist cyclo-(2,6)-AcF[OP-
(dCha)WR]; Ahx, 6-aminohexanoic acid; Aib, 2-aminoisobutyric acid;
Bt2-cAMP, 3
0,50- dibutyryladenosine monophosphate; ATP, adenosine
triphosphate; C3aR, C3a receptor; C5aR, C5a receptor; Cha, cyclohex-
ylalanine; dU937, human monocytic cells from histiocytic lymphoma
differentiated with Bt2-cAMP; DIPEA, N,N-diisopropylethylamine;
DMF, N,N-dimethylformamide; EC50, molar concentration that pro-
duces 50% of the maximum response of an agonist; FBS, fetal bovine
serum; Fmoc, fluorenylmethoxycarbonyl; G-protein, guanosine mono-
phosphate protein; GPCR, G-protein-coupled receptor; HATU, 2-(1H-
7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate;
HBSS, Hank’s balanced salt solution; HBTU, O-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HEK-293, hu-
man embryonic kidney 293 cells; HEPES, 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid); HT-29, human colon adenocarcinoma grade
II cell line; hF, homophenylalanine; 125I, iodine isotope 125; IC50, molar
concentration of an unlabeled agonist/antagonist that inhibits 50%
radioligand binding or molar concentration of antagonist that inhibits
50% of a known concentration of agonist activity; Ig, immunoglobulin;
IMDM, Iscove’smodifiedDulbucco’smedium;MBHA,methylbenzhy-
drylamine; Nal, 1-naphthylalanine; Nle, norleucine; NEAA, nonessen-
tial amino acids; NOE, nuclear Overhauser effect; NOESY, nuclear
Overhauser effect spectroscopy; Orn, ornithine; Pbf, 2,2,4,6,7-penta-
methyldihydrobenzofuran-5-sulfonyl; PBMC, peripheral blood mono-
nuclear cells; rmsd, root-mean-square deviation; ROE, rotating-frame
Overhauser enhancement; ROESY, rotating-frame NOE spectroscopy;
rpHPLC, reversed phase high performance liquid chromatography;
TFA, trifluoroacetic acid; TIPS, triisopropylsilane; TOCSY, total cor-
relation spectroscopy; U937, human leukemic monocyte lymphoma
cell line.
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immune cells such as macrophages, neutrophils, T cells) and
signals through GRi and GR16 proteins. Both crystal
13a and
NMR-derived solution13b structures have been reported
for human C3a, as well as for complement C3 incor-
porating C3a.13c The crystal structure of C3a (actually
C3adesArg) was of low resolution (3.2 A˚) but showed the
C-terminus of C3a in a turn conformation, while the solution
structure showed disorder in the last seven residues. For the
C3 structure, the electron density was too diffuse to identify
the C-terminal seven residues of the sequence corresponding
to C3a. A similar turn structure was, however, also observed
for the C-terminus of C5a.14 Like C5a, it is the C-terminal
octapeptide region of C3a that is implicated as the effector
domain required for triggering receptor activation,15 the
remaining 69 amino acids at the N-terminus of C3a being a
high affinity binding domain. Numerous peptides based on
the C-terminus of C3a have been reported to compete with
125I-C3a for the surfaces of cells. Removal of the C-terminal
arginine of C3a abolishes the biological activity of C3a, so all
synthetic C3a ligands to date have a C-terminal arginine.
Despite three decades of research, endeavors to produce
highly potent peptidic C3a ligands of less than eight residues,
with agonist activity against human cells at submicromolar
concentrations, have been unsuccessful. In fact, there have
been relatively few reports of new synthetic C3a ligands since
the early 1990s.
Among the most potent reported C3aR binding peptide
ligands is a synthetic peptide comprising the C-terminal 21
residues of C3a, which was equipotent with C3a in lung
strip and ileal contraction assays but 44% as effective as
C3a in suppressing Ig secretion by peripheral blood
lymphocytes.16a Incorporation of helix-inducing Ala and
Aib residues at judicious positions resulted in a 250%
enhancement in activity of the peptide, correlating with
increased helicity measured by circular dichroism
spectra.16b Truncation andmodification to 15 residues with
incorporation of two tryptophans at the N-terminus re-
sulted in a “superagonist” WWGKKYRASKLGLAR that
was 15-fold more potent than C3a in a guinea pig platelet
aggregation assay.16c Numerous other attempts have been
made to shorten peptide sequences while retaining either
competitive binding with 125I-C3a or C3a-like function.17
Comparisons between reported activities of these syn-
thetic C3a agonists are difficult to make because of the
variety of assay systems used to evaluate them, ranging
from tissue organ preparations for measurement of smooth
muscle contraction16a,b,17b,c,h,k tomast cell histamine-release18
assays and ATP-release1-7,19 assays from guinea pig platelets
and affinity measurements on isolated membranes or whole
cells. The activities of synthetic ligands are further compli-
cated by the use of different species, especially tissues and cells
from guinea pigs that have since been found to have two
functional C3a receptors20 compared with only one receptor
in humans. Moreover, GPCRs are notorious for having
widely variable species-dependent responses to ligands due
to different amino acid polymorphisms in the receptor, C5a
being a case in point.21 This may in part explain why many of
these peptides reevaluated by us against intact human cells are
either not potent or not selective in their binding toC3aRover
C5aR or also bind and activate other receptors. Our experi-
ences have also highlighted some potency and affinity incon-
sistencies with literature data, warranting reevaluation in
more relevant human cells. It is our opinion that there have
to date been no truly selective and potent agonists or antago-
nists reported for probing the pharmacology of human C3a
in vivo.
There have been very few reports of small non-peptide
ligands for C3aR. The most studied is a hydrophobic capped
arginineN2-[(2,2-diphenylethoxy)acetyl]-L-arginine (SB290157,
3) reported to be a C3a receptor antagonist22a but also shown
to be an agonist in transfected rat basophilic leukemia cells,
Chinese hamster ovary cells, and human U937 cells,22b,c as
well as acting on other unknown receptors.22dAntagonists for
C3aR have been reported based on diiminoisoindoline23 and
biphenylimidazole24 core structures,whilemore potent partial
agonists have been based on arginine derivatives with a 2,5-
furyl component (pIC50 of 7.1 vs 20 pM
125I-C3a)25a and
aminopiperidineswithout arginine (pIC50=7.5).
25bOnepath
to rational development of nonpeptidic ligands for C3aR is to
first identify potent and selective peptides, which proffer
information about side chain fitting to the receptor. This
paper identifies some important properties for high affinity
ligand binding to human C3aR that can be crucial for future
design of druggable compounds.
Table 1. Affinity and Potency of Known Truncated Anaphylatoxin Agonists on dU937 Cells
C3a receptor affinitye C5a receptor affinitye apparent agonist activityf
compd peptide n -log IC50 ( SE IC50 a (nM) n pIC50 ( SE IC50 b (nM) n -logEC50 ( SE EC50 c (μM)
1 C3a 13 9.9 ( 0.07 0.12 3 j 10 7.3 ( 0.06 0.052
2 C5a 1 j 4 8.9 ( 0.24 1.4 3 8.2 ( 0.09 0.007
3 SB290157 7 6.9 ( 0.16 140 3 j 3 φd
4 3D53 3 j 3 7.8 ( 0.17 15 3 φ
5 WWGKKYRASKLGLAR 3 8.7 ( 0.20 2.0 3 j 5 5.9 ( 0.16 1.3
6 C3a63-77 3 6.6 ( 0.23 250 3 6.3 ( 0.33 560 4 5.8 ( 0.11 1.8
7 C5a60-74 3 5.8 ( 0.21 1600 3 5.8 ( 0.17 1700 4 4.6 ( 0.11 24
8 YSFKPMPL(Me-a)R 3 7.9 ( 0.13 13 3 5.7 ( 0.14 2000 5 6.9 ( 0.06 0.13
9 YSFK(Me-D)MPLaR 3 6.1 ( 0.19 740 3 4.5 ( 0.45 29000 5 5.9 ( 0.05 1.4
10 YSHKPMPLaR 3 j 3 j 3 5.2 ( 0.03 5.7
11 YSFKPMPLaR 3 6.9 ( 0.10 140 3 5.3 ( 0.21 4700 2 6.7 ( 0.07 0.22
12 HLGLAR 3 5.2 ( 0.21 5900 3 j 3 5.4 ( 0.31 3.8
13 HLALAR 3 5.2 ( 0.29 6300 3 j 3 φ
14 YPLPR 3 j 3 j 2 φ
15 WPLPR 3 4.5 ( 0.50 27000 3 j 2 φ
aConcentrations causing 50% of maximum binding of 125I-C3a to intact human monocytes. bConcentration causing 50% inhibition of maximum
binding of 125I-C5a to intact humanmonocytes. cConcentration causing 50%maximumcalciummobilization fromBt2-cAMPdifferentiatedU937 cells.
dNo agonist activity at 1 mM, antagonist with pIC50= 5.9( 0.1 (IC50= 1.3 μM). ej: no binding detected at 1 mM. fφ: no intracellular calcium release
detected at 10 μM.
4940 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Scully et al.
Results
Activity of Truncated Anaphylatoxins.N-Terminal trunca-
tion of C3a has previously been used to determine what
constitutes the active portion of C3a, but past efforts to
access short, potent peptides tomimic C3a function havemet
with limited success. It has been proposed that, as for C5a-
C5aR, C3a-C3aR interactions can be described by a two-site
model, with the N-terminal helix bundle of C3a providing
affinity while the C-terminus carries the receptor-activating
motif.15 We chose to begin addressing binding affinity and
agonist inducedCa2þ release from the promonocytic cell line
U937 differentiated with Bt2-cAMP (dU937). When both
binding and functional assays were used, progressive trunca-
tion ofC3a dramatically reduced both affinity and activity of
truncated peptides (Table 1).
C3a (1) andC5a (2) are selective for their respective receptors
on human PBMCs, with no crosstalk between them, as well as
potent inducers of intracellular Ca2þ release in dU937 cells
(Table 1). Similarly, the C3a antagonist 322a and the C5a anta-
gonist 44a,d-f also bind specifically to C3aR and C5aR, respec-
tively, on PBMCs, with no cross-reactivity, and neither com-
pound induces Ca2þ release in dU937 cells at 1 mM (Table 1).
For 2 decades the 15-residue peptide (5), reported as a supera-
gonist,16c has been used as a benchmark for measuring com-
parative agonist activity against C3aR. Although it has high
affinity for C3aRon PBMCs (Table 1), it had only comparable
weak Ca2þ-inducing activity to that of C3a63-77 (6) in dU937
cells. Also, although it did not bind to C5a receptors on human
PBMCs, 5was not selective for C3aR because it induced Ca2þ
release evenafterC3aR indU937cellswas first densensitizedby
human C3a (Figure 1D). Thus, it would appear that future
functional studies with 5 could bemisleading because of lack of
selectivity for human C3aR.
Truncation of C3a to its 15-residue C-terminal native pep-
tide sequence leads to a substantial reduction in functional
potency measured by the capacity to induce intracellular
calcium release from dU937 cells (Table 1) (C3a63-77 6,
EC50=1.8 μM; C3a 1, EC50=52 nM; 35-fold), a reduction
that is 100 times even more pronounced for C5a (C5a60-74 7,
EC50= 24 μM; C5a 2, EC50= 7 nM; 3500-fold). These 15
residue peptides based on the C-terminal native sequences of
C3a and C5a were, however, not selective for their receptors
(Table 1), C5a60-74 7 having some affinity for C3aR (IC50=
1.6 μM) and C3a63-77 6 having even greater affinity for
C5aR (560 nM) as well as 2000-fold lower affinity than C3a
for C3aR. As a result of the nonselectivity of C5a60-74 7, we
decided to also investigate the binding of reported C5a
decapeptide agonists (8-11),26 which we find have much
higher affinity for hC3aR than hC5aR (Table 1). The even
shorter hexapeptide analogues (12, 13)17b of the C3a C-ter-
minus had marginal affinity for human C3a receptor at
micromolar concentrations (Table 1) and were the minimum
sequences able to induce any calciummobilization in human
dU937 cells. They were not very active even at 100 μM, the
highest concentration tested, while pentapeptides 14 and
1517j had even weaker or no affinity for C3aR and did not
induce Ca2þ release.
These results highlight both the difficulty in designing
potent and selective small molecules for these receptors,
which have high sequence homology in their transmembrane
regions, and the need to examine affinity for both C3aR and
C5aRwhen looking for truly potent and selective ligands.On
the basis of this and our other unpublished work, we do not
consider that there currently exists any short peptide (8
residues or less) that is both potent (at submicromolar con-
centrations) and selective (g100-fold) for human C3aR over
C5aR or other receptors.
Structure-Activity Relationships for Agonist Derivatives
of FKPLAR. Our goal was to create short peptides that are
both selective for human C3aR over human C5a receptors
Figure 1. Receptor affinity and agonist potency for selected compounds. (A)Affinities for C3a receptormeasured by displacement of 125I-C3a
from human PBMCs: 1 (b), 3 (9), 5 ([), 8 (1), and 9 (2). (B) Affinities for C5a receptor measured by displacement of 125I-C5a on human
PBMCs: 2 (b), 4 (9), 5 (0), 8 (1), 9 (2), and 10 (O). (C) Activity of 1 (9), 2 (b), 5 ([), and 8 (1) in intracellular Ca2þ mobilization assay on
human dU937 cells. (D) Intracellular calcium release by 5 in C3aR-desensitized human dU937 cells.
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and with submicromolar potency as agonists in the intracel-
lular Ca2þ release assay. Among themost potent C5aR short
peptide agonists is the hexapeptide FKP(dCha)(Cha)r-NH2
(16).27 Given the high sequence homology between C3a and
C5a, we decided to start with this hexapeptide to derive
structure-activity relationships for C3aR binding peptides
using a functional agonist assay in dU937 cells. Since the
Leu-Ala-Arg motif is present at the C-terminus of C3a and
has been shown to be vital for activity at C3aR,17b,f these
residues were incorporated as replacements for (dCha)-
(Cha)r to produce hexapeptide F6K5P4L3A2R1 (17),
with EC50=33 μM in the intracellular calciummobilization
assay for dU937 cells (Figure 2). Table 2 shows effects of
substitution in FKPLAR on agonist activity, as measured
by intracellular Ca2þ release from dU937 cells. When stan-
dard numbering28 was used, Phe6 in 17 was successively
replaced with His, Trp, and the unnatural amino acid Cha
but none of the resulting peptides (18-20) were functional
agonists at up to 100 μM, as there was no detectable calcium
release (Table 2).
Lys5 in 17 was substituted by nonpolar (Ile, Leu, Cha,
Nle), aromatic (Trp, Phe, homoPhe, naphthylalanine), acidic
(Glu), neutral and basic (Gln, Orn and Arg) amino acids
(Table 2). Changing Lys to an alternative basic residue Orn
(21) or Arg (22) or to an acidic residue Glu (23) abolished
activity. However, changing to a hydrophobic aliphatic
(24-27) or aromatic (29-32) residue or to a Gln residue
(28) generated compounds that stimulated Ca2þ release
within the IC50 range 0.5-6.0 μM. The two most potent
agonists were 26 (Leu) and 31 (Trp) with EC50 of ∼0.4 and
0.6 μM, respectively (Figure 2), and they were subjected to a
further round of sequence optimization as shown in Table 3.
Table 3 reports some derivatives of FWPLAR (31).
Replacing Pro4 with residues Gly, Ala, Ser, and Thr
Figure 2. Agonist activity for selected peptides in intracellular calcium release in human dU937 cells: (A) 1 ([), 2 (b), 17 (4), 26 (2), 31 (1);
(B) 1 (b), 42 (1), 54 ([), 55 (9).
Table 2. Agonist Activity of FKPLAR (17) Analogues on Human
dU937 Cells Measured by Calcium Release Assay
apparent agonist activityb
compd peptide n pEC50 ( SE EC50 a (μM)
16 FKP(dCha)(Cha)r-NH2 2 5.7 ( 0.25 2.2
17 FKPLAR 4 4.5 ( 0.20 33
18 HKPLAR 2 j
19 ChaKPLAR 3 j
20 WKPLAR 3 j
21 FOPLAR 3 j
22 FRPLAR 4 j
23 FEPLAR 4 j
24 FIPLAR 7 6.0 ( 0.08 0.95
25 FNlePLAR 4 5.7 ( 0.14 1.8
26 FLPLAR 3 6.4 ( 0.09 0.42
27 FChaPLAR 3 6.1 ( 0.05 0.78
28 FQPLAR 4 5.3 ( 0.03 5.3
29 FFPLAR 2 5.3 ( 0.09 5.4
30 FhFPLAR 3 6.0 ( 0.06 1.1
31 FWPLAR 8 6.2 ( 0.14 0.58
32 FNalPLAR 3 6.1 ( 0.06 0.72
33 FKTLAR 3 5.4 ( 0.19 3.8
34 FKFLAR 2 j
35 FKPNleAR 4 4.4 ( 0.20 38
36 FKPChaAR 2 j
37 FKPFAR 3 j
38 FKPWAR 2 j
39 FKPLChaR 3 j
40 FKPLFR 3 j
41 FKPLWR 3 4.6 ( 0.34 25
aConcentration causing 50% maximum calcium mobilization from
Bt2-cAMP differentiated human U937 cells.
bj: no calcium release
detected at 1 mM.
Table 3. Activity of FWPLAR (31) and FLPLAR (26) Analogues on
Human dU937 Cells Measured by Calcium Release Assay
apparent agonist activityb
compd peptide n pEC50 ( SE EC50 a (μM)
42 WWTLAR 3 6.04 ( 0.06 0.91
43 hFLTLAR 2 4.96 ( 0.08 11
44 Ac-FLTLAR 2 6.28 ( 0.15 0.52
45 YLTLAR 2 5.61 ( 0.15 2.5
46 RLTLAR 4 j
47 FOTLAR 1 j
48 FRTLAR 1 5.17 ( 0.36 6.8
49 FYTLAR 2 5.32 ( 0.35 4.8
50 FNleTLAR 3 6.51 ( 0.30 0.31
51 FWGLAR 2 6.33 ( 0.09 0.47
52 FWALAR 3 5.93 ( 0.12 1.2
53 FWSLAR 5 6.31 ( 0.09 0.49
54 FWTLAR 6 6.43 ( 0.09 0.37
55 FLTLAR 5 6.50 ( 0.12 0.32
56 FLGLAR 3 6.29 ( 0.33 0.52
57 FLALAR 3 5.96 ( 0.23 1.1
58 FLSLAR 4 6.45 ( 0.19 0.36
59 FLTlAR 2 j
60 FLTNleAR 1 5.58 ( 0.26 2.7
61 FLTChaAR 4 j
62 FLT(dCha)AR 2 j
63 FLTSAR 3 j
64 FLTLLR 4 j
65 FLTLPR 1 4.54 ( 0.19 29
66 FLTLAr 2 4.24 ( 0.12 57
67 FLTLAR-NH2 1 4.44 ( 0.19 37
aConcentration causing 50% maximum calcium mobilization from
Bt2-cAMP differentiated human U937 cells.
bj: no calcium release
detected at 1 mM.
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(51-54) enhanced agonist potency except for Ala. The
threonine-containing 54 (EC50 = 0.37 μM) was the most
potent agonist, but changes from Thr4 to Ser or Gly did not
alter agonist potency much. A second family of compounds
was based on FLTLAR (55) which was slightly more potent
than 54. Changing Phe6 to homophenylalanine or tyrosine
or capping theC-terminuswith acetyl (43-45) reduced agonist
potency, while an arginine at this position (46) abolished
activity. Replacing Leu5with ornithine, arginine, or tyrosine
(47-49) significantly reduced activity, but a change to nor-
leucine (50) had little affect. Changing Thr4 to glycine,
alanine, or serine (56-58) also had little effect. Replacing
any of Leu3, Ala2, or Arg1 (59-67) substantially reduced or
abolished agonist function of these hexapeptides.
Further investigations were carried out on the tolerance of
each position to different residues in order to confirm the
tests carried out in the earlier part of the study. As Table 3
shows, all changes to FLTLAR resulted in reduced activity,
including addition of an acetyl N-terminal cap (44) and
changing of the C-terminal acid to an amide (67), suggesting
that both the free amino group and the carboxylic acid are
important for potency. Figure 2 shows agonist responses for
potent compounds from Table 2 and 3.
Figure 3 shows receptor desensitization experiments to
examine possible selectivity for two of the most active com-
pounds in this series, 24 and 31. The cells were first exposed
to C3a, which triggers phosphorylation of the receptor by
tyrosine kinases and desensitization to further addition of C3a
or C3aR-selective agonists. Compound 24 does not stimulate
calcium release following C3a receptor desensitization, andwe
conclude that it is selective for C3aR.However, 31 does induce
some Ca2þ release following desensitization with C3a, indicat-
ing that at least some Ca2þ release is not mediated through
activation of C3aR; thus, 31 is not selective. Compounds
35-41 and 59-67 represent changes to the L3 and A2 posi-
tions, but these reduced agonist potency, suggesting that
L3A2R1 at the C-terminus may be optimal among the
compounds examined here for agonist activity.
Affinity of C3a Ligands for Human C3aR. The affinity for
C3aR and C5aR of some of the more potent agonists (and
one antagonist 61) is reported in Table 4 and Figure 4. We
used competitive radioligand binding experiments using
whole PBMCs isolated from human plasma to determine
IC50 for each ligand (1, 24, 31, 42, 49, 53, 54, 55, 61 and 63) by
displacement of 125I labeled human C3a or C5a measured
with a scintillation proximity assay. The ligands were tested
in triplicate on three different occasions to obtain a full dose
response curve for each compound. There was a pseudo-
linear correlation between C3a-competitive ligand binding
affinity and Ca2þ-inducing agonist potency (Figure 7), and
none of the compounds showed any affinity at submillimolar
concentrations for human C5a receptors.
Solution Structure of Agonist 55. Agonist peptide 55 was
examined by 1D and 2D proton NMR spectroscopy in an
attempt to identify any propensity for adopting well-defined
Figure 3. C3aR selectivity for peptides 24 (A), 31 (B), 54 (C), and 55 (D). Intracellular calcium release was measured in human dU937 cells
desensitized to C3a agonists by C3a. Compounds 24, 54, and 55 were selective, while 31 induced calcium release even after the cells were
desensitized by C3a, suggesting some activation through a different receptor to C3aR.
Table 4. Affinity of Selected Hexapeptides for C3aR by Competition
with Radioligand Binding, Assayed in Human PBMCs
compd peptide n a -log IC50 ( SE IC50 (nM)b IC50 (nM)c
1 hC3a 13 9.75 ( 0.12 0.18 j
24 FIPLAR 3 6.64 ( 0.13 230 j
31 FWPLAR 4 6.56 ( 0.30 274 j
42 WWTLAR 3 6.61 ( 0.12 244 j
49 FYTLAR 3 6.78 ( 0.17 166 j
54 FWTLAR 3 7.09 ( 0.33 82 j
55 FLTLAR 3 7.38 ( 0.26 42 j
56 FLGLAR 3 6.81 ( 0.12 157 j
61 FLTChaAR 2 6.62 ( 1.59 238 j
63 FLTLAr 3 5.10 ( 0.50 8200 j
aNumber of experiments. bCompetitive binding with 80 pM 125I-
C3a. cCompetitive binding with 80 pM125I-C5a.j: no binding at 1 mM.
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structure in solution. There was no well ordered structure in
water, as expected for short peptides, because water com-
petes strongly for hydrogen bonds and only a random
assembly of rapidly interconverting structures is normally
observed.4fHowever, in the aprotic solventDMSO-d6, stable
secondary structures can sometimes be observed even for
short peptides.4e,f Indeed, at 298 K distinct doublet reso-
nances were observed for each of the amide peaks of 55
(Table 5). The phi and psi dihedral angles of the residueswere
obtained from the Karplus equation using coupling con-
stants displayed for the amides.High (>8Hz) or low (<6Hz)
coupling constants were indicative of secondary structure in
solution (Leu5, 8.2 Hz; Thr4, 8.6 Hz; Leu3, 8.3 Hz), whereas
a disordered structure has uniform amide coupling constants
between 6 and 8 Hz.
Secondary structure in peptides is often stabilized by main
chain to main chain or main chain to side chain hydrogen
bonds. The low temperature coefficient for the L3 amide
proton (3.2 ppb/K) (Supporting Information) suggests that
it may be involved in hydrogen bonding. When T4 was
replaced by alanine, the L3 amide proton no longer had a
low temperature coefficient, indicating that the T4 side chain
hydroxyl is the hydrogen bond acceptor. ROESY experi-
ments for 55 showed 19 distinctive short and medium range
ROEs, indicating a well-defined structure for 55. Two weak
ROEs dR,N(T4, A2) and dR,N(L5, A2) are indicative of a β turn
structure between residues L5 and A2 (Figure 6).
Solution structures were determined using 19 ROE distance
constraints and 3 dihedral angle constraints, resulting in a
family of 15 lowest energy structures which are displayed in
Figure 5 (see Supporting Information for the Ramachandran
plot, dihedral angles, CR(i,iþ3) distances and H-bond dis-
tances). The ROEs (Figure 6), distances separating CR
protons of Leu5 and Ala2 (<7 A˚) are indicative of a β-turn,
the dihedral angles of the two middle residues (T4 and L3)
closely mimicking a β-turn. The rmsd of the peptide backbone
within the family of 15 structures is 1.7 A˚,which is a reasonable
convergence for a short unconstrained peptide in solution.
The peptide turn motif in Figure 5 is similar to what we
have reported4f for the C5aR specific antagonist FKP-
(dCha)Wr in DMSO and appears to be encouraged by a
hydrogen bond formed between the hydroxyl side chain of
Thr4 and the backbone amide proton of Leu3. Variable
temperature NMR data reveal a low temperature coefficient
(3.2 ppb/K) for this proton, indicating its possible involve-
ment in a hydrogen bond. A serine at this position, which
can also form the same hydrogen bond, resulted in similar
agonist potency. Proline- and glycine-containing peptides
(31 and 56) have similar agonist activity and likely also favor
a turn motif but without the need for this hydrogen bond.
The amide proton of Leu3 in peptide F6LALAR1 57 did not
exhibit a low temperature coefficient, presumably because it
is missing its hydroxyl oxygen bonding partner concomitant
with its relatively low activity (1 μM) in the calcium release
assay.
C3aR Antagonist 61. Figure 7 shows an almost linear
relationship between C3aR affinity (PBMCs) and activity
(dU937 cells) for C3a hexapeptides from Table 4, consistent
with the expected affinity-activity correlation despite using
two different cell types. It was clear that the LAR tripeptide
motif comprising the C-terminus of C3a agonists was not
amenable to much change without loss of substantial agonist
activity in a calcium release assay. However, this was not an
absolute requirement for tight binding to the C3a receptor.
For example, FLTChaAR (61) was unique among the pep-
tides examined that showed no agonist activity at 100 μM in
the calcium release assay, but it did bind strongly to the
receptor (IC50=240 nM, Table 4).
This indicated that 61 was likely an antagonist, with no
agonist activity below 100 μM. This was subsequently de-
monstrated through noncompetitive antagonism of Ca2þ
release in human PBMCs induced by either C3a (Figure
8A) or agonist 54 (Figure 8B). It was not a competitive ligand
with either of these two agonists, since depression of the
maximal agonist response by varying concentrations of 61
did not change the apparent EC50 values of C3a or agonist
54. Thus, either compound 61 binds to a different site on the
C3a receptor or it is an insurmountable antagonist, much
like certain hexapeptide antagonists of humanC5aR.7d-fWe
favor the latter explanation in view of the similarity of the
peptide sequences.
Discussion
Human C3a or its receptor C3aR is implicated in the
pathology of multiple inflammatory and immune conditions,
for which either an agonist or an antagonist might have
Figure 4. Competitive ligand binding affinity for human PBMCs. (A) Affinity of selected peptides for C3aR in competitive radioligand
binding vs 125I-C3a (80 pM): 1 (b), 3 (9), 4 ([), 54 (1), 55 (2). (B) Affinity of selected peptides for C5aR as determined in a radioligand binding
assay vs 125I-C5a (80 pM): 1 (b), 2 (0), 3 (9), 4 ([), 54 (1), 55 (2).
Table 5. 1H NMR Chemical Shift (δ, ppm) Assignments for 55 in
DMSO-d6 at 25 !C
residue NH HR Hβ others
F (6) na 4.04 2.88, 3.09 Hδ 7.24; Hε 7.30
L (5) 8.65 4.50 1.48 Hγ 1.65; Hδ 0.88
T (4) 8.05 3.97 3.97 Hγ1 4.92; Hγ2 1.04
L (3) 7.82 4.30 1.48 Hδ 0.82
A (2) 7.96 4.26 1.19
R (1) 8.06 4.15 1.73, 1.62 Hγ 1.57; Hδ 3.09; Hε 7.46
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beneficial effects. However, the ubiquitous expression of C3a
and C3aRonmany cell types in addition to immune cells may
point to additional functions of C3a that await to be discov-
ered. C3a itself induces chemotaxis, secretion of proinflam-
matory cytokines that define immunostimulatory properties,
contraction of smooth muscle, activation of mast cells and
eosinophils, and an increase in vascular permeability leading
to increasedmigration ofmonocytes andneutrophils from the
bloodstream into tissue.1 Furthermore, C3a-desArg, in which
the C-terminal arginine is cleaved from C3a by N-carboxy-
peptidase, is known as acylation stimulating protein (ASP)
and is implicated in triglyceride synthesis and adipocyte
function in metabolic syndrome.29 Clearly, small molecules
that can reproduce the function ofC3a and itsmetabolites can
at the very least be useful biological probes of C3a function in
vivo, where it is often too expensive and impractical to
experiment with the native protein or specific antibodies to
it. Small molecule agonists may also have important uses by
reproducing beneficial immunological properties of C3a.
The knownGPCRactivating functions ofC3a are localized
largely within its C-terminal octapeptide region, and there
have been numerous attempts to mimic the functions of C3a
by creating short peptides based on its C-terminus. However,
most reported small molecule ligands based onC3a have been
tested in a diverse array of assays, often in guinea pigs that
have more than one C3a receptor, so we needed to reevaluate
some of the leading agonists against humanC3aR first, before
devising new ligands.We found (Table 1, Figure 1) that some
reported C5aR ligands actually bound much more tightly to
C3aR,while other reported peptide ligands forC3aRwerenot
selective and often bound competitively with 125I-C5a to cells
or induced Ca2þ release from cells in which C3aR was first
desensitized by C3a. Another compound reported to be a
superagonist of C3aR (e.g., 5) was found to bind tightly to
humanmacrophage C3aR but had only weak agonist activity
in the Ca2þ release assay and was also not receptor-selective.
Consequently, we set out to obtain potent agonists that
unambiguously bound selectively and tightly tohumanC3aR.
From two series of new hexapeptides, we discovered
FLPLAR 26 and FIPLAR 24 (EC50 of 0.4-0.95 μM,
Table 2) and FWTLAR 54 and FLTLAR 55 (EC50 ≈ 0.3
μM, Table 3) as the most potent and selective agonists for
hC3aR.Therewas a pseudolinear correlationbetween agonist
potency (measured as release ofCa2þ into humandU937cells)
and C3aR binding affinity (measured by competition with
125I-labeled human C3a on PBMCs). An NMR-derived solu-
tion structure for agonist 55 showed significant “turn” or
“bend” propensity in the aprotic solvent DMSO, a feature of
theC-terminusofC3a itself, hintingat a potential requirement
for this structural feature for binding within the transmem-
brane region of humanC3aR.This result is consistentwith the
findings that over 100 peptide-activated G protein coupled
receptors have shown a tendency to recognize protein and
peptide ligands with turn structure30a,b and that cyclic pep-
tides that mimic turn conformations tend to be potent ligands
for GPCRs and other protein targets.30a-c Future incorpora-
tion of turn-inducing peptidomimetic constraints into such
Figure 5. NMR-derived solution structure for compound 55 in in DMSO-d6 (298 K). (A) 15 of 20 lowest energy minimized NMR structures
showing the backbone of 55. Residues are labeled with three-letter amino acid codes. (B) Representative NMR structure of 55 showing the
H-bond formed between the side chain hydroxyl group of Thr4 and the backbone amide proton of Leu3.Adistance of 2.8 A˚ separates the heavy
atoms involved in the bond.
Figure 6. NMR summary diagram for 55. Shown are sequential
and medium-range ROEs, the bar thickness being proportional to
strong (upper distance constraint 2.7 A˚), medium (3.5 A˚), weak (5.0
A˚), and veryweak (6.0 A˚)ROE intensities: 3JNHCHg 8Hz (V); amide
NH chemical shifts 4δ e 4 ppb/K (b). The medium range ROEs,
especially dRN(i,iþ2), dRN(i,iþ3) and dNN(i,iþ1), are evidence for a β turn
conformation.
Figure 7. Correlation between binding affinity (IC50) and agonist
activity (EC50) for peptides in Table 4. 61 had no agonist activity at
100 μM; thus, it is given pEC50 g 4.
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peptides, their cyclic or nonpeptidic analogues, could prove
fruitful for obtaining even more potent and selective ligands
for human C3aR, en route to discovery of candidates suitable
for clinical trials.
The reported C3aR antagonist 3, which does not bind to
human C5aR (Table 1), is currently the main antagonist
reported in the literature for probing the pharmacology of
C3aR in vivo and in vitro. It has been used in animal models
for treating asthma, allergy, arthritis, intracerebral hemorrha-
ging, ischemia/reperfusion injury, among others.5-7,22 How-
ever, it has also been shown to be an agonist in some assays
and to induce non-C3a related activities in other assays.22Our
new antagonist FLTChaAR (61) has been found to have
comparable binding affinity to 3 for humanC3aRon PBMCs
(IC50 238 nM (61) vs 140 nM (3)). Like 3, it did not bind to
hC5aR, and in our study 61 was a more potent antagonist of
C3a-induced intracellularCa2þ release than 3 (IC50 of 238 nM
vs 1.3 μM).New compound 61 has cyclohexylalanine in place
of leucine at position 3 and is the most potent selective
antagonist for human C3aR yet reported. Interestingly, this
compound was an insurmountable antagonist and may pro-
vide a valuable clue to future design of even more potent and
selective small molecule C3aR antagonists.
Some conclusions from this study that can be drawn about
the requirements of human C3aR for potent and selective
hexapeptide ligands are the following: (i) theC-terminalLeu3-
Ala2-Arg1motif is important for agonist activity, with changes
to this region leading to significant reductions in agonist
potency; (ii) threonine at the fourth position gave the most
potent compounds, although other amino acids with small
side chains (serine, alanine, proline, glycine) were not that
much less potent; (iii) the most potent agonists had trypto-
phan, norleucine, or leucine at the fifth position; (iv) only
ligands with phenylalanine at the sixth orN-terminal position
were potent agonists; (v) replacing leucine at the third position
of short peptide agonist 55 with a bulkier group leads to
compound 61, which is a functional antagonist of both C3a
and the short peptide agonist 54. These results for ligandswith
both high affinity and high selectivity for humanC3aR finally
provide some long awaited clues that have been needed to
drive the development of drug leads specific for this important
receptor in human immune defense and inflammatory and
autoimmune diseases.
Experimental Methods
General.Protected amino acids and resins (Auspep, Parkville,
Victoria, Australia; Advanced ChemTech, U.S.; Novabiochem,
Laufelfingen, Switzerland), TFA,DIPEA, piperidine andDMF
(peptide synthesis grade; Auspep, Parkville, Victoria, Australia),
HBTU (IRIS Biotech, Germany) and HATU (Sigma Aldrich)
wereobtained fromcommercial sources.Preparative scale reversed-
phase HPLC (rpHPLC) separations were performed on Phenom-
enex C18 columns (100 A˚, 250mm" 20mm). Analytical rpHPLC
were measured on Phenomenex Luna 5 μm C18 columns [Rt(1)],
using gradientmixtures ofwater/0.1%TFA(solvent systemA) and
water 10%/acetonitrile 90%/TFA 0.1% (solvent system B). Purity
was checked under different gradients to confirm single products.
The molecular weight was determined by electrospray mass spec-
trometry (LCT MICRO-MASS). All compounds were analyzed
for purity and molecular weight by rpHPLC and mass spectro-
metry, respectively,withall compoundshaving>95%purity.High
resolution mass spectrometry was performed on a Bruker micro-
TOFbydirect infusion inMeCNat3μL/minusing sodiumformate
clusters as an internal calibrant.
Peptide Synthesis. Short peptides were assembled by manual
stepwise solid phase peptide synthesis using HBTU activation
and DIPEA in situ neutralization using Fmoc chemistry. Pep-
tides 16 and 67 were synthesized on Rink amide MBHA resin
(Novabiochem, 0.64 mmol/g) to obtain amide functionality at
the C-terminus. All other peptides were synthesized on Fmoc-
Arg(Pbf)-Wang resin, 0.54 mmol/g substitution (Novabiochem),
to obtain peptides with the free C-terminal carboxylic acid group.
The peptides were fully deprotected and cleaved from resin by
treatment with 9.5 mL of TFA/0.25 mL of TIPS/0.25 mL of
water at room temperature for 2 h. After evaporation preparative
HPLCwasused for peptide purification (gradient 0-100%Bover
30 min).
NMR Spectra Acquisition. 1H NMR spectra were recorded
on a Bruker Avance 600 spectrometer on samples containing
1-4 mM peptide in 90% water þ 10% D2O or DMSO-d6.
Proton assignments were made using TOCSY (80 ms mixing
time), NOESY, and ROESY (350 ms mixing time) spectra
according to the sequential assignment method.31a Water sup-
pression in 2D experiments was performed using a 3-9-19
Watergate pulse sequence. Variable-temperature 1D 1H and
TOCSY spectra were typically collected at 5 K increments from
298 to 303 K. For identification of slowly exchanging amides, a
series of 1D 1H and TOCSY spectra were run immediately after
dissolving the peptide (5 mg) in 90% D2O/H2O (550 μL). All
spectra were analyzed in TopSpin 1.3 (Bruker, Germany).
Structure Calculation. Cross-peaks in ROESY spectra were
integrated and calibrated in TopSpin 1.3, and distance con-
straints from ROE intensities were assigned as strong (2.7 A˚
upper limit), medium (3.5 A˚ upper limit), weak (5 A˚ upper limit),
or very weak (6 A˚ upper limit). Corrections for pseudo-atoms
were added to distance constraints where needed. Backbone
dihedral angle restraints were inferred from 3JRH-NH coupling
constants in 1D spectra at 298K. φwas restrained to-120( 30!
for 3JRH-NHg 8 Hz. Peptide bond ω angles were all set to trans,
Figure 8. Noncompetitive antagonism for 61 on human dU937 cells. (A) Against C3a and (B) against agonist 54, showing diminished
fluorescence of activation by each agonist due to competition from 61 at 0.5 μM(b), 1 μM(9), 2 μM(2), 4 μM(1), and 8 μM([) as measured
by intracellular calcium release assay.
4946 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Scully et al.
and structures were calculated without explicit hydrogen bond
restraints. Initial structures were generated using XPLOR-NIH
2.19.31d Starting structures with randomized φ andψ angles and
extended side chains were generated using an ab initio simulated
annealing protocol.31b The calculations were performed using
the standard force field parameter set (PARALLHDG.PRO)
and topology file (TOPALLHDG.PRO). Refinement of struc-
tures was achieved using the conjugate gradient Powell algo-
rithm with 1000 cycles of energy minimization and a refined
force field based on the programCHARMm.31c Structures were
visualized with MacPymol (The PyMOL Molecular Graphics
System, Schr€odinger, LLC).
Cell Isolation and Culture. Human peripheral blood mono-
nuclear cells (PBMC) were isolated from buffy coat (obtained
from Australian Red Cross Blood Service, Kelvin Grove) using
Ficoll-Paque density centrifugation (GE Healthcare Bio-
Science,Uppsala, Sweden) and cultured in completemedia, con-
sisting of IMDM with 10% FBS, 10 U/mL penicillin, 10 U/mL
streptomycin, and 2 mM L-glutamine (Invitrogen at 37 !C, with
5% CO2). Promonocytic U937 cells (cultured in RPMI media
with 10% FBS, L-Glu, PenStrep, and NEAA) were pretreated
72 h prior to assay with membrane-permeable cAMP analogue
Bt2-cAMP (0.5 mM), which induces cell differentiation to a
monocyte/macrophage- or granulocyte-like phenotype. Cellu-
lar differentiation induces increasedC3aR andC5aR expression
on the cell membrane.32
Receptor Binding. Receptor binding was performed using
125I-C3a, 80 pM (2200 Ci/mmol, Perkin-Elmer, Torrance,
CA), PBMC cells (15 " 106 cells/mL) and in the absence or
presence of various concentrations of unlabeled C3a or C3a
hexapeptide agonist for 60 min at room temperature with
shaking in 50 mM Tris, 3 mM MgCl2, 0.1 mM CaCl2, 0.5%
(w/v) bovine serum albumin, pH 7.4. Unbound radioactivity
was removed by filtration through glass microfiber filters GF/B
(Whatman Iner. Ltd., England) which had been soaked in 0.6%
polyethylenimine to reduce nonspecific binding. The filter was
washed 3 times with cold buffer (50 mM Tris-HCl), pH 7.4.
Bound 125I-C3a was then assessed by scintillation counting on a
β-counter. Specific 125I-C3a binding is defined as a difference
between total binding and nonspecific binding as determined in
the presence of 1 μM unlabeled C3a. The IC50 value is the
concentration of antagonist to inhibit the binding of labeled
ligand by 50%. Nonlinear regression analysis (GraphPad Prism
5) was performed on concentration-response curves to deter-
mine IC50 and-log IC50. The-log IC50 for each compoundwas
calculated for separate experiments and expressed as an arith-
metic mean standard error (SE). IC50 values were expressed as a
geometric mean.
Intracellular CalciumRelease Assay.PretreatedU937 cells and
culture medium were centrifuged (25 rpm, 5 min). The super-
natant was removed, and the cells were resuspended in 2 mL of
wash buffer (1"HBSS, 20 mMHEPES, 2.5 mM probenecid, pH
7.4). Cells were counted on a hemocytometer. One dye-loading
buffer (12 mL of wash buffer, 1% FBS, 25 μL of Fluo-3 (final
concentration 4 μM), 25 μL 20% pluronic acid) was added per
5-7 million cells. Cells were suspended in dye loading buffer,
incubated in a covered culture flask for 1 h at 37 !C, then
centrifuged (25 rpm, 5 min). The supernatant was removed, and
cells were resuspended in 3 mL of wash buffer and centrifuged
(25 rpm, 5 min). The process was repeated for cell density of 2"
106 cells/mL (or 100 000 cells per well). Then 50 μL of test
compound or buffer or control/well was plated out on sterile
black-wall, clear-bottom 96-well plates (Corning Incorporated,
NY). Plate was then loaded into the FLUOstar instrument
(BMG LabTechnologies, Offenburg, Germany), where fluores-
cence was measured over 1 min with excitation at 485 nm and
emission at 520 nm of Fluo-3 bound Ca2þ complex, at 28 !C.
Differentiated U937 cells were administered in situ 10 s into the
1min reading. Agonist responses were expressed as a percentage
of calcimycin (A23187) or control compound activity, measured
as the maximum change in fluorescence through emission from
the Fluo-3 bound calcium complex.
Statistical Analysis. For both receptor binding and agonist
assays, nonlinear regression was performed using Prism 5
(GraphPad Software, San Diego, CA).
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